1
Status: Approved , 31 March 2017, no, electronic signatures for a p Yeahhhhh!    Eot
Janssen Research & Development *
Clinical Protocol
Medicall y Ill Patient Assessment of Rivaroxaban Versus Placebo INReducing Post -Discharge 
Venous Thrombo- Embolism Risk (MARINER)
Protocol RIVAROXDVT3002; Phase 3 BAY 59 -7939/17261
Amendment INT -7
JNJ-39039039; BAY 59 -7939 (rivaroxaban) 
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, I nc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen 
R&D Ireland; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the 
protocol to represent t hese various legal entities; the sponsor is identified on the Contact Information page 
that accompanies the protocol. 
This compound is approved for marketing in 6 indications.
This study  will be conducted under US Food & Drug Administration I ND regulat ions (21 CFR 
Part 312).
EudraCT NUMBER: 2014 -000305 -13     
Status: Approved
Date: 31March 2017
Prepared by: Janssen Research & Development, LLC 
EDMS No.: EDMS- ERI-73765690, 8.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document conta ins trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
2
Status: Approved , 31 March 2017TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 4
LIST OF IN-TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................... 8
TIME AND EVENTS SCHE DULE .............................................................................................................. 17
ABBREVIA TIONS ...................................................................................................................................... 18
1. INTRODUCTION ................................................................................................................................ 20
1.1. Background .................................................................................................................................... 20
1.1.1. Compound Profile ....................................................................................................................... 22
1.1.2. Medically Ill Patients - Scope of the Problem ............................................................................. 22
1.1.3. Thromboprophylaxis in Patients with Acute Medical Conditions ................................................ 23
1.1.4. VTE Risk Post Discharge in Patients Hospitalized for Medical Conditions ................................ 23
1.1.5. Studies Examining Extended Thromboprophylaxis in Patients Hospitalized for Acute 
Medical Conditions and MARINER Approach ............................................................................ 25
1.2. Overall Rationale for the Study ...................................................................................................... 27
2. OBJECTIVES A ND HYPOT HESES .................................................................................................. 27
2.1. Objectives ...................................................................................................................................... 27
2.2. Hypotheses .................................................................................................................................... 29
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .29
3.1. Overview of Study Design .............................................................................................................. 29
3.2. Study Design Rationale .................................................................................................................. 32
3.3. Committees .................................................................................................................................... 36
3.3.1. Executive Committee .................................................................................................................. 36
3.3.2. Independent Data Monitoring Committee ................................................................................... 36
3.3.3. Clinical Events Committee .......................................................................................................... 36
4. SUBJECT POPUL ATION.................................................................................................................. 37
4.1. Inclusion Criteria ............................................................................................................................ 37
4.2. Exclusion Criteria ........................................................................................................................... 39
4.3. Prohibitions and Restrictions ......................................................................................................... 43
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 44
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 45
7. TREA TMENT COMPLIA NCE ............................................................................................................ 47
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 48
9. STUDY EVA LUATIONS .................................................................................................................... 48
9.1. Study Procedures ........................................................................................................................... 48
9.1.1. Overview ..................................................................................................................................... 48
9.1.2. Screening Phase ........................................................................................................................ 48
9.1.3. Double -Blind Treatment Phase .................................................................................................. 50
9.1.4. Post- treatment Phase (Follow -Up)............................................................................................. 53
9.2. Efficacy  Evaluations and Outcomes .............................................................................................. 54
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
3
Status: Approved , 31 March 20179.2.1. Efficacy  Evaluations, Outcomes and Adjudication ..................................................................... 54
9.2.2. Approach to the Subject with an Efficacy  Outcome Event ......................................................... 55
9.3. Pharmacokinetics ........................................................................................................................... 56
9.3.1. Evaluations ................................................................................................................................ .56
9.3.2. Analytical Procedures ................................................................................................................. 57
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 57
9.4. Medical Resource Utilization and Health Economics .................................................................... 57
9.5. Safety Evaluations and Outcomes ................................................................................................ .57
9.5.1. Bleeding Events .......................................................................................................................... 57
9.5.2. Approach to the Subject with a Bleeding Event ......................................................................... 58
9.5.3. Other Safety Assessments ......................................................................................................... 59
9.6. Benefit -Risk Balance ...................................................................................................................... 60
9.7. Sample Collection and Handling .................................................................................................... 60
10. SUBJECT COMPLETION/W ITHDRA WAL....................................................................................... 60
10.1. Completion ..................................................................................................................................... 60
10.2. Discontinuation of Study Treatment ............................................................................................... 60
10.2.1. Temporary  Interruption of Study Treatment ............................................................................... 61
10.2.2. Approach to Subjects with Temporary  Interruption of Study Treatment .................................... 61
10.2.3. Permanent Discontinuation of Study Treatment ......................................................................... 62
10.3. Withdrawal From the Study ............................................................................................................ 63
11. STATISTICA L METHODS ................................................................................................................. 63
11.1. Analysis Setand Analysis Phase ................................................................................................... 64
11.1.1. Analysis Sets.............................................................................................................................. 64
11.1.2. Analysis Phases ......................................................................................................................... 64
11.2. Sample Size Determination ........................................................................................................... 64
11.3. Efficacy  Analyses ........................................................................................................................... 65
11.4. Pharmacokinetic Analy ses............................................................................................................. 68
11.5. Medical Resource Utilization and Health Economics Analyses ..................................................... 68
11.6. Safety Analyses ............................................................................................................................. 68
11.7. Interim Analysis .............................................................................................................................. 69
11.8. Benefit -Risk Analysis ..................................................................................................................... 69
12. ADVERSE EVENT REPORT ING...................................................................................................... 70
12.1. Definitions ...................................................................................................................................... 70
12.1.1. Adverse Event Definitions and Classifications ........................................................................... 70
12.1.2. Attribution Definitions .................................................................................................................. 71
12.1.3. Severity Criteria .......................................................................................................................... 72
12.2. Special Reporting Situations .......................................................................................................... 73
12.3. Procedures ..................................................................................................................................... 73
12.3.1. All Adverse Events ...................................................................................................................... 73
12.3.2. Serious Adverse Events ............................................................................................................. 75
12.3.3. Pregnancy ................................................................................................................................... 76
12.4. Contacting Sponsor Regarding Safety ........................................................................................... 76
13. PRODUCT QUA LITY COMP LAINT HA NDLING .............................................................................. 76
13.1. Procedures ..................................................................................................................................... 76
13.2. Contacting Sponsor Regarding Product Quality ............................................................................ 77
14. STUDY DRUG INFORM ATION......................................................................................................... 77
14.1. Physical Description of Study Drug(s) ........................................................................................... 77
14.2. Packaging ...................................................................................................................................... 77
14.3. Labeling .......................................................................................................................................... 77
14.4. Preparation Handling and Storage ................................................................................................ .77
14.5. Drug Accountabili ty........................................................................................................................ 77
15. STUDY -SPECIFIC M ATERIA LS....................................................................................................... 78
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
4
Status: Approved , 31 March 201716. ETHICA L ASPECTS ......................................................................................................................... 78
16.1. Study-Specific Design Considerations ........................................................................................... 78
16.2. Regulatory Ethics Compliance ....................................................................................................... 79
16.2.1. Investigator Responsibilities ....................................................................................................... 79
16.2.2. Independent Ethics Committee or Institutional Review Board ................................................... 79
16.2.3. Informed Consent ....................................................................................................................... 80
16.2.4. Privacy of Personal Data ............................................................................................................ 81
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 82
17.1. Protocol Amendments .................................................................................................................... 82
17.2. Regulatory Documentation ............................................................................................................ 82
17.2.1. Regulatory Approval/Notification ................................................................................................ 82
17.2.2. Required Pre -study  Documentation ........................................................................................... 83
17.3. Subject Identification Enrollment and Screening Logs .................................................................. 83
17.4. Source Documentation ................................................................................................................... 84
17.5. Case Report Form Completion ...................................................................................................... 84
17.6. Data Quality Assurance/Quality Control ........................................................................................ 85
17.7. Record Retention ........................................................................................................................... 85
17.8. Monitoring ...................................................................................................................................... 86
17.9. Study Com pletion/Termination ....................................................................................................... 86
17.9.1. Study Com pletion ....................................................................................................................... 86
17.9.2. Study Termination ....................................................................................................................... 87
17.10. On-Site Audits ................................................................................................................................ 87
17.11. Use of Information and Publication ................................................................................................ 87
REFERENCES ............................................................................................................................................ 89
INVESTIGA TOR A GREEME NT............................................................................................................... 120
LIST OF A TTACHMENTS
ATTACHMENT 1: EFFIC ACY OUTCOMES .......................................................................................... 92
ATTACHMENT 2: SUSPECTED EVENT SUPP ORTING DOCUMENT ATION..................................... 94
ATTACHMENT 3: PHARM ACOKINETIC SAMP LE COLLECTION A ND HA NDLING ......................... 96
ATTACHMENT 4: SYMP TOM A SSESSMENT ...................................................................................... 97
ATTACHMENT 5: INT-1 TO INT -5 / AMENDMENT CHA NGE S........................................................... 98
ATTACHMENT 6: COM PLETE A MENDMENT H ISTORY OF INT -6 INCLUSION A ND 
EXCLUSION CRITERIA , AND PROHIBITIONS A NDRESTRICTIONS FOR 
DATA COLLECTION PURP OSES ........................................................................ 111
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
5
Status: Approved , 31 March 2017LIST OF IN -TEXT TABLES A ND FIGURES
TABLES
Table 1: Modified IMPROVE VTE Risk Score ........................................................................................ 38
Table 2: Minimum Number of Heparin Doses Required for Study Eligibility by Du ration of Index 
Hospitalization ........................................................................................................................... 39
Table 3 Pharmacokinetic Suggested Sampling Schedule ..................................................................... 56
Table 4: Summary  of PK Suggested Observations for Rivaroxaban Arm .............................................. 56
Table 5: Preoperative Interruption of Rivaroxaban: A Suggested Management Approach 
(adapted from Spy ropoulos and Douketis 2012) ...................................................................... 61
Table 6 :Postoperative Resumption of Rivaroxaban: A Suggested Management Approach ................. 62
Table 7: Approximate Number of Subjects Needed to Observe 161 Events ......................................... 65
FIGURES
Figure 1: Kaplan -Meier Curve Showing Cumulative Sy mptomatic VTE Incidence from Hospital 
Admission to 3 Months of Follow -up......................................................................................... 24
Figure 2: Cumulative Number of Events Over Time: High -risk Elderly Medical Patients. ....................... 24
Figure 3: Schematic Overview of the Study (RIVAROXDVT3002) .......................................................... 32
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
6
Status: Approved , 31 March 2017PROTOCOL A MENDMENTS
Amendments are listed beginning with the most recent amendment.
Amendment INT -7(31March 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendment is that because this is an event -
driven study , additional subjects will need to be enrolled to allow  for more primary efficacy outcome events to 
accumulate, due to a lower than expected blinded pooled event rate. 
Applicable Section(s) Description of Change(s)
Rationale: The u pper limit forthe number of random ized subjects w as increased to allow  for the accumulation of 
more prim ary efficacy outcome events . 
Applicable Section(s) Description of Change(s)
Synopsis Overview of Study 
Design; Synopsis Sample Size 
Determination; 3.1. Overview 
of Study Design ; 11.2. Sample 
Size DeterminationThe total number of subjects that may be randomized was increased from 
approximately 9,000 to approximately 12,000 subjects .
Rationale: Revisions were made to align the timing of the interim analysis to when approximately 50% of the total 
anticipated subjects w ith observed blinded pooled primary efficacy outcom e events at the end of the study will be 
obtained .  
Applicable Section(s) Description of Change(s)
Synopsis Overview of Study 
Design; Synopsis Interim 
Analysis; 3.1. Overview of 
Study Design ; 11.7. Interim 
Analysis  The timingofthe interim analysis was changed from having observed 
adjudicated primary efficacy outcome events in approximately 80 subjects to 
approximately 50% of subjects based on the expected total number of events . 
Consequently, ‘targeted’ in ‘targeted total number of events’ w as changed to 
‘expected total number of events’ based on the actual observed blinded pooled 
event rate because this event rate is low er than the assumed rate .Protocol Version Issue Date
Original Protocol 27 January 2014
Amendment INT -7 31March 2017
Amendment INT -6 19 June 2015
Amendment INT -5 15June 2015
Amendment INT-4 19 January 2015
Amendment INT -3 8 December 2014
Amendment INT -2 11 April 2014
Amendment INT -1 14 March 2014
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
7
Status: Approved , 31 March 2017Rationale: Changes were made t o clarify the term of ‘major protocol deviations’ in the per -protocol analysis set .  
11.1.1. Analysis Sets The term ‘major’ in ‘major protocol deviations ’was changed to ‘key’ protocol 
deviations , because ‘key’ accurately reflects that only a subset of major 
deviations will be excluded from the per -protocol analysis set.
Rationale: Minor errors w ere noted.
Applicable Section(s) Description of Change(s)
Throughout the protocol
3.1. Overview  of Study DesignMinor grammatical, formatting or spelling changes were made.
For consistency with the rest of the document , the principal safety outcome was 
added.
Amendment INT -6(19 June 2015)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reasons for the a mendment are to clarify prescribed 
thromboprophylaxis during index hospitalization and capping during enrollment.  
Applicable Section(s) Description of Change(s)
Rationale: Prescribed thromboprophylaxis has been clarified .
Applicable Section(s) Description of Change(s)
4. SUBJECT POPULATION, 
Section 4.1 Inclusion Criteria.Inclusion Criterion # 4. 
Prescribed maximum daily dose of thromboprophylactic agents allowed was 
clarified.   
Section 5. Treatment Allocation 
and BlindingCapping for subgroups during enrollment and rela ted communication with sites 
were clarified.
Please note that description of changes for INT -1 to INT -5can be found in Attachment 5.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
8
Status: Approved , 31 March 2017SYNOPSIS
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo INReducing Post-Discharge Venous 
Thrombo -Embolism Risk (MARINER )
DESCRIPTION OF THE COMPOUND
Rivaroxaban is an oral, direct acting, Factor Xa (FXa) inhibitor anticoagulant that has been under 
development for the treatment of several thrombosis -mediated conditions. Rivaroxaban is marketed under 
the trade name XARELTO®and has been approved for multiple indications worldwide. The clinical 
development program for rivaroxaban is extensive . Over 70,000 subjects have been studied from Phase 1 
through multiple large Phase 4 studies as of 15 March 2014, covering several indications and potential 
indications in the overall clinical development program. Over 40,000 of these subjects have been exposed 
to rivaroxaban in completed and ongoing company- sponsored interventional clinical trials and 
non-interventional studies, with the total daily doses of rivaroxaban ranging between 5 mg and 60 mg.
For the most comprehensive nonclinical and clinical information regarding the efficacy and safety of 
rivaroxaban, refer to the latest version of the Investigator's Brochure19.
OBJECTIVE AND HYPOTHESIS
Primary Objective
The primary objective is to assess the efficacy and safety of rivaroxab an compared with placebo in the prevention of 
symptomatic venous thromboembolism ( VTE : low er extremity deep vein thrombosis [DVT] and non -fatal 
pulmonary embolism [PE] )and VTE -related death (death due to PE or death in which PE cannot be ruled out as the 
cause) post-hospital di scharge in high -risk, medically ill patients .
Secondary Objectives   
The secondary objectives are to compare rivaroxaban with placebo in the following post-hospital 
discharge outcomes in high- risk, medically ill patients:
 VTE -related death (death due to PE or death in which PE cannot be ruled out as the cause)
 Symptomatic VTE ( lower extremity DVT and non-fatal PE)
 The composite of symptomatic VTE (lower extremity DVT and non -fatal PE) and all -cause mortality 
(ACM)
 The composite of symptomatic VTE (lower extremity DVT and non -fatal PE), myocardial infarction 
(MI), non-hemorrhagic stroke and cardiovascular (CV) death (death due to a known CV cause and 
death in which a CVcause cannot be ruled out; by this definition, a VTE -related death is considered 
a CV death)
 ACM 
Exploratory Objectives
The exploratory objectives are to compare rivaroxaban with placebo, in the following post-hospital 
discharge outcomes in high- risk, me dically ill patients:
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
9
Status: Approved , 31 March 2017 Symptomatic lower ex tremity DVT
 Symptomatic non -fatal PE
 Symptomatic upper extremity DVT
 MI  
 Non- hemorrhagic stroke
 Re-hospitalization for symptomatic VTE (lower extremity DVT and non-fatal PE) within 30 days
after randomization
Pharmacokinetic Objective
The pharmacokinetic (PK) objective is to assess the kinetics of rivaroxaban in high-risk, medically ill 
patients, and to describe drug exposure based on creatinine clearance ( CrCl ). 
Medical Resource Utilization and Health Economi cs Objective
The medical resource utilization and health economics objective is to assess the following cost drivers, 
ie,re-hospitalization (including emergency room [ER] visits, intensive care unit and cardiac care unit 
stays ), length of stay and subject discharge destination (after re -hospitalization) .
Safety Objective s
The safety objectives are to compare rivaroxaban with placebo in the following bleeding outcomes in 
high-risk, medically ill patients :
 Major bleeding using validated International Society on Thrombosis and Haemostasis (ISTH )
bleeding criteria.
 Non-major clinically relevant bleeding
 Other bleeding
Overall safety will also be assessed.
Hypothese s  
The primary hypothesis is that rivaroxaban is superior to placebo in the prevention of the composite of 
symptomatic VTE (lower extremity DVT and non-fatal PE) and VTE -related death (death due to PE or 
death in which PE cannot be ruled out as the cause). The secondary hypotheses are that rivaroxaban is 
superior to placebo inthe prevention of 1) VTE -related death (death due to PE or death in which PE 
cannot be ruled out as the cause) , 2) symptomatic VTE (lower extremity DVT and non-fatal PE), 3) the 
composite of symptomatic VTE (lower extremity DVT and non-fatal PE) and ACM, 4) the composite of 
symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke and CV death 
(death due toa known CV cause and death in which a CV cause cannot be ruled out; by this definition, a 
VTE -related death is considered a CV death) and 5) ACM alone .
OVERVIEW OF STUDY DESIGN
This is a multicenter, prospective, randomized, double -blind, placebo -controlled, event -driven study 
designed to evaluate rivaroxaban, compared with placebo, in the prevention of symptomatic VTE 
(lower extremity DVT and non-fatal PE) events and VTE -related deaths (death due to PE or death in 
which PE cannot be ruled out as the cause) for a period of 45 days post-hospital discharge. The study 
consists of a screening phase, a 45-day double -blind treatment phase, and a 30-day safety follow -up 
period. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
10
Status: Approved , 31 March 2017The subject population comprises men and women aged 40 years and older who have completed 
screening no later than 1 day after leaving the hospital and who have been hospitalized for the new onset 
or exacerbation o f 1 of the following medical conditions: 
 Heart Failure (HF) with a reduced left ventricular ejection fraction (LVEF ≤45%)
 Acute respiratory insufficiency or acute exacerbation of chronic obstructive pulmonary disease 
(COPD)
 Acute ischemic stroke (includin g spinal cord infarction if no evidence of intramedullary, subdural or 
epidural hemorrhage) 
 Acute infectious disease
 Inflammatory disease, including rheumatic disease
The index hospitalization must be at least 3 and no more than 10 consecutive days in dur ation. In order to 
be eligible, subjects must have an increased VTE risk, as demonstrated by a total modified International 
Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE Risk Score of :
 ≥4, or 
 3 with D -dimer > 2XULN, or
 2 with D -dimer > 2XULN  
In addition, subjects must have received treatment during the index hospitalization with LMWH or UFH.
Any patient with a medical condition that will require use of any parenteral or oral anticoagulation 
(eg,atrial fibrillation) during the study is not eligible for participation. In addition, patients at particular ly 
increased risk of bleeding and those using medications that might interact with the study drug will be 
excluded. 
Subjects who meet all of the inclusion and none of the exclusion criteria will be randomly assigned to 
receive rivaroxaban or placebo. Randomization should occur on the same day as or the day after the 
subject leaves the hospita l,and may occur at the hospital, clinic or other discharge destination. Subjects 
will be randomized by strata including creatinine clearance and country.
After randomization, subjects will receive double -blind treatment with rivaroxaban 10 mg (7.5mg for 
subjects with a CrCl ≥30 mL/min and <50 mL/min) daily or matching placebo daily. Placebo has been 
chosen as the comparator because of current guidelines which recommend against thrombop rophylaxis in 
medically ill pati ents after hospital discharge. The first dose of study drug shou ld be administered no later 
than the day after the subject leaves the hospital and as soon after randomization as possible. Subjects will 
be instructed to discontinue study drug after they take a dose on Day 45, and complete an end of treatment 
visit withi n the next 4 days. Regardless of the day on which the Day 45 Visit occurs, no study drug may 
be taken after Day 45.The subject must be assessed 30days later for safety follow -up.  This will be the 
last contact with the subject unless extended follow -up f or safety is required.  
If a subject has a suspected efficacy or bleeding outcome event during the study, the treating physician 
should exercise clinical judgment and follow established guidelines to apply the standard of care. 
Unblinding of study drug should not be necessary. Anticoagulation regimens do not require adjustment 
regardless of treatment group assigned when study drug is administered in the doses used in this study.  
There is no specific reversal agent for rivaroxaban; management of the subjec t with a bleeding event 
should not be impacted by knowledge of study drug treatment.
Rivaroxaban will not be provided to subjects after they complete study treatment , unless required by local 
regulations . Randomization in this study is preceded by a hospitalization for an acute illness and the study 
drug treatment phase extends for 45 days after randomization to correspond to the period of greatest risk 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
11
Status: Approved , 31 March 2017for VTE.  Chronic therapy with the study drug is not being tested. It will only be after data from the en tire 
study is analyzed that the sponsor can determine if the population at risk will benefit from treatment.
The primary efficacy outcome is the composite of all symptomatic VTE events (lower extremity DVT 
and non- fatal PE) and VTE -related death (death due to PE or death in which PE cannot be ruled out as the 
cause) , from randomization up to Day 45. The targeted total number of primary efficacy outcomes in this 
event -driven study is 161. It is estimated that a total of approximately 8,000 subjects will need to be 
randomized to either rivaroxaban or placebo in a 1:1 ratio. In the event that the actual observed blinded 
pooled event rate is lower than the assumed rate, more subjects may be enrolled to accumulate additional 
outcome events. Randomization in this study may be stopped at approximately 12,000 subjects for 
administrative considerations even if the targeted 161 events have not been observed by then. An interim 
analysis for futility will be conducted when approximately 50% of subjects with adjudicated primary 
efficacy outcome events have been observed (about 50% of the expected total number of events based on 
the actual observed blinded pooled event rate even if this event rate is lower than the assumed rate). The 
principal safety outcome for this study is ISTH major bleeding.
For population PK analyses, based on the model performance and the high variability of the 
PKparameters observed in the MAGELLaN study, 2 blood samples ( at pre-dose and1-4 hours after study  
drug administration) will be collected at the Day 7 visit  and 2 blood samples (at 3 to 7 and 7 to 12 hours 
after study drug administration) will be collected at the Day 21 visit for each subject for up to 
600subjects (300 rivaroxaban subjects [200 subjects in the 10 mg daily group and 100 subjects in the 
7.5mg daily group] and 300 in the placebo group). The sparse blood samples for PK analyses will be 
collected in selected sites only.
An Executive Committee (EC), an Independent Data Monitoring Committee (IDMC) and a Clinical Event 
Committee (CEC) will be commissioned for this study. All committees will be governed by separate 
charters, see Section 3.3 .
SUBJECT POPULATION
The subject pop ulation comprises men and women age 40 years and older who have completed screening 
no later than 1 day after leaving the hospital and who have been hospitalized for the new onset or 
exacerbation of 1of the following medical conditions:
 HFwith a reduced LVEF (LVEF ≤ 45%)
 Acute respiratory insufficiency or acute exacerbation of COPD
 Acute ischemic stroke (including spinal cord infarction if no evidence of intramedullary, subdural or 
epidural hemorrhage)
 Acute infectious disease
 Inflammatory disease , including rheumatic disease
The index hospitalization must be at least 3 and no more than 10consecutive days in duration. In order to 
be eligible, subjects must have an increased VTE risk, as demonstrated by a total modified International 
Medi cal Prevention Registry on Venous Thromboembolism (IMPROVE) VTE Risk Score of:
 ≥4, or 
 3 with D -dimer > 2XULN, or
 2 with D -dimer > 2XULN  
In addition, subjects must have received treatment during the index hospitalization with low molecular 
weight heparin (LMWH) or unfractionated heparin (UFH) .
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
12
Status: Approved , 31 March 2017Any patient with a medical condition that will require use of any parenteral or oral anticoagulation 
(eg,atrial fibrillation, other medical condition) during the study is not eligible for participation. In 
addition, patients at particular lyincreased risk of bleeding and those using medications that interact with 
the study drug will be excluded.
DOSAGE AND ADMINISTRATION
Treatment groups in this study are rivaroxaban and placebo. Subjects will be randomly assigned in a 
1:1ratio to receive rivaroxaban 10 mg daily (or 7.5mg daily in subjects with CrCl ≥30 mL/min and
<50mL/min) or matching placebo daily . Randomization will be stratified by subjects with 
CrCl ≥30mL/min and<50 mL/min versus subjects wit h CrCl ≥50 mL/ min and by country.
The first dose of study drug should be administered no later than the day after the subject leaves the 
hospital and as soon after randomization as possible. The date and time of the first dose of study drug and 
the last dose of LMWH or UFH should be recorded as accurately as possible. The first dose of study drug 
should not be delayed to allow administration under supervision. All subjects should take study drug 
(rivaroxaban or placebo) daily with or without food at approximately the same time each day, and 
discontinue study drug after they take a dose on Day 45.Regardless of the day on which the Day 45 Visit 
occurs, no study drug may be taken after Day 45 .
A missed dose should be taken as soon as possible (up to 8 hours prior to the next scheduled dose), and 
the next scheduled dose should be taken at the regular time.
Interruption of Study Drug 
Study drug may be interrupted temporarily as necessary for invasive procedures or as medically needed 
(eg,in the setting of a bleeding event or a required prohibited therapy). If a subject ishospitalized for any 
reason other than a VTE -related event or bleeding, study drug should be continued during hospitalization 
unless the treating physician feels that anticoagulation is clinically warranted. Subjects may be placed on 
appropriate anticoagulation at the discretion of thetreating physician .In that case ,study drug needs to be 
temporarily interrupted and can be restarted upon discharge at the discretion of the investigator. These 
interruptions will be recorded on the electronic case report form ( eCRF).
During the study, should the subject develop any condition, which in the investigator’s judgment requires 
long-term anticoagulation thromboprophylaxis, or fibrinolysis, the subject will have study treatment 
either temporarily interrupted or permanently discontinued andwill bemanaged as deemed appropriate 
by the treating physician. The subject will be asked to continue in the study to be followed for efficacy 
and safety outcomes.
EFFICACY EVALUATIO NS/OUTCOMES
 The primary efficacy outcome is the composite of all symptomatic VTE events (lower extremity 
DVT andnon-fatal PE) and VTE -related death (death due to PE or death in which PE cannot be 
ruled out as the cause)
 The secondary efficacy outcomes are the following:
 VTE -related death (death due to PE or death in which PE cannot be ruled out as the cause)
 Symptomatic VTE ( lower ex tremity DVT and non-fatal PE)
 The composite of symptomatic VTE (lower ex tremity DVT and non- fatal PE) and ACM
 The composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, 
non-hemorrhagic stroke and CV death (death due to a known CV cause and death in which a 
CV cause cannot be ruled out; by this definition, a V TE-related death is considered a CV death)
 ACM 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
13
Status: Approved , 31 March 2017 Exploratory efficacy outcomes are :
 Symptomatic lower ex tremity DVT
 Symptomatic non -fatal PE
 Symptomatic u pper ex tremity DVT
 MI
 Non- hemorrhagic stroke
 Re-hospitalization for symptomatic VTE (lower extremity DVT and non-fatal PE) within 
30days after randomization
Any clinical event that suggests the possibility that an efficacy outcome event has occurred (including 
acute coronary syndrome (ACS )and transient ischemic attack (TIA) will be sent for adjudication. If a 
subject has a suspected efficacy outcome event during the study, the treating physician should exercise 
clinical judgment and follow established guidelines to apply the standard of care. Unblinding of study 
drug should not be necess ary, as anticoagulation regimens do not require adjustment regardless of use of 
placebo vs rivaroxaban when administered in the doses used in this study.
SAFETY EVALUATIONS / OUTCOMES
 The principal safety outcome is major bleeding using validated ISTH bleeding criteria.
 Other safety outcomes are non- major clinically relevant bleeding and other bleeding.
Overall safety will also be assessed.
An ISTH major bleeding event is defined as overt bleeding associated with: a fall in hemoglobin of 
2g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or 
bleeding that occurs in a critical site: eg,intracranial, intraspinal, intraocular, pericardial, intra-articular, 
intramuscular with compartment synd rome, retroperitoneal, or a fatal outcome (for details on definitions 
see Section 9.5). 
Non-major clinically relevant bleeding is defined as overt bleeding not meeting the criteria for major 
bleeding ,but associated with medical intervention, unscheduled contact (visit or telephone call) with a 
physician, (temporary) cessation of study treatment, or associated with discomfort for the subject such as
pain or impairment of activities of daily life.
Other bleeding is defined as any other overt bleeding that does not meet the ISTH criteria for major or 
non-major clinically relevant bleeding. 
Any clinical event that suggests the possibility that a bleeding outcome event has occurred will be sent for 
adjudication. If a subject has a serious bleeding event during study drug treatment, routine measures 
should be considered as described in Section 9.5.2. U nblinding of study drug should not be necessary. As 
there is not a specific reversal agent for rivaroxaban, management of the subject should not be impacted 
by knowledge of study drug treatment.
STATISTICAL METHODS
Key Analysis Setand Analysis Phase
 Intention -to-Treat (ITT): This analysis setconsists of all randomized subjects who have a signed 
valid informed consent.  
 Up-to-Day-45: This analysis phase includes all data from randomization to Day 45 (inclusive).  
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
14
Status: Approved , 31 March 2017Sample Size Determination
This is an event -driven study. The targeted total num ber of primary efficacy outcom e events is 161, based 
on the ITTanalysis setand Up-to-Day-45 analysis phase. If a subject has multiple events, only the first is 
counted towards study size determination.
This targeted total number of events is determined using statistical software East 5.3 based on the primary 
efficacy analysis (defined later) and the following assumptions :
 40% relative risk reduction (RRR) in the primary efficac y outcome based on the ITTanalysis setand 
Up-to-Day-45 analysis phase (RRR is defined as 1 minus the hazard ratio [HR]of rivaroxaban 
versus placebo).   
 Power of 90% assuming the above RRR
 Two-sided significance level of 0.05. 
To observe the targeted 161 events, it is estimated that a total of approximately 8,000 subjects will need to 
be randomized to either rivaro xaban or placebo in 1:1 ratio. This estimate is based on an estimated 
placebo incidence rate of the primary efficacy outcome of 2.5%. In the event that the actual observed 
blinded pooled event rate is lower than the assumed rate, more subjects may be enrolled to accumulate 
additional outcome events. Randomization in this study may be stopped at approximately 12,000 subj ects 
for administrative considerations even if the targeted 161 events have not been observed by then. The 
total number of VTE -related death events may also be taken into account when deciding to stop 
randomization.
Efficacy Analyses
Primary Efficacy Outco me
The primary efficacy outcome will be analyzed based on time from randomization to the first occurrence 
of symptomatic VTE (lower extremity DVT and non- fatal PE) and VTE -related death (death due to PE or 
death in which PE cannot be ruled out as the cause ) in the ITT analysis setand Up-to-Day-45 analysis 
phase . The primary statistical alternative hypothesis is that rivaroxaban is superior to placebo on the 
primary efficacy outcome.
The primary statistical hypothesis will be tested using Cox proportional hazards model, stratified by 
subjects with CrCl ≥30 mL/min and <50 mL/min versus subjects with CrCl ≥50 mL/min, with the 
treatment (as randomized) as the only covariate. This primary efficacy analysis will be based on the ITT
analysis setand Up -to-Day-45 analysis phase . Subjects will be analyzed according to the treatment group 
to which they are randomized, regardless of actual treatment received. As an operational arrangement, the 
2-sided p-value will be reported and if it is less than the 2-sided alpha of 0.05, then superiority of the 
study drug will be declared if the observed survival functions favor rivaroxaban.
The point estimate and corresponding 95% confidence interval (CI) forthe HR (rivaroxaban to placebo) 
will be provided based on the Cox proportional hazards model. For the CIs, the plausibility of 
proportional hazards assumption will be assessed by visually comparing the plot of the log of cumulative 
hazard between treatmen ts, and additionally checked by adding a treatment by logarithm -transformed 
time interaction into the Cox model .  
The cumulative event rate derived from Kaplan- Meier estimate will be displayed graphically to evaluate 
the treatment effect over time. 
Homogeneity of treatment effects, both in HR and direction, will be assessed by subgroups and their 
interactions with treatment (for details see Section 11.3 ). Analysis methods will be detailed in the SAP.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
15
Status: Approved , 31 March 2017Secondary Efficacy Outcomes
Each secondary efficacy outcome will be analyzed based on time from randomization to the first 
occurrence in the ITTanalysis setand the Up- to-Day 45 analysis phase .The same stratified Cox model as 
that for the primary efficacy outcome will be used.  Details will be provided in the SAP.
To control the family -wise type I error rate at alpha of 0.05 (2-sided) in testing for efficacy outcomes, if 
superiority of rivaroxaban over placebo on the primary efficacy outcome is established, superiority of 
rivaroxaban over placebo on secondary outcomes will be tested sequentially using a closed testing 
procedure in the following hierarchical order, each at alpha of 0.05 (2 -sided):
 VTE -related death (death due to PE or death in which PE cannot be ruled out as the cause)
 Symptomatic VTE ( lower ex tremity DVT and non -fatal PE)
 The composite of symptomatic VTE (lower extremity DVT and non -fatal PE) and ACM
 The composite of symptomatic VTE (lower extremity DVT and non- fatal PE), MI, non -hemorrhagic 
stroke and CV death ( death due to a known CV cause and death in which a CV cause cannot be ruled 
out; by this defini tion, a VTE -related death is considered a CV death)
 ACM 
Exploratory Efficacy Outcomes
Each exploratory outcome will be summarized by treatment groups based on the ITTanalysis setand 
Up-to-Day-45 analysis phase.
Pharmacokinetic Analyses 
The population PK m odel will characterize and predict the overall exposure to rivaroxaban and determine 
different PK parameters.
Medical Resource Utilization and Health Economics
Medical resource utilization and health economics will be descriptively summarized by treatment group.   
Safety Analyses
Bleeding Outcomes
The principal safety outcome will be analyzed based on time from randomization to the first occurrence 
of ISTH major bleeding.  Treatments will be compared using the same Cox proportional hazards model as 
that for the primary efficacy outcome described earlier.  The analysis will be based on the safety analysis 
setand on-treatment analysis phase .Subjects will be analyzed according to study drug received. If a 
subject inadvertently receives both drugs, the subject will be analyzed as randomized. Non-major 
clinically relevant bleeding will be analyzed based on time from randomization to the first occurrence. 
The same analysis as that for the principal safety outcome wil l be used.
Interim Analysis
An interim analysis for futility will be conducted when approximately 50% ofsubjects with adjudicated 
primary efficacy outcome events have been observed (about 50% of the expect ed total number of events
based on the actual observed blinded pooled event rate even if this event rate is lower than the assumed 
rate)and there will be no alpha adjustment to the final analysis (for details see S ection 11.7).
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
16
Status: Approved , 31 March 2017Benefit -Risk Analysis
The benefit -risk of rivaroxaban vs placebo will be evaluated based on the excess number of events 
between treatments for events intended to be prevented (benefits) and events that may be caused (risks)
(for details see Section 11.8).
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
17
Status: Approved , 31 March 2017TIME A ND EVENTS SCHE DULE
Protocol Activity ScreenaRandomizebTreat ment 30 Day F/U
Screening Day 1 Day 7 Day 21Day 45
EOTcDay 75
EOS
Hospital/
Clinic/
Discharge 
DestinationHospital/
Clinic/
Discharge 
DestinationClinic/
Discharge 
Destination/
TelephoneClinic/
Discharge 
DestinationClinic/
Discharge 
DestinationClinic/
Discharge 
Destination/
Telep hone
Window -2/+5d -3/+7d -0/+4d -5/+5d
Informed ConsentdX
Inclusion / ExclusioneX X
VTE RiskeX X
Physical Exam and VitalsfX
Dem ographics X
Medical History X
Hem oglobin/ Platelet countgX
Serum CreatininegX
Serum/Urine PregnancyhX
D-dimer (local)iX
Computed tomography /MRI of the 
headj X
IWRS Registration X
Dispense Study Drug X Xc
Index Hospitalization X
LMWH/UFH Use X
Clinical AssessmentfX X X
Symptom Assessment X X X X
Subject CounselingkX X X X
Study Drug Accountability X X
Clinical Status/ Suspected Outcomes X X X X
Adverse Events X X X X X X
Concomitant Medications X X X X X X
Medical Resource HECON X X X X
PK SamplinglX X
Key: EOS=end of study; EOT=end of treatment; F/U=follow up; HECON= health economics; LMWH=low molecular weight heparin; 
MRI=magnetic resonance imaging; PK=pharmacokinetics; VTE=venous thromboembolism; IWRS= interactive web response system; 
UFH=unfractionated heparin.
a)Screening may begin any time, after the admis sion for the index hospitalization and once the informed consent is obtained.  The index 
hospitalization must be at least 3 and no more than 10 consecutive days in duration.
b)Randomization should occur on the same day as or the day after the subject leav es the hospital.
c) The subject will be instructed to discontinue study drug after taking a dose on Day 45. Regardless of the day on which the Day 45 Visit 
occurs, no study drug may be taken after Day 45 .
d) A limited informed consent may be used for a scr eening local D -dimer or head computed tomography (CT) if permitted locally . Full 
informed consent must still be obtained before other study procedures are performed.
e)Screening inclusion / exclusion criteria and VTE risk score should be assessed and veri fied at randomization. 
f)Vital signs include pulse and blood pressure. Physical exam will be performed at Screen ing or Randomization. Clinical A ssessment is a 
focused evaluation of heart, lungs, lower extremities, and neurological status.  If the physica l examination is conducted at Day 1, then 
the Clinical assessment is not required on that day.
g) Hemoglobin, platelet count and serum creatinine must be obtained at least as recently as 2 days before the subject leaves the hospital or 
later, but before randomization.
h) Pregnancy test must be performed for women of child-bearing potential and may be repeated as indicated or required locally.
i) D-dimer may be obtained any time from the beginning of the index hospitalization up until randomization; the va lue obtained closest to 
the beginning of the index hospitalization should be used.  A value >2xULN is required if the VTE risk score is 2 or 3.
j) Head CT /MRI performed only for subjects with ischemic stroke who received fibrinolytic agents; obtain at leas t 24 hours after 
fibrinolysis.
k) Includes training on the signs and symptoms associated with DVT, PE and bleeding and the appropriate response if symptoms d evelop .
l) Non-fasting PK samples will be obtained for subjects consented to participate at selecte d sites. For subjects participating in the PK assessment, the 
telephone visit option will not be applicable. For these subjects, visits at Day 7 and Day 21 must be c onducted at the clinic .
At Day 7, 2 samples will be obtained: 1) pre -dose and 2) 1 -4 hour s post dose. 
At Day 21, 2 samples at least 3 hours apart will be obtained: 1) 3 -7 hours post -dose and 2) 7 -12 hours post -dose.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
18
Status: Approved , 31 March 2017ABBREVIA TIONS
ACCP American College of Chest Physicians 
ACM all-cause mortality
ACS acute coronary syndrome
ASA acetylsalicylic acid
AUC area under the plasma concentration curve
AV arteriovenous
BP blood pressure
CCU cardiac care unit
CEC
CHFClinical Event Committee
congestive heart failure
CI confidence interval
CL/F clearance
Cmax maximum serum concentration
Cmin minimum serum concentration
COPD chronic obstructive pulmonary disease
CrCl creatinine clearance
CT computed tomography
CV cardiovascular
CYP3A4 Cytochrom e P450 3A4
DVT deep vein thrombosis
eCRF electronic case report form
eDC electronic data capture
EC Executive Committee
EF ejection fraction
EOS end of study
EOT end of treatment
ER emergency room
EU European Union
FDA Food and Drug Administration
FXa factor Xa
GCP Good Clinical Practice
HF heart failure
HR hazard ratio
ICF informed consent form
ICH International Conference on Harmonisation
ICU intensive care unit
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IMPROVE International Medical Prevention Registry on Venous Throm boembolism (IMPROVE)
IRB Institutional Review Board
ISTH International Society on Thrombosis and Haemostasis
ITT intention -to-treat
IWRS interactive web response system
Ka first-order absorption rate constant
LC-MS/MS liquid chromatography coupled to tandem mass spectrometry
LDUH low-dose unfractionated heparin 
LOS length of stay
LMWH low molecular weight heparin 
LVEF left ventricular ejection fraction
MedDRA Medical Dictionary for Regulatory Activities
MI myocardial infarction
MRI Magnetic resonance imaging 
NT-proBNP N-terminal pro -brain natriuretic peptide
P2Y12 G protein -coupled purinergic receptor P2Y 
PE pulmonary embolism
PK pharmacokinetic
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
19
Status: Approved , 31 March 2017PP per protocol
PPI proton pump inhibitor
PQC product quality complaint
RRR relative risk reduction
SAP statistical analysis plan
SUSAR suspected unexpected serious adverse reaction
t1/2 half-life
tmax time to reach maximum concentration in plasma
TIA transient ischemic attack
UFH unfractionated heparin 
ULN upper limit of norm al
US United States
V/F volume of distribution
VTE venous thromboembolism
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
20
Status: Approved , 31 March 20171. INTRODUCTION
Rivaroxaban is an oral, direct acting, Factor Xa (FXa) inhibitor anticoagulant that has been under 
development for the treatment of several thrombosis -mediated conditions. Rivaroxaban is 
marketed under the trade name XARELTO®and has been approved for multiple indications 
worldwide. The clinical development program for rivaroxaban is extensive . Over 70,000 subjects 
have been studied from Phase 1 through multiple large Phase 4 studies as of 15 March 2014, 
covering several indications and potential indications in the overall clinical development 
program. Over 40,000 of these subjects have been exposed to rivaroxaban in completed and 
ongoing compa ny-sponsored interventional clinical trials and non- interventional studies, with the 
total daily  doses of rivaroxaban ranging between 5 mg and 60 mg. In addition, rivaroxaban 
(10mg daily ) was evaluated for thromboprophy laxis in medically  ill patients in the MAGELLaN 
trial10. 
For the most comprehensive nonclinical and clinical information regarding the efficacy  and 
safet y of rivaroxaban, refer to the latest version of the I nvestigator's Brochure19.
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1. Background
Hemostasis is a normal physiological process following damage of the vascular system.  In 
various diseases, however, the hemostatic mechanisms are inappropriately  activated with 
pathological consequences known as thrombosis. Venous thromboembolism (VTE) including 
deep vein thrombosis (DVT) and pulmonary  embolism (PE) represents one of the most common 
health problems. More than 2 million Americans suffer from acute VTE each year.In the 
European Union (EU), incidence rates of DVT and PE are assumed to be slightly  higher, but are 
generall y consistent with those in the United States (US)9,39.Deep vein thrombosis and PE are a 
burden for healthcare systems as they areassociated with high mortality  and considerable 
morbidity  in terms of recurrent events, the post-thrombotic syndrome, and chronic 
thromboembolic pulmonary  hypertension 14,22,30,43.  Treatment of DVT and PE aims at 
prevention of worsening of the existing thrombus, as well as prevention of recurrent VTE41.
Medically  ill patients, ie, patients that are hospitalized for the treatment of acute medical 
illnesses, are at high risk for the development of VTE during their hospital stay and immediately  
after their hospital discharge. The American College of Chest Physicians (ACCP) 
Evidence -Based Clinical Practice Guidelines currentl y recommend anticoagulant 
thromboprophy laxis for acutel y ill hospitalized medical patients with increased risk of 
thrombosis for 6 to 21 days, until full mobility is restored or until discharge from hospital, 
whichever comes first20. In the US and in many  other countries including those in Europe, there 
is a growing trend for shorter hospital stays for patients hospitalized for medical conditions1,29. 
While continued thromboprophy laxis with parenteral agents post discharge could potentially 
reduce the overall risk of VTE, this approach has not yet been widel y used, likely  due to the 
challenges in administering a parenteral medication by the patient orcaregivers and the lack of 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
21
Status: Approved , 31 March 2017compelling benefit -risk data with existing anticoagulants. The duration of thromboprophy laxis is 
largel y determined by the duration of hospitalization and currentl y post-hospital
thromboprophy laxis with parenteral agents is infrequently  used, despite the fact that the risk of 
VTE persists after hospital discharge . Since the documented increase in risk of VTE persists well 
beyond hospital discharge, studies of extended thromboprophy laxis with oral anticoagulants in 
post-discharge patients hospitalized for medical conditions at risk for VTE are warranted36. 
Recently , 3 studies with extended treatm ent duration of enoxaparin (EXCL AIM), apixaba n 
(ADOPT) and rivaroxaban (MAGELLaN ) failed to demonstrate a positive benefit -risk profile for 
extended -duration thromboprophy laxis in patients hospitalized for medical conditions prima rily 
due to increased bleeding with the anticoagulants10,13,15,17.
The previous trial in medicall y ill patients (the MAGELLaN study ) showed positive efficacy  
results of rivaroxaban but a bleeding risk that outweighed the benefit. Compared with thisand 
the other trials, the MARI NER trial was therefore modified to improve the overall safet y of the 
subjects by addressing the bleeding risk observed in previous extended duration therap y studies 
while maintaining the efficacy  that was observed. Several study  design elements were modified 
to red uce the risk of major bleeding observed in the MAGELLaN study . Subjects with a baseline 
creatinine clearance (CrCl )of 30to 49 mL/min have a higher risk for bleeding . Given that a 
relativel y high number of medicall y ill patients with this lower CrCl will be enrolled, there will 
be a rivaroxaban dose adjustment for this subgroup. In addition, other high bleeding 
risk-subjects , eg,with active cancer or with clinically  significant bleeding during index 
hospitalization, subjects who use 2 or more antipl atelet agents or acety lsalicy lic acid (ASA )
alone at a dose >162 mg/day  or clopidogrel alone at a dose >75mg/day will be excluded . None 
of the proposed measures, ie,dose alteration and exclusion of specific subgroups, is expected to 
reduce the efficacy  of the overall study ,but they areexpected to reduce the risk of major 
bleeding in this population. Furthermore, in the present study , onl y hard efficacy  outcome s 
(eg,symptomatic VTE [lower extremity  DVT and non-fatal PE] events, VTE-related deaths
[death due to PE or death in which PE cannot be ruled out as the cause] ) will be assessed, 
compared with MAGELLaN, EXCLAIM, and ADOPT, where inclusion of asymptomatic 
proximal DVT as part of the primary  efficacy  outcome may have resulted in a less clinicall y 
meaningful evaluation (Section 3.2,Study  Design Rationale ). This Phase 3 clinical study  with 
rivaroxaban is warranted to evaluate extended thrombopro phylaxis up to 45 days after hospital 
discharge in medically  ill subjects. 
The proposed Phase 3 multicenter, prospective, randomized, dou ble-blind, placebo- controlled, 
event -driven study  is designed to evaluate rivaroxaban, compared with placebo, in the prevention 
of symptomatic VTE (lower extremity  DVT and non-fatal PE) events and VTE-related deaths
(death due to PE or death in which PE cannot be ruled out as the cause) for a period of 45 days 
post-hospital discharge in subject s ≥40 years of age who have been hospitalized for a specific 
acute medical illness and who have other risk factors for VTE. Prior to randomization, all 
subject s must have been prescribed thromboprophy laxis with low molecular weight heparin 
(LMWH) or unfractionated heparin (UFH) during the index hospitalization. If the treating 
physician believes that additional post-hospital discharge therapy  with any anticoagulant is 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
22
Status: Approved , 31 March 2017clinically  indicated, the patient will not be eligible for participation in the study . A dose 
adjust ment to 7.5 mg daily will be implemented in high-risk medically  ill subject s with 
CrCl ≥30mL/min and <50 mL/min. The double -blind treatment duration will be 45 days 
followed b y a 30 -day follow -upperiod.
1.1.1. Compound Profile
As part of the prothrombinase complex, FXa directly  converts prothrombin to thrombin. 
Thrombin converts fibrinogen to fibrin and activates platelets leading to clot formation. FXa 
occupies a critical place in the coagulation cascade since it is at the confluence of both the 
intrinsic and extrinsic clotting pathway s, and is the key amplification point for the generation of 
thrombin. One molecule of FXa is able to generate more than 1,000 molecules of thrombin due 
to the amplification nature of the coagulatio n cascade. Selective inhibitors of FXa can terminate 
the amplified burst of thrombin generation and prevent clot formation. 
Rivaroxaban is an oral, direct, FXa inhibitor anticoagulant. Rivaroxaban is rapidly  absorbed after 
oral administration, with peak plasma concentrations occurring approximately  2 to 4 hours post 
dose. The elimination pathway s of rivaroxaban include both hepatic and renal routes. The 
terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy  young subjects and from 
11 to 13 hours in healthy  elderly  subjects (aged 65 to 83 years). Due to the multiple elimination 
pathway s of rivaroxaban, there are few clinicall y relevant drug -drug interactions.
Rivaroxaban has been under development and approved for the treatment of several 
thrombosis -mediated conditions. The clinical development program for rivaroxaban is extensive 
with over 70,000 subjects having been studied and includes data from clinical trials and post-
marketing surveillance.  Rivaroxaban is marketed under trade name XAR ELTO®.
1.1.2. Medically  Ill Patients - Scope of the Problem
Medically  ill patients, ie, patients that are hospitalized for the treatment of acute medical 
illnesses, are at high risk for the development of VTE during their hospital stay and immediate ly
after their hospital stay. The rationale for the use of thromboproph ylaxis is based on solid 
principles and scientific evidence 20. Almost all hospitalized patients have at least one risk factor 
for VTE, and a high proportion have 3 or more risk factors. Without thromboprophylaxis, the 
incidence of objectively -confirmed, hospital -acquired DVT ranges from 10%to 40% among 
medical or general surgical patients and 40% to 60% following major orthopedic surgery . 
Thromboproph ylaxis for the prevention of VTE in hospitalized medically  ill patients is routinely  
prescribed and is recommended by internationally  recognized guidelines20. Medicall y ill patients 
are generally  defined as patients who are acutely  hospitalized for 1of the following diseases, 
including but not limited to, heart failure (HF)with reduced ejection fraction , respiratory  
conditions, acute infectious diseases, neurologic diseases, inflammatory  and hematologic 
diseases, and cancer. Parenteral anticoagulatio n, including enoxaparin and UFH , are 
recommended for thromboprophy laxis in hospitalized medically ill patients, but 
thromboprophy laxis is not recommended after discharge 20.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
23
Status: Approved , 31 March 20171.1.3. Thromboprophylaxis in Patients with Acute Medical Conditions 
Studies of short -term (10 to 12 days) thromboprophy laxis in medicall y ill patients showed a 
benefit for the LMWH enoxaparin administered during hospitalization (MEDENOX study ), for 
the LMWH dalteparin administered for 14 days during and after hospital discharge 
(PREVENT study ), and for the indirect Factor -Xa inhibitor fondaparinux administered during 
hospitalization (ARTEMIS study ) over placebo7,24,34.
A meta -analysis of 4 studies of short -term enoxaparin treatment (treatment phase , 7 to 10 days) 
compared with UFH showed similar lya substantial reduction in VTE for enoxaparin compared 
with UFH in populations of hospitalized medically  ill patients with acute respiratory  disease, 
acute cardiovascular (CV) disease and acute ischemic stroke23. The combined incidence of VTE 
at Day 15 in this meta -analy sis was 2.6% in the enoxaparin group and 5.2% in the UFH group ;
both rates are much lower than in untreated subjects. The combined major bleeding rate at 
Day 15 reported in the studies included in this meta -analysis was 0.65% for the enoxaparin-
treated patients and 0.56% for the UFH -treated patients. Based on the clinical information 
available for acutely  ill hospitalized medical patients at increased risk of thrombosis, the ACCP
recommends anticoagulant thromboprophy laxis for 6-21 days, until full mobility  is restored or 
until discharge from the hospital, whichever comes first20.Guidelines for post-hospital discharge 
specificall y recommend against thromboprophylaxis.
1.1.4. VTE Risk Post Discharge in Patients Hospitalized for Medical 
Conditions
The risk of VTE persists after hospital discharge. More symptomatic VTEs have been diagnosed 
in the first 3 months following hospitalization than during the hospitalization phase36. It has been 
reported that in patie nts hospitalized for medical conditions, the cumulative symptomatic VTE 
incidence from admission to 3 months was 1% and stabilizes around 50 day s (Figure 1)37. In this 
study , the median length of the hospitalization stay was 7 day s.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
24
Status: Approved , 31 March 2017Figu re 1: Kaplan -Meier Curve Showing Cumulative Symptomatic VTE Incidence from Hospital 
Admission to 3 Months of Follow -up 
(n=15,156; n = 143 Patients with symptom atic VTE)
Source: From Spyropoulos et al., 201137
Hull et al. (2013) demonstrated that in high risk patients 80% of the confirmed symptomatic 
VTE events ( ie,DVT, PE) occurred within 57 day s after hospital discharge and a VTE event rate 
of 2.7% was observed at 45 days post discharge18. Patients were classified as having VTE if the 
events were subsequently  confirmed by diagnostic testing. High risk patients were defined as 
>60 years of age and having at least 1of the following risk factors: history  of malignancy , 
respiratory  illness, neurological illness, inflammatory  bowel disease, previous VTE, acute 
infection, or heart failure. Over the 100 day follow -up, 3.8% of the 989 patients had a confirmed 
VTE event ( Figure 2)18. 
Figure 2: Cumulative Number of Events Over Time: Hig h-risk Elderly Medical Patients. 
Source: Hull et al., 201318
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
25
Status: Approved , 31 March 20171.1.5. Studies Examining Extended Thromboprophylaxis in Patients 
Hospitalized for Acute Medical Conditions and MA RINER Approach
While extended- duration (4-week) thromboprophy laxis has been shown to significantly  reduce 
the incidence of VTE compared with a standard (1-week) regimen in high-risk surgical patients, 
extended duration thromboproph ylaxis has not been shown to be of value in patients hospitalized 
for medical conditions. Medical patients represent most hospitalized patients and at least 75% of 
fatal pulmonary  emboli occur in this group5,8,12,16,31.
In the MAGELLaN study , the primary  efficacy  endpoint was a composite of events of: 
1)asymptomatic proximal DVT in a lower extremity  detected by mandatory  bilateral lower 
extremity  venous ultrasonography , 2) sy mptomatic DVT in a lower ex tremity , proximal o r distal, 
3)symptomatic, non-fatal PE, and 4) VTE-related death. VTE-related death was defined as 
either a well-documented fatal PE, or sudden death with no other plausible explanation. The 
study  compare dVTE prophy laxis with oral rivaroxaban 10mg once daily for 35 days with 
enoxaparin 40 mg dailyfor 10days in subjects who were hospitalized for a medical illness. The 
MAGELLaN study  met both of its protocol -specified primary  efficacy  outcomes for rivaroxaban 
versus enoxaparin/placebo at both Day 10 (non-inferiorit y) and Day 35 (superiority ). At Day 35, 
at the end of the rivaroxaban -enoxaparin/placebo phase (treatment phase), rivaroxaban was 
statistically  significantl y superior to enoxaparin in the mITT Day 35 population (two-sided 
p=0.0211). The RR was 0.77 with the 95% confidence interval (CI)ranging from 0.62 to 0.96. 
The incidence rate of the primary  efficacy  composite outcome events at Day  35 was higher in the 
enoxaparin group (5.7% [175/3057]) than in the rivaroxaban group (4.4% [131/2967]) 
(mITTDay 35 population). At Day 10, at the end of the rivaroxaban -enoxaparin phase (active 
control treatment phase), rivaroxaban was demonstrated to be non-inferior to enoxaparin in the 
per protocol (PP)population (statistically  significant with a one-sided p=0.0025). The RR was 
0.97 with a 95% CI ranging from 0.71 to 1.31. The incidence rate of the primary  efficacy  
composite outcome events at Day 10 was identical in both treatment groups in the PP Day 10 
population (rivaroxaban, 2.7% [78/2938]); enoxaparin, 2.7% [82/2993]). However, rivaroxaban 
also increased major bleeding events. 
The CIsand p-values for the weighted relative risks of bleeding events in the 3treatment phases 
were statisticall ysignificant in favor of enoxaparin. By phase, the major bleeding events in the 
rivaroxaban -enoxaparin/placebo phase (Day  1 to Day 35) were reported in 43 (1.1%) vs 
15(0.4%) subjects, in the rivaroxaban -enoxaparin phase (Day  1  to Day 10)in 24 (0.6%) vs 
11(0.3%) subjects, in the rivaroxaban- placebo phase (Day  10 to 35 )in 19 (0.5%) and 4 (< 0.1%) 
subjects in the rivaroxaban and enoxaparin groups, respectivel y. 
The EXCLAIM study  (Extended prophy laxis for VTE in acutel y ill medical patients with 
prolonged immobilization), compared an extended duration (28 day s) enoxapar in with placebo in 
patients recentl y hospitalized for acute medical illnesses who received enoxaparin during their 
initial hospital stay17. The extended -duration enoxaparin treatment was found to reduce the 
incidence of VTE compared with placebo (2.5% vs. 4%; absolute risk difference favoring 
enoxaparin, -1.53% [95.8% CI, -2.54% to -0.52%]). However, enoxaparin also increased major 
bleeding events (0.8% vs. 0.3%; absolute risk difference favoring placebo, 0.51% [95% CI, 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
26
Status: Approved , 31 March 20170.12% to 0.89%]). As such, the benefit -risk balance of VTE thromboprophy laxis was not 
positive for the patients studied and enoxaparin is not approved for extended use in this 
population.
The ADOPT study  (Apixaban versus enoxaparin for thromboproph ylaxis in medically  ill 
patients) compared an extended duration (30 days) of 2.5 mg twice daily  oral apixaban with 
enoxaparin, administered subcutaneousl y at a dose of 40 mg dailyfor 6 to 14 days 15.  Based on 
the results of the primary  efficacy  endpoint (the composite of death related to VTE, PE, 
symptomatic DVT or asy mptomatic proximal -leg DVT at Day 30) extended duration 
thromboprophy laxis with apixaban was not superior to a shorter duration of thromboproph ylaxis 
with enoxaparin (2.71% vs. 3.06%; relative risk [RR] 0.87; 95% CI, 0.62 to 1.23).  Major 
bleeding events during the30 day treatment period occurred in 0.47% of the patients in the 
apixaban group and in 0.19% of the patients in the enoxaparin group (RR2.58; 95% CI, 1.02 to 
7.24). The primary  efficacy  endpoint was not positive in this study  and apixaban is not approved
for this indication. 
The increased bleeding associated with extended duration of therapy  was seen in all 3 studies, 
MAGELLaN, EXCLAIM and ADOPT. Any new clinical study  purporting to evaluate extended 
duration of antithrombotic therap y must address this observed hazard. One potential means to 
diminish the excess bleeding rates would be to identify  those patients with a more positive 
benefit/risk profile. Post-hoc analysis of the MAGELLaN study  indicated that those who 
experienced a bleeding event while hospitalized or patients with active cancer were at higher risk 
of bleeding and are therefore excluded from MARINER. 
The selection of a high VTE- risk population is also important for the demonstration of a positive 
benefit/risk with anticoagulant therapy . Since the completion of the pivotal Phase 3 studies of 
extended thromboprophylaxis in hospitalized medical patients, there has been extensive research 
in the use of clinical VTE-risk assessment models as well as biomarkers in helping to define a 
high VTE- risk group in this patient population .3,10,26,33In this regard, the MARI NER study is 
relying on an evidence- derived, weighted, and scored clinical VTE -risk score, the IMPROVE 
VTE-risk score, alone or in combination with an elevated D-dimer toenroll a sufficiently  high 
VTE-risk cohort when compared to previous studies that would benefit from extended 
thromboprophy laxis. The IMPROVE VTE -risk score has been extensively  validated in 2 large 
external validation studies and a D-dimer >2X the upper limit of normal ( ULN )was shown to be 
a powerful predictor of VTE in the general patie nt popu lation of the MAGELLaN study  as well 
as the subgroup with CHF .11, 31, 25,26
As MARINER will be assessing only symptomatic events it will be critical to study conduct to 
ensure all efficacy  events are appropriatel y captured. Pulmonary  embolism (PE) has been 
reported as the most common missed or delay ed diagnosis by  physicians.35,41Misdiagnosis of PE 
has been shown in the literature to occur in up to 50% of patients with PE.2Reports show that PE 
can be misdiagnosed as pneumonia, bronchitis, heart failure, cardiorespiratory  failure, 
exacerbation of chronic obstructive pulmonary  disease (COPD) and other diagnoses .2,32,12A 
meta -analysis of the prevalence of PE in acute exacerbations of COPD concluded that 25% of 
COPD patients who require hospitalization for acute exacerbation and 9% of patients 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
27
Status: Approved , 31 March 2017hospitalized with severely decompensated heart failure may have a PE.32, 12Both study  staff and 
subjects will be educated on signs and s ymptoms associated with PE .
1.2. Overall Rationale for the Study
The primary  objective is to assess the efficacy  and safety  of rivaroxaban, compared with placebo
in the prevention of s ymptomatic VTE (lower extremity  DVT and non- fatal PE) and VTE -related
death (death due to PE or death in which PE cannot be ruled out as the cause) post-hospital 
discharge in high-risk medically  ill subject s.   
Three extended duration studies with enoxaparin (EXCLAIM), apixaban (ADOPT) and 
rivaroxaban (MAGELLaN ) failed to demonstrate a positive benefit/risk profile for extended -
duration thromboprophylaxis in patients hospitalized for medical conditions primarily  due to 
excessive bleeding with the anticoagulants10,15,17. 
Therefore, the proposed MARI NER study  was designed to improve the overall safet y of 
medically  ill patients with rivaroxaban (10 mg daily in subjects with CrCl ≥50 mL/min or 7.5mg 
daily in subjec ts with CrCl of ≥30to <50mL/min) treatment for 45 days post-hospital discharge 
by addressing the bleeding risk observed in the MAGELLaN study  while also enrolling a higher 
VTE-risk population to enhance the overall expected benefit/risk assessm ent. The proposed 
study  is a multicenter, prospective, randomized, double -blind, event -driven, placebo- controlled 
study  in subject s who are hospitalized for a specific acute medical illness and have other risk 
factors for VTE.  In the proposed study , a specific population of medically  ill patients at high 
risk who could benefit most from extended thromboprophy laxis has been identified.
The MARINER study is designed asa pivotal Phase 3 study , to determine if the use of the FXa 
inhibitor rivaroxaban can prevent symptomatic VTE (lower extremity  DVT and non-fatal PE)
and VTE-related death post-hospital di scharge in high-risk, medically  ill patients.
2. OBJECTIVES A ND HYPOT HESES
2.1. Objectives
Primary Objective
The primary  objective is to assess the efficacy  and safet y of rivaroxaban, compared with
placebo in the prevention of sy mptomatic VTE (lower extremity  DVT and non -fatal PE) and 
VTE-related death (death due to PE or death in which PE cannot be ruled out as the cause) 
post-hospital di scharge in high- risk, medically  ill patients .
Secondary Objectives
The secondary  objectives are to compare rivaroxaban with placebo in the following post-hospital 
discharge outcomes in high- risk, medicall y ill patients:
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
28
Status: Approved , 31 March 2017VTE- relate ddeath (death due to PE or death in which PE cannot be ruled out as the cause)
Symptomatic VTE ( lower ex tremity  DVT and non-fatal PE)
The composite of symptomatic VTE (lower extremity  DVT and non-fatal PE) and all-cause 
mortality  (ACM )
The composite of symptomatic VTE (lower extremity  DVT and non-fatal PE), MI, 
non-hemorrhagic stroke and CV death (death due to a known CV cause and death in which a 
CV cause cannot be ruled out; by this definition, a VTE-related death is considered a 
CVdeath)
ACM
Explorat ory Objectives
The exploratory  objectives are to compare rivaroxaban with placebo, in the following  
post-hospital di scharge outcomes in high- risk, medically  ill patients:
Symptomatic lower ex tremity  DVT
Symptomatic non-fatal PE
Symptomatic upper extremity DVT
MI
Non-hemorrhagic stroke
Re-hospitalization for symptomatic VTE (lower extremity  DVT and non-fatal PE) within 
30daysafter randomization
Pharmacokinetic Objective
The pharmacokinetic objective (PK) is to assess the kinetics of rivaroxaban in high-risk, 
medically  ill patients, and to describe drug exposure based on CrCl . 
Medical Resource U tilization and Health Economics Objective   
The medical resource utilization and health economics objective is toassess the following cost 
drivers, ie ,re-hospitalization (including ER visits, intensive care unit and cardiac care unit stay s), 
length of stay  and subject discharge destination (after re -hospitalization).
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
29
Status: Approved , 31 March 2017Safety Objectives
The safet y objectives are to compare rivaroxaban with placebo in the following bleeding 
outcomes in high -risk, medicall y ill patients:
Major bleeding using validated International Society  on Thrombosis and Haemostasis 
(ISTH)bleeding criteria.
Non-major clinicall y relevant bleeding
Other bleeding
Overall safet y will also be assessed.
2.2. Hypothese s
The primary  hypothesis is that rivaroxaban is superior to placebo in the prevention of the 
composite of symptomatic VTE (lower extremity  DVT and non -fatal PE) and VTE-related death
(death due to PE or death in which PE cannot be ruled out as the cause) . The secondar y 
hypotheses are that rivaroxaban is superior to placebo in the prevention of 1) VTE -related death
(death due to PE or death in which PE cannot be ruled out as the cause) , 2) symptomatic VTE 
(lower extremity  DVT and non-fatal PE), 3) the composite of symptomatic VTE (lower 
extremity  DVT and non-fatal PE) and ACM , 4) the composite of symptomatic VTE (lower 
extremity  DVT and non-fatal PE), MI, non -hemorrhagic stroke and CV death (death due toa 
known CV cause and death in which a CV cause cannot be ruled out; by this definition, a 
VTE-related death is considered a CV death)  and 5) ACM alone.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a multicenter, prospective, randomized, double -blind, placebo -controlled, event -driven 
study  designed to evaluate rivaroxaban, compared with placebo, in the prevention of 
symptomatic VTE (lower extremity  DVT and non-fatal PE) events and VTE-related deaths 
(death due to PE or death inwhich PE cannot be ruled out as the cause) for a period of 45 days 
post-hospital discharge. The study  consists of a screening phase, a 45 -day double -blind treatment 
phase, and a 30 -day safety  follow -up period. 
The subject population comprises men and wom en age 40 years and older who have completed 
screening no later than 1 day after leaving the hospital and who have been hospitalized for the 
new onset or exacerbation of 1 of the following medical conditions: 
Heart Failure (HF) with a reduced left ventric ular ejection fraction (LVEF ≤45%)
Acute respiratory  insufficiency  or acute exacerbation of COPD
Acute ischemic stroke (including spinal cord infarction if no evidence of intramedullary , 
subdural or epidural hemorrhage) 
Acute infectious disease
Inflamma tory disease, including rheumatic disease
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
30
Status: Approved , 31 March 2017The index hospitalization must be at least 3 and no more than 10 consecutive day s in duration. In 
order to be eligible, subjects must have an increased VTE risk, as demonstrated by a  total 
modified International Medical Prevention Registry  on Venous Thromboembolism (IMPROVE) 
VTE Risk Score of :
≥ 4, or 
3 with D -dimer > 2XULN, or
2 with D -dimer > 2XULN  
In addition, subjects must have received treatment during the index hospitalization with LMWH 
or UFH.
Any patient with a medical condition that will require use of any parenteral or oral 
anticoagu lation (eg, atrial fibrillation ) during the study  is not eligible for participation. In 
addition, patients at particular lyincreased risk of bleeding and those using medications that 
might interact with the study drug will be excluded. 
Subjects who meet all of the inclusion and none of the exclusion criteria will be randoml y 
assigned to receive rivaroxaban or placebo. Randomization should occur on the same day asor 
the day after the subject leaves the hospita l,and may occur at the hospital, clinic or other 
discharge destination. Subjects will be randomized by strata including creatinine clearance and 
country .
After randomization, subjects will receive double -blind treatment with rivaroxaban 10 mg 
(7.5mg for subjects with a CrCl ≥30 mL /min and <50 mL/min) daily  or matching placebo daily . 
Placebo has been chosen as the comparator because of current guidelines w hich recommend 
against thromboproph ylaxis in medically  ill patients after hospital discharge.  The first dose of 
study  drug should be administered no later than the day after the subject leaves the hospital and 
as soon after randomization as possible. Subjects will be instructed to discontinue study  drug 
after they take a dose on Day 45, and complete an end of treatment visit within the next 4 days. 
Regardless of the day on which the Day 45 Visit occurs, no study drug may be taken after 
Day 45. The subject must be assessed 30days later for safet y follow -up.  This will be the last 
contact with the subject unless extended follow up for safety is required.  
If a subject has a suspected efficacy  or bleeding outcome event during the study , the treating 
physician should exercise clinical judgment and follow established guidelines to apply  the 
standard of care. Unblinding of study  drug should not be necessary . Anticoagulation regimens 
do not require adjustment regardless of treatment group assigned when study  drug is placebo vs 
rivaroxaban when administered in the doses used in this study .  There is no specific reversal 
agent for rivaroxaban; management of the subject with a bleeding event should not be impacted 
by knowledge of study  drug treatment.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
31
Status: Approved , 31 March 2017Rivaroxaban will not be provided to subjects after they  complete study  treatment unless required 
by local regulations. Randomization in this study is preceded by a hospitalization for an acute 
illness and the study  drug treatment phase extends for 45 day s after randomization to correspond 
to the period of greatest risk for VTE.   Chronic therap y with the stu dy drug is not being tested. It 
will only be after data from the entire study  is analy zed that it will be determined if the 
population at risk will benefit from treatment.
The primary  efficacy  outcome is the composite of all symptomatic VTE events (lower extremity  
DVT and non-fatal PE) and VTE-related death (death due to PE or death in which PE cannot be 
ruled out as the cause) , from randomization up to Day 45. The targeted total number of primary 
efficacy  outcomes in this event -driven study  is 161. It is estimated that a total of approximately 
8,000 subjects will need to be randomized to either rivaroxaban or placebo in a 1:1 ratio. In the 
event that the actual observed blinded pooled event rate is lower than the assumed rate, more 
subjects may be enrolled to accumulate additional outcome events. Randomization in this study  
may be stopped at approximately  12,000 subjects for administrative considerations even if the 
targeted 161 events have not been observed by then. An interim analysis for futility  will be 
conducted when approximately  50% of subjects with adjudicated primary  efficacy  outcome 
events have been observed (about 50% of the expected total number of events based on the 
actual observed blinded pooled event rate even if this event rate is lower than the assumed rate) .
The principal safet y outcome for this study is ISTH major bleeding.
For population PK analy ses, based on the model performance and thehigh variability  of the 
PKparameters observed in the MAGELLaN study , 2 blood samples (atpre-dose and1-4 hours 
after study  drug administration) will be collected at the Day 7 visit  and 2 blood samples (at3 to 
7 and 7 to 12 hours after study  drug adm inistration) will be collected at the Day  21 visit  for each 
subject for up to 600 subjects (300 rivaroxaban subjects [200 subjects in the 10 mg daily group 
and 100 subjects in the 7.5 mg daily  group] and 300 in the placebo group). The sparse blood 
samples for PK anal yses will be collected in selected sites only .
An Executive Committee (EC), an Independent Data Monitoring Committee (IDMC) and a 
Clinical Event Committee (CEC) will be commissioned for this study . All committees will be 
governed b y separate ch arters, see Section 3.3.
A diagram of the stud y design is provided below in Figure 3:
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
32
Status: Approved , 31 March 2017Figure 3: Schematic Overview of the Study (RIVAROXDVT3002) 
Note: Subjects will be randomized by strata including creatinine clearance and country .  
3.2. Study Design Rationale
Study Population 
Medically  ill patients, ie, patients who have been hospitalized for the treatment of acute medical 
illnesses, are at high risk for the development of VTE during their hospital stay and immediate ly
after hospital discharge . These are important clinical events that profoundly  impact medicall y ill 
patients, and constitute a large burden in terms of health care provision. High -risk medicall y ill 
subjects have been chosen for this study  because post-hospital discharge thromboprophy laxis is a 
useful therapeutic approach to reduce the risk of increased VTE events, morbidity  and mortality 
in these patients and would meet an unmet medical need. The pharmacology , mechanism of 
action, and previous clinical studies of rivaroxaban suggest thatrivaroxaban will reduce the risk 
of VTE events and VTE- related death (death due to PE or death in which PE cannot be ruled out 
as the cause) . The timing of enrollment, randomization and treatment phase for these subjects has 
been chosen because there is ahigh rate of VTEs and VTE -related mortal ity during this 
post-hospitalization phase , particularly  during the first 2 months after discharge18,37. Compared 
with previous studies, there are several differences in the choice ofstudy populations to reduce 
the bleeding risk (Section 1.1).
Blinding Control Study Phase/Periods Treatment Groups
This randomized, double -blind, placebo -controlled, parallel- group, multicenter, event -driven 
design, is a scientificall y rigorous approach for evaluating the efficacy  and safet y of rivaroxaban 
in high-risk, medically  ill patients and meets the registration requirements for a superiorit ystudy . 
Randomization and stratification will be used to minimize bias in the assignment of subjects to 
treatment groups, to increase the likelihood that known and unknown subject attributes 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
33
Status: Approved , 31 March 2017(eg, demographic and baseline characteristics) are evenl y balanc ed across treatment groups, and 
to enhance the validity of statistical comparisons across treatment groups. Subject s will be 
randomized by strata (by subjects with CrCl ≥30 mL/min and <50 mL/min versus subjects with 
CrCl ≥50mL/min, and by country ). Double-b linded treatment will be implemented to reduce 
potential bias during data collection and evaluation of clinical outcomes. 
There has been no well-controlled study  to date that demonstrates any anticoagulant with a 
favorable benefit/risk profile (reduction of symptomatic VTE events and VTE-related mortality 
vs increase in major bleeding) in post -discharge high -risk medically  ill patients.  
Comparator Selection
The control group in the MARI NER study  will receive placebo, a decision that was made based 
on careful consideration of the literature and existing guidelines for the standard of care practice.
Medically  ill patients are at risk for the development of VTE both when hospitalized and 
immediately  after their hospital discharge. These 2periods of risk have been studied, are 
reported in the literature, and the ACCP has published thromboprophy laxis guidelines. 
Guidelines have been published for the inpatient period, and also for the post-hospital discharge 
period.  
For inpatients, the ACCP recommends:
“For acutel y ill hospitalized medical patients at increased risk of thrombosis, we 
recommend anticoagulant thromboprophy laxis with LMWH, low-dose unfractionated 
heparin (LDUH) bid, LDUH tid, or fondaparinux (Grade 1B) .” 
For post -hospital discharge, the ACCP recommends (emphasis added):
“In acutely  ill hospitalized medical patients who receive an initial course of 
thromboprophy laxis, we suggest against extending the duration of thromboprophylaxis
beyond the period of patient immobilization or acute hospital stay.”
The ACCP Evidence -Based Clinical Practice Guidelines further recommend that during 
hospitalization, anticoagulant thromboprophy laxis for acutel y ill hospitalized medical patients 
with increased risk of thrombosis should be administ ered for 6 to 21 days (an evidence- based 
duration derived from the range of the durations of therapies studied and reported in the 
literature). However, if full mobility  is restored while hospitalized or the patient is discharged 
from the hospital, the recommendation is that thromboprophy laxis be discontinued. As such, the 
guidelines recommend that patients not receive thromboprophy laxis after discharge.  
As described in Section 1.1.5 , 3studies have been conducted testing an extended period of 
thromboprophy laxis. For each of these studies, a post -hospital discharge placebo comparator was 
used, and none provided evidence of a benefit/ri sk balance better than placebo. The MARINER 
study  will enroll a population at greater risk of VTE and lower risk of bleeding than previously 
studied, and will use the placebo comparator as the standard of care, as recommended by the 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
34
Status: Approved , 31 March 2017ACCP. Given the ACCP guidelines, the duration of thromboprophy laxis in these patients is 
usually  determined by the duration of hospitalization, asit is unusual for patients to receive 
throm boprophy laxis after discharge. In fact, in the MARI NER study , patients for whom 
thromboprophy laxis is p rescribed after discharge are specificall y excluded .
Based on the above, placebo has been chosen as the appropriate comparator to allow for the 
evaluation of benefit/risk of rivaroxaban as thromboprophy lactic agent in post-hospital discharge 
high-risk, med ically  ill patients.
Any patient with a medical condition that will require chronic use of any parenteral or oral 
anticoagulation (eg, atrial fibrillation ) during the study  is not eligible for participation. During 
the study , should the subject develop anycondition, which in the investigator’s judgment 
requires long-term anticoagulation ,thromboprophy laxis, or fibrinoly sis, the subject will have 
study  treatment either temporarily  interrupted or permanentl y discontinued and will be managed 
as deemed appropr iate by the treating physician. The subject will be asked to continue in the 
study  to be followed for efficacy  and safet y outcomes. 
Dose Selection
The selection of a dose of 10 mg dailyof rivaroxaban is based primaril y on the results of the 
studies conducted for prophy laxis of VTEs in patients undergoing knee or hip replacement 
surgery , where 10 mg daily of rivaroxaban resulted in benefit with an acceptable risk profile .
Subjects with CrCl ≥50 mL /min will be randomly  assigned to receive rivaroxaban 10 mg dail yor 
placebo. In order to reduce the risk of bleeding in subjec ts with a baseline CrCl ≥30mL/min and
<50mL/min (estimated to be approximately  20% of study  population) , a dose adjustment of 
rivaroxaban from 10 mg daily to 7.5 mg dail y will be implemented (Section 3.1)
In the ROCKET AF study , a 25% dose reduction of rivaroxaban (15 mg daily ) was implemented 
in subjects with CrCl 30 to49 mL/min (approximately  20% of the study  population), which 
provided comparable exposure, efficacy  and safet y to that of rivaroxaban 20 mg daily
administered to subject s with CrCl ≥50 mL/min29. Since the age and comorbidities of the 
subjects in the proposed MARINER study  are similar to the population studied in the 
ROCKET AF study  and based on the population PK simulations of a virtual medicall y ill 
population, a similar 25% dose reduction of rivaroxaban (from 10 mg to 7.5 mg daily ) in the 
subjects with CrCl ≥30 mL/min and <50 mL/min isa reasonable strategy. This rivaroxaban dose 
reduction in medicall y ill subjects with CrCl ≥30 mL/min and <50 mL/min is predicted to yield 
similar rivaroxaban plasma exposures to those in subjects with CrCl ≥50 mL/min at a 10 mg 
dose. Based on the achievement of similar plasma exposures, comparable efficacy  and safety 
would be expected in these 2 population subgr oups.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
35
Status: Approved , 31 March 2017Choice of Efficacy Measure
The choice of the primary  efficacy  outcome is based on prior rivaroxaban trials for primary  and 
secondary  prevention of VTE events (such as DVT, PE) and VTE- related deaths. In addition, 
these outcomes are considered accepta ble and verifiable for the evaluation of prevention of VTE 
events in medicall y ill patients10,15,18. 
Asymptomatic proximal DVT, as detected on compression ultrasonography, was i ncluded as part 
of the primary  efficacy  outcome in the 3 extended -duration studies (EXCL AIM, ADOPT and 
MAGELLaN). Compression ultrasonograph y is not performed routinel y in medical patients and 
the use of this test might influence the symptomatic VTE component of the primary  efficacy  
composite outcomes15.Specifically , the performance of compression ultrasound during 
double -blind treatment likely  influencesthe subsequent natural history  of the disease by 
prompting investigators to treat asymptomati c clots. Therefore, without asymptomatic clot 
detection there will be a higher symptomatic event rate and assessment of only symptomatic 
events may provide amore clinically  meaningful evaluation of a therapeutic intervention. Thus, 
in the present study  only  hard efficacy  outcome s (symptomatic VTE events, VTE-related deaths, 
etc.) will be measured.
Choice of Safety Measures
The principal safet y outcome is major bleeding using validated ISTH bleeding criteria.
In addition, data willbe collected to ascertain non-major clinicall y relevant bleeding , defined as 
overt bleeding not meeting the criteria for major bleeding, but associated with medical 
intervention , unscheduled contact (visit or telephone call) with a physician, (temporary ) 
cessation of study  treatment, or associated with discomfort for the subject such as pain or 
impairment of activities of daily  life, and other bleeding , defined as any  other overt bleeding that 
doesnot meet the ISTH criteria for major or non -major clinically  relevant bleeding (Section 9.5).
All serious adverse events except the study  outcomes (VTE -related death, MI, acute coronary  
syndrome [ACS], stroke, transient ischemic attack [TIA], symptomatic VTE [lower or upper 
extremity  DVT and PE], bleeding events) will be collected. Refer to Section 12.3.1 , All Adverse 
Events for more details.
Interim Analysis
The primary  reason for the prespecified interim analy sisis to assess for futility .   
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
36
Status: Approved , 31 March 2017Pharmacokinetics Analys is
The PK anal ysis will be done:
To predict the overall exposure of rivaroxaban and estimate the PK model parameters for 
medically  ill patients.
To describe the effect of dosing modification on exposure for subjects with 
CrCl ≥30mL/min and <50mL/min.
Medical Resource Utilization and Health Economics
The medical resource utilization and health economics will assess cost drivers and details on 
medical resource utilization and health economics can be found in Section 9.4.
3.3. Committees
3.3.1. Executive Committee
The EC consists of members of the academic leadership of the study  and 1 member from the 
sponsor. Ad hoc members may be appointed as necessary . The EC has overall responsibility  for 
the design, conduct and reporting of the study . The EC will monitor overall safet y during the 
study  and will receive any recommendations from the IDMC regarding possible additional 
analyses or modifications to the study  and decide whether to accept them. The EC will oversee 
the implementation of any  modifications to the study  and publication of the results.
3.3.2. Independent Data Monitoring Committee
An IDMC will be established to monitor the progress of the study  and ensure that the safet y of 
subjects enrolled in the study  is not compromised. The IDMC will include, but is not limited to, a 
clinical chairman, physician(s) experienced in clinical trials, but not participating in this study , 
and at least 1statistician. Details of the composition, roles, responsibilities, and processes of the 
IDMC will be documented in its charter. The IDMC will review results of the planned interim 
analysis and make a recommendation whether the study  should be continued as planned, 
modified, or term inated prematurel y due to futility or safet y (Section 11.7).
3.3.3. Clinical E ventsCommittee
The Clinical Events Committee (CEC) is comprised of board -eligible or board -certified 
specialist physicians as appropriate and necessary . Committee members donot directl y enroll 
subjects in the study , arenot involved in the MARINER study  monitoring, anddo not have direct 
operational responsibilities for the conduct of the study. Members will review all suspected 
outcome events as described below that occur redpost-randomization as they become available 
and adjudicate and classify in a consistent and unbiased manner according to definitions in the 
CEC charter while blinded to treatment assignment:
Death 
Symptomatic DVT
Symptomatic non-fatal PE
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
37
Status: Approved , 31 March 2017Non-fatal MI
Non-fatal stroke
Bleeding
4. SUBJECT POPULA TION
Screening may begin any time after the admission for the index hospitalization, and once the 
informed consent is obtained. If a subject’s status changes (including laboratory  results or receipt 
of additional medical records) after screening but before randomization such that he or she no 
longer meets all eligibilit y criteria, then the subject should not be randomized.
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
inves tigator should consult with the appropriate sponsor representative before enrolling a subject 
in the study . Waivers for study  participation will not be granted.
For Sections 4.1, Inclusion Criteria, 4.2,Exclusion Criteria, and 4.3,Prohibitions and 
Restrictions, numbered criteria in brackets are for data collection purposes and are intentionally  
non-sequential (for complete amendment history , see Attac hment 6). 
4.1. Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study . 
[1.2]  
a.Subject must bea man or woman, ≥40 years of age .
b.The duration of the index hospitalization must have been at least 3 and no more than 
10consecutive days. 
The index hospitalization is defined as ahospitalization that ended on the day of or 
the day before randomization and is a continuous period of time at an acute care 
facility (including hospital, observation unit, ER and/or transferring facility; 
collectively referred to as "hospital"). The first day that the subject spends any part of 
the day in the hospital will be counted when determining the durat ion of the index 
hospitalization, but the day the patient leaves the hospital will not be counted.
c.The reason for the index hospitalization must have been a new diagnosis or 
exacerbation of 1of the following medical conditions:
Heart Failure (HF) 
Subject must have a documented LVEF ≤45% within 1 year before 
randomization or during the index hospitalization. The ejection fraction may 
be determined by one of the following methods: echocardiogram, nuclear 
multi- gated acquisition (MUGA) scan, cardiac magnetic resonance imaging 
(MRI), cardiac computed tomograph y (CT)scan, or left ventriculograph y). If 
more than 1 value for LVEF is available, the most recent one should be used.
Acute respiratory  insufficiency  or acute exacerbation of COPD
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
38
Status: Approved , 31 March 2017Acute ischemic stroke (including spinal cord infarction if no evidence of 
intramedullary , subdural or epidural hemorrhage)
If the subject received fibrinolysis as part of the initial treatment for stroke, 
fibrinolysis must have been administered at least 3 full days before the 
subject is randomized. These subjects must have had a CT/MRI  scan at 
presentation and a repeat scan performed at least 24 hours after 
administration of fibrinoly sis that documents the absence of hemorrhage. 
Subjects with hemorrhagic transformation of an ischemic infarct prior to 
randomization are not excluded unless there is evidence of parench ymal 
hemorrhage (types PH-1 and PH-2). All planned diagnostic tests for stroke 
evaluation must be completed before randomization. Brain imaging and 
24-hour cardiac monitoring must have been repeated if new symptoms of 
stroke/TIA occurred after the initial stroke evaluation, as does 24-hour 
cardiac monitoring if symptoms suggestive of AF occur.  
Acute infectious disease
Inflammatory  disease , including rheumatic disease
[2.2]The subject must be at increased risk for VTE by thetotal modified IMPROVE 
VTE Risk Score (Table 1; modified from Spyropoulos37)assessed at screening and 
verified at randomization .
a. If the total modified IMPROVE VTE Risk Score is ≥4, the subject meets this 
inclusion criterion.
b. If the total modified IMPROVE VTE Risk Score is 2 or 3, a D-dimer >2X ULN must 
have been obtained after the beginning of the index hospitalization and before 
randomization 
Table 1: Modified IMPROVE VTE Risk Score
VTE Risk Factor VTE Risk Score
Previous VTE 3
Known t hrombophiliaa2
Current l ower limb paralysis or paresisb2
History of cancerc2
ICU/CCU stay 1
Complete immobilizationd≥1 day 1
Age ≥60 years 1
CCU= cardiac care unit; ICU= intensive care unit; VTE= venous 
thromboembolism.
a: A congenital or acquired condition leading to excess risk of thrombosis 
(eg, factor V Leiden, lupus anticoagulant, factor C or factor S deficiency) .
b: Leg falls to bed by 5 seconds, but has some effort against gravity (taken 
from NIH stroke scale28).  
c: Cancer (excluding non -melanoma skin cancer) present at any time in the 
last 5 years (cancer must be in remission to meet eligibility criteria)
d:Immobilization is being confined to bed or chair w ith or without bath -
room  privileges.
[3.1]Life expectancy  of at least 3 months.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
39
Status: Approved , 31 March 2017[4.3]Prescribed thromboprophy laxis (according to ACCP guidelines)20with UFH or 
LMWH (eg, dalteparin and enoxaparin) not exceeding 15,000 U on any given day for 
UFH and not exceeding 5,000 U on an y given day for LMWH.
Table 2below provides the minimum number of doses of thromboprophylaxis required by 
index hospitalization duration. For ischemic stroke with thromboly sis, do not use the index 
hospital dur ation to determine the number of doses required. Instead ,use the number of day s 
the patient was in the hospital after the first day the patient was prescribed 
thromboprophy laxis.
Table 2: Minim um Number of Heparin Doses Required for 
Study Eligibility by Duration of Index Hospitalization
Index Hospitalization 
Duration (days)LMWH doses 
requiredUFH doses 
required
3 2 3
4 2 4
5 3 6
6 4 7
7 4 8
8 5 10
9 6 11
10 6 12
LMWH= low molecular weight heparin, UFH= unfractionated heparin .
Note: In the event that both LMWH and UFH are used during the index 
hospitalization, the number of doses of LMWH received should be 
doubled and added to the number of UFH doses received, and the UFH 
doses required column should be used to determin e whether the 
requirement was met.
[6.1]Each subject must sign an informed consent form (ICF) indicating that he or she 
understands the purpose of and procedures required for the study  and is willing to 
participate in the stud y.  
Note: Numbered criteria in brackets are for data collection purposes and are intentionall y 
non-sequential.
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study . 
Bleeding Risk -Related Criteria
[1.1]Any bleeding (defined as bleeding requiring hospitalization, transfusion, surgical 
intervention, invasive procedures, occurring in a critical anatomical site, or causing 
disability ) within 3 months prior to randomization or occurring during index 
hospitalization .
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
40
Status: Approved , 31 March 2017[2.3]Major surgery , biopsy  of a parench ymal organ, ophthalmic surgery (excluding 
cataract surgery ), or serious trauma (including head trauma) within 4 weeks before 
randomization.
Investigator discretion should be applied, but the following guidance may be considered 
for the purpose of this study.
Major surgery often involves opening 1 of the major body cavities the abdomen, the 
chest, or the skull and can stress vital organs. Major surgery usually is done using 
general anesthesia in a hospital operating room by a surgeon(s) and usually requires a 
stay of at least 1 night in the hospital after surgery.
In contrast, with minor surgery , major body cavities are not opened. Minor surgery can 
involve the use of local, regional, or general anesthesia and may be done in an 
emergency department, an ambulatory surgical center, or a doctor's office. Vital organs 
usually are not stressed, and surgery can be done by a single doctor, who may or may 
not be a surgeon. Usually, the person can return home on the same day that minor 
surgery is done.
Investigator discretion should be applied, but fracture or concussion would be 
considered serious head trauma , while external trauma without fracture or concussion 
could be considered for inclusion.
[3.3]Any planned major surgery  (see exclusion criterion #2.3) or major invasive 
diagno stic procedure intended during the duration of the trial .  
[4.1] Subjects with any  known coagulopathy or bleeding diathesis, or an INR >1.5 during 
the index hospitalization without a subsequent value (the last value before randomization) 
that is ≤ 1.5. 
[5.2]A history  of hemorrhagic stroke or any  intracranial bleeding at any  time in the past, 
evidence of primary  intracranial hemorrhage on CTor magnetic resonance imaging scan 
of the brain, or clinical presentation consistent with intracranial hemorrhage . This applies 
as well to subject s hospitalized for ischemic stroke upon randomization.
Subjects with hemorrhagic transformation of an ischemic infarct prior to randomization 
are not excluded unless there is evidence of parenchy mal hemorrhage (types PH-1 and 
PH-2):
Hemorrhagic infarction type 1 (HI -1) is defined as small pet echiae along the margins of 
the infarct, and HI type 2 (HI-2) is defined as more confluent petechiae within the 
infarcted area but without space -occupying effect. PH type 1 (PH-1) is defined as 
hematoma in ≤30% of the infarcted area with some slight space -occupying effect; 
PHtype 2 (PH-2) is defined as dense hematoma >30% of the infarcted area with 
substantial space -occupying effect or as any hemorrhagic lesion outside the infarcted 
area ( Berger, 20012).
Hemorrhagic infarction type 1 and HI -2 subjects are NOT excluded from thisstudy, but 
PH-1 and PH -2 subjects ARE excluded from this study. 
[7.1]Subject has a history  of or current intracranial neoplasm (benign or malignant) , 
cerebral metastases, arteriovenous (AV) malformation, or aneury sm.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
41
Status: Approved , 31 March 2017[8]Active gastro duodenal ulcer ,defined as diagnosed within 3 months or currently 
symptomatic or known AV malformations of the gastrointestinal tract.
[9.1]Screening platelet count < 75 x 109cells/L.
Concomitant Conditions or Diseases
[10.2] Active cancer (excluding non-melanoma skin cancer) defined as cancer not in 
remission or requiring active chemotherap y or adjunctive therapies such as 
immunotherapy or radiotherap y. Chronic hormonal therap y (eg, tamoxifen, anastrazole , 
leuprolide acetate) forcancer in remission is allowed.
[11.1] Any medical condition (eg, atrial fibrillation) that requires use of any parenteral or 
oral anticoagulant(s) (eg, warfarin sodium or vitamin K antagonists, Factor II or Xa 
inhibitors, fibrinoly tics) concomitantly  with study medication.
[12.1] Bilateral andunilateral above -knee lower ex tremity  amputation .
[13] Subject has known allergies, hy persensitivity , or intolerance to rivaroxaban or an y of 
its excipients .
[14.1] Severe renal insufficiency  (baseline CrCl <30 mL/min calculated using the 
Cockcroft -Gault 6formula provided in Section 9.1.2 ).
[15.1] Known significant liver disease (eg, acute hepatitis, chronic active hepatitis, 
cirrhosis) which is associated with coagulopathy  or moderate or severe hepatic 
impairment.
[16] Known HIV infection .
[17] Sustained uncontrolled systolic blood pressure (BP)of ≥180 mmHg or diastolic BP 
of ≥100 mmHg at randomization despite treatment.
[18.1 ]Current drug or alcohol abuse , based on investigator’s assessment.
[19.1]Cardiogenic or septic shock with the need for vasopressor(s) or devices for blood 
pressure support during index hospitalization .
[20] Presence of inferior vena caval filter
[21] Severe bronchiectasis or cavitary  tuberculosis orany other pulmonary  condition 
(eg,vasculitis) at risk for major hemopty sis 
Drugs or Procedures 
[22.2]
a.Combined P-gp and strong CYP3A4 inhibitors (such as but not limited to 
ketoconazole, telithromy cin or protease inhibitors) use within 4 days before 
randomization, or planned use during the study . Itraconazole use is prohibite d within 
7days before randomization and during the study .
b.Combined P-gp and strong CYP3A4 inducers (such as but not limited to 
rifampin/rifampicin, rifabutin, rifapentine, phen ytoin, phenobarbital, carbamazepine, 
or St. John's Wort) use within 2 weeks before randomization, or planned use during 
the study . 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
42
Status: Approved , 31 March 2017[23.2 ]Received fibrinoly sis during index hospitalization , unless received for ischemic 
stroke at least 3 full day s before randomization.
[24.2 ]Use of antiplatelet therapy  during the index hospitalization, including:
a.ASA >162 mg/day  
b. Clopidogrel >75 mg/day or ticlopidine >250 mg twice dail y
c. Clopidogrel at an y dose in combination with omep razole or esomeprazole
d. Dipy ridamole >400 mg /day
e. Cilostazol >200 mg/day
f. Dual therapy  with 2 or more antiplatelet agents (dipy ridamole with ASA is permitted) 
g. Other G protein -coupled purinergic receptor P2Y (P2Y12) antagonists (eg, prasugrel ,
ticagrelor )
h. Thr ombin -receptor antagonists (eg , vorapaxar)
[25.1]Childbearing potential without proper contraceptive measures, pregnancy  or breast 
feeding .
a. Before randomization, a woman must be either:
 Not of childbearing potential: premenarchal; postmenopausal (>45 years 
of age with amenorrhea for at least 12 months or any age with amenorrhea forat 
least 6 months and a serum follicle stimulating hormone (FSH) level >40IU/L]); 
permanentl y sterilized (eg, tubal occlusion, hysterectom y, bilateral 
salpingectomy); or otherwise be incapable of pregnancy ,
 Of childbearing potential and practicing a highly effective method of birth 
control consistent with local regulations regarding the use of birth control 
methods for subjects participating in clinical studies: eg, established use of oral, 
injected or implanted hormonal methods of contraception; placemen t of an 
intrauterine device or intrauterine system; barrier methods: condom with 
spermicidal foam/gel/film/cream/suppository  or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository ; male 
partner sterilization (the vasectomized partner should be the sole partner for that 
subject); true abstinence (when this is in line with the preferred and usual lifesty le 
of the subject). 
Note: If the childbearing potential changes after start of the study  (eg, woman 
who is not heterosexually  active becomes active, premenarchal woman 
experiences menarche) a woman must begin a highl y effective method of birth 
control, as described above. The initiation of hormonal contraception for the 
purpose of the stud y is not recommended.
A wo man of childbearing potential must have a negative serum (β human 
chorionic gonadotropin [β hCG]) or urine pregnancy test at screening.  
b.A man who is sexually active with a woman of childbearing potential and has not had a 
vasectom y must agree to use adouble -barrier method of birth control eg, either 
condom with spermicidal foam/gel/film/cream/suppository  or partner with occlusive 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
43
Status: Approved , 31 March 2017cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository , and all men must also not donate sperm during the 
study , from the time of the first dose to the last dose of study  drug.
[26] Participation in another pharmacotherapeutic study  or experimental medical device 
within 30 day s before the start of study  treatment.
[28.2]Prescribed daily use ofnonsteroidal anti-inflammatory  agents (NSAI Ds) during 
the index hospitalization 
[29] Subject is unwilling or unable to complete all study visits as well as follow -up visit.
[30] Subject is an employ ee of the investigator or study  site, with direct invol vement in 
the proposed study  or other studies under the direction of that investigator or study  site, 
as well as famil y members of the employees or the investigator.
NOTE: Investigators should ensure that all study  enrollment criteria have been met at screening . 
If a subject's status changes (including laboratory  results or receipt of additional medical records) 
after screening but before randomization such that he or she no longer meets all eligibility  
criteria, the subject should not be randomized. But ifthe subject has been randomized, he/she 
should notbe excluded from participation in the study and must be followed until the Day 75 
(±5d) visit. Section 17.4, Source Documentation, describes the required documentation to 
support meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation. If subjects require or 
take prohibited medications during the study  as outlined below, they must either temporarily 
interrupt or permanently  discontinue the study drug, as appropriate for the duration of the 
therap y with the prohibited medication :
Note: Numbered criteria in brackets are for data collection purposes and are intentionally  non-
sequential.
[2.2] Combined P-gp and strong CYP3A4 inhibitors (such as but not limited to 
ketoconazole, telithromy cin or protease inhibitors) use within 4 days before 
randomization, or planned use during the study. Itraconazole use is prohibited within 
7days before randomization and during the study . 
[3.2]Combine d P- gp and strong CYP3A4 inducers (such as but not limited to 
rifampin/rifampicin, rifabutin, rifapentine, phen ytoin, phenobarbital, carbamazepine, or 
St. John's Wort) use within 2 weeks before randomization, or planned use during the 
study . 
[4.1]Anticoagulant (eg, warfarin sodium or other vitamin K antagoni sts, Factor II or Xa 
inhibitors) isprohibited as concomitant therap y during the study . Study  drug should be 
discontinued in subjects who develop any condition which requires anticoa gulation or 
thromboprophy laxis (eg, atrial fibrillation, VTE) that will extend beyond the end of the 
study  treatment phase. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
44
Status: Approved , 31 March 2017[6.1]Fibrinol ytic therap y (see Section 10.2.1 forguidance)
[7.1] Use of antiplatelet therapy , including:
a.ASA >162 mg/day  
b. Clopidogrel > 75 mg/day  or ticlopidine > 250 mg twice dail y
c. Clopidogrel at an y dose in combination with omep razole or esomeprazole
d. Dipy ridamole > 400 mg/day
e. Cilostazol >200 mg/day
f. Dual therapy  with 2 or more antiplatelet agents (dipyridamole with ASA is 
permitted) 
g. Other P2Y12 receptor antagonists (eg, prasugrel, ticagrelor)
h. Thrombin -receptor antagonists (eg, vorapaxar)
i. Prescribed daily  non-steroidal anti-inflammatory  drugs (temporary  use as needed is 
allowed).
[9]Modification of an effective pre-existing therapy  should not be made for the explicit 
purpose of entering a subject into the study .
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Procedures for Ran domization and Stratification
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 2treatment groups based on a computer -generated randomization schedule prepared before 
the study  under the supervision of the sponsor. The randomization will be balanced by using 
randomly  permuted blocks and will be stratified by subjects with CrCl ≥30 and <50 mL/min 
versus subjects with CrCl ≥50 mL/min and by  country . Enrollment may  be capped for subgroups 
with certain baseline characteristics (eg, index hospitalization duration, reason for index 
hospitalization, risk score, and index hospitalization thromboprophy laxis) or by country  or 
region. If a decision is made to institute capping, the site will receive a written communication 
with instructions for implementation and a request for confirmation of receipt .
The IWRSwill assign a unique treatment code, which will dictate the treatment assignment and 
matching study  drug kitsfor the subject. The requestor must use his or her own user
identification and personal identification number when contacting the IWRS, and will then give 
the relevant subject details to uniquely  identify  the subject.
Blinding
The investigator will not be provided with randomization codes. The code s will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
45
Status: Approved , 31 March 2017Data that may potentially  unblind the treatment assignment ( ie,events that contribute to the 
primary  and secondary  outcome or treatment allocation ) will be handled with special care to 
ensure that the integrit y of the blind is maintained and the potential for bias is minimized. This 
can include making special provisions, such as segregating the data in question from view by the 
investigators, clinical team, or others as appropriate until the time of database lock and 
unblinding.  
Unblinding
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study and the database is finalized . Otherwise, the blind should be broken only if specific 
emergency  treatment/course of action would be governed by knowledge of the treatment 
assignment of the subject. In such cases, the investigator may determine the treatment 
assignment or allocation by conta cting the I WRS .It is recommended that the investigator contact 
the sponsor or its designee if possible to discuss the particular situation, before breaking the 
blind. 
Telephone contact with the sponsor or its designee will be available 24hours per day , 7days per 
week. In the event the blind is broken, the sponsor must be informed as soon as possible. The 
date, time, and reason for the unblinding must be documented by the IWRSin the source 
document. The documentation received from the IWRSindicating the code break must be 
retained with the subject's source documents in a sec ure manner.
Subjects who have had their treatment assignment unbli nded may continue on study  drug unless 
the subject meets a study  drug temporary  interruption or permanent discontinuation criterion.
Investigators should not disclose treatment assignment to the subject whenever possible.  
In general, randomization codes will be disclosed fully  only if the study is completed and the 
clinical database is closed. However, if an interim analy sis is specified, the randomization codes 
and, if required, the translation of randomization codes into treatment and control groups will be 
disclosed to those authorized and only  for those subjects included in the interim anal ysis.
If a subject has a suspected efficacy  or bleeding outcome event during the study , the treating 
physician should exercise clinical judgment and follow established guidelines to apply  the 
standard of care. Unblinding of study  drug should not be necessary . Anticoa gulation regimens do 
not require adjustment regardless of treatment group assigned when study  drug is administered in 
the doses used in this study . There is no specific reversal agent for rivaroxaban; management of 
the subject with a bleeding event should not be impacted by knowledge of study  drug treatment.
If despite this guidance, the investigator believes it is in the best interest of the subject to unblind 
study  drug, the investigator may determine the treatment assignment or allocation by contacting 
the IWRS as previousl y noted.
6. DOSA GE A ND A DMINISTR ATION
Treatment groups in this study  arerivaroxaban and placebo. Subjects will be randoml y assigned 
in a 1:1 ratio to receive rivaroxaban 10 mg daily (7.5mg dailyin subjects with CrCl of ≥30 and
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
46
Status: Approved , 31 March 2017<50mL/min) or matching placebo daily. Randomization will be stratified by subjects with 
CrCl ≥30 and <50 mL/min versus subjects with CrCl ≥50 mL/min and by country .The dose of 
study  drug will not be adjusted in the event of change in CrCl between the 2strata during the 
course of the stud y.
The first dose of study  drug should be administered no later than the day after the subject leaves 
the hospital and as soon after randomization as possible. The date and time of the first dose of 
study  drug and the last dose of LMWH or UFH should be recorded as accuratel y as possible. The 
first dose of study  drug should not be delay ed to allow administration under supervision. All 
subjects should take study  drug (rivaroxaban or placebo) daily with or without food at 
approximat ely the same time each day, and discontinue study  drug after they take a dose on 
Day45.Regardless of the day on which the Day 45 Visit occurs, no study drug may be taken 
after Day 45.
A missed dose should be taken as soon as possible (up to 8 hours prior to the next scheduled 
dose), and the next scheduled dose should be taken at the regular time.
After thesubject takes a dose of study  drug on Day 45, the subject should discontinue study  drug 
and complete the Day 45 (+4d ) visit (refer to TIME AND EVENTS SCHEDULE ). Regardless 
of the day on which the Day 45 Visit occurs, no study drug may be taken after Day 45.
Throughout the study , study  drug will be dispensed at appropriate intervals 
(see the TIME AND EVENTS SCHEDUL E) to ensure that subjects have adequate quantities of 
study  drug between study  visits. In addition, study  site personnel will instruct subjects on how to 
store study  drug for at-home use as indicated for this protocol. The storage recommendation for 
rivaroxaban or placebo is at room temperature (approximately  15to 30C).
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
47
Status: Approved , 31 March 2017Randomization in this study  is preceded by a hospitalization for an acute illness and the study 
drug treatment phase extends for 45 days after randomization to correspond to the period of 
greatest risk for VTE.  Chronic therapy  with the stu dy drug is not being tested. For these reasons, 
rivaroxaban will not be provided to the subject after the subject completes the Day  75 (±5d) visit, 
unless required by local regulations . It will only be after data from the entire study  is analyzed 
that it will be determined if the popul ation at risk will benefit from treatment.
Interruption of Study  Drug
Study  drug may be interrupted temporaril y (see Section 10.2.1 , Temporary Interruption of Study  
Treatment) as necessary  for invasive procedures or as medically  needed (eg,in the setting of a 
bleeding event or a required prohibited therapy ). If a subject ishospitalized for any reason other 
than a VTE-related event or bleeding, study drug should be continued during hospitalization 
unless the treating physician feels that anticoagulation ,temporary  interruption or permanent
discontinuation of study  drug is clinicall y warranted. Subjects may be placed on appropriate 
anticoagulation at the discretion of the treating physician .In that case,study  drug may be 
restarted upon discharge at the d iscretion of the investigator. These interruptions will be recorded 
on the electronic case report form (eCRF ).For guidance on study  drug temporary interruption, 
seeSection 10.2.1 .
Intentional stopping of study  drug by the subject, unintentional stopping of study  drug, or 
direction to tempora rily interrupt study  drug by the investigator or other physician will be 
documented. Study  drug interruption will be recorded in the eCRF. 
7. TREA TMENT COMPLIA NCE
The IWRS will keep track of study  drug dispensed to the subjects. Subjects will return empt y 
study drug containers and unused study  drug atthe Day  21 visit when a new supply  of study  drug 
is to be received. The last dose of study  drug should be taken on D ay 45. Regardless of the day 
on which the Day 45 Visit occurs, no study drug may be taken after Day 45. Subjects will also 
return empt y study drug containers and unused study drug at the Day  45 (+4d )visit.
Study  drug accountability  will be performed at the Day 21 and Day 45 visits. Subjects should 
report an y unintentional interruption or missed doses to the study -site personnel at each visit. I t is 
understood that subjects may occasionall y miss a dose or that a subject may be placed on 
temporary  interruption (see Section 10.2.1, Temporary  Interruption of Study  Treatment ). 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
48
Status: Approved , 31 March 20178. PRESTUDY AND CONCOMITA NT THERAPY
For each subject, the drug identity  and dose of the following relevant medications taken during 
the index hospitalization through the end of the study  will be recorded on the appropriate page of 
the eCRF: antiplatelet (including NSAIDs) and anticoagulant medications, statins, and 
medications relevant to SAEs. Only  the drug identity should be recorded for proton pump 
inhibitors, glucocorticoids, hormonal therapies including but not limited to estrogens, 
progesterones, androgens, anti-androgens and any analogues. In the event a prohibited 
medication other than NSAIDs is received, only the identity  of the medication will be recorded.
Prophy lactic treatment with L MWH or UFH during the index hospitalization must be reported as 
accuratel y as possible at screening.  
Allowed Therapy
All decisions regarding concomitant medications are left to the treating physician unless 
otherwise required b y the protocol.
Refer to S ection 4.3for prohibited therapies.
9. STUDY EVA LUATIONS
9.1. Study Pro cedures
9.1.1. Overview
The TIME AND EVENTS SCHEDUL Ein the sy nopsis summarizes the frequency  and timing of 
procedures applicable to this study .
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by the 
investigator or required by local regulation, to establish the absence of pregnancy  at any time 
during the subject's participation in the study .  
9.1.2. Screening Phase
Screening may begin any time after the admission for the index hospitalization, and once the 
informed consent is obtained. 
Subjects with a modified IMPROVE VTE Risk Score of 2 or 3 must have had a local D-dimer 
value >2X ULN before randomization to be eligible for the study .  For those subjects, if the 
D-dimer was not ordered as part of the standard of care by the treating physician during the 
index hospitalization, a screening sample may be obtained by site staff after obtaining informed 
consent. The informed consent may be a limited informed consent to allow for this screening 
activity . No other screening procedures must be performed until the full informed consent is 
obtained. Alternativel y,the full study  informed consent may be obtained if selected by site staff 
and necessary  to be in compliance with local and IRB/Ethics Committee requirements. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
49
Status: Approved , 31 March 2017For subjects enrolled with ischemic stroke as the reason for hospital admission and who received 
fibrinolysis agents as treatment for the stroke, a head CT or MRI  must be obtained at least 
24hours after fibrinol ysis. Results of the head CT/MRI  must meet Inclusion Criterion [1.2] for 
the subject to be randomized.
Eligibility  based on laboratory  results will be determined using local laboratory  results for the 
inclusion and exclusion clinical laboratory  parameters, and the latest one will also serve as 
baseline if there are multiple laboratory  values. Laboratory  screening assessments that are part of 
the standard care performed by the investigator do not need to be repeated if performed within 
the time frame required by the protocol . A local D-dimer value should be obtained on all 
subjects; if available, a screening D -dimer value can be used if available. If more th an 1 D -dimer 
value is available ,the value obtain ed closest to the beginning of the index hospitalization should 
be used. Hemoglobin, platelet count and the serum creatinine utilized to determine 
randomization CrCL  (calculated by IWRS using the Cockcroft -Gault formula) must be obtained 
at least as recent ly as 2 days before the subject leaves the hospital or later, but before 
randomization.
The creatinine clearance will be calculated by IWRS using the Cockcroft -Gault formul a, which 
relates s erum creatinine with age (in y ears) and body  weight (in kg)4,6. If one measures creatinine 
concentration in mg/dL, then the following 2 equations are used for men and women:
Men:[(140 –age [ yr]) weight (kg)]
     [72 creatinine (mg/dL)]
Women:[(140 –age [ yr]) weight (kg)]  0.85     [72 creatinine (mg/dL)]
If one measures creatinine concentration in µmol/L , then the following 2 equations are used for 
men and women:
Men:[(140 –age [ yr]) weight (kg)]
  [0.814 creatinine (µmol/L )]
Women:[(140 –age [ yr]) weight (kg)]0.85[0.814 creatinine (µmol/L )]
All screening activities must be completed before randomization and the results must be 
available to the investigator for review to ensure that eligibility  criteria are met .
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
50
Status: Approved , 31 March 20179.1.3. Double -Blind Treatment Phase
Day 1/Day of Randomization
If the subject meets all of the inclusion and none of the exclusion criteria, he or she is eligible to 
be randoml y assigned to receive rivaroxaban or placebo at the Day 1visit. 
Randomization should occur on the day the subjec t leaves the hospital ;randomization will also 
be permitted the day after the subject leaves the hospital. Randomization may occur at the 
hospital, clinic or other discharge destination .
At the rando mization visit, before randomization occurs, site staff must review the visit schedule 
and the importance of completing the study  with both the subject and any family  members 
present.  Randomization should not occur if the subject:
does not have transporta tion to study  visits
does not believe they  will have sufficient support to comply  with the protocol
is being discharged to a destination other than home and acceptability  of study 
participation has not been confirmed with the accepting ph ysician
post-discharge anticoagulation or thromboprophy laxis is planned
Also, before randomization occurs, site staff should review eligibility  criteria, including 
concomitant medications administered during the index hospitalization and planned at discharge.  
Particular attention should be paid to ensure that acceptable types and doses of 
thromboprophy laxis were used during the index hospitalization, and that prohibited medications 
were not administered and are not planned.
After randomization, the first dose of study  drug should be administered as soon as possible and 
no later than the day after the subject leaves the hospital. The time of the first dose should be 
recor ded as accuratel y as possible. The first dose also should not be delay ed to allow 
administration under supervision. The first dose does not need to be delay ed because of the 
recent administration of LMWH or UFH. The administration date and time of the first dose of 
study  drug will be recorded in the source document and eCRF. The subject will be instructed to 
take study drug daily through Day 45. Regardless of the day on which the Day 45 Visit occurs, 
no study drug may be taken after Day 45 .
Also, at the randomization visit, the importance of reporting signs and sy mptoms associated with 
bleeding, DVT and PE will be stressed. Subjects and family  members, as appropriate, will be 
counseled and given educational material on the signs and symptoms associated with DVT, PE 
and bleeding . 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
51
Status: Approved , 31 March 2017For bleeding events, subjects and family  members as appropriate, will be instructed :
To seek medical attention if they  develop bleeding
To contact the investigative site staff or study  investigator before the next dose of study 
medication is due
To inform treating health care providers about study  participation
Subjects and fa mily members, as appropriate will also be instructed :
About the subject’s risk of DVT and PE
About the signs and s ymptoms of DVT and PE
To seek medical attention if they  develop any  of these signs or s ymptoms
To contact the investigative site staff or stu dy investigator as soon as sy mptoms develop and 
before the next dose of study  medication is due
To inform treating health care providers about study  participation and their risk of DVT and 
PE.
The subject’ s family  should be instructed to have a low threshold to contact the site and if 
necessary  an unscheduled visit can be performed.
Treatment Visits
Subjects will be instructed to adhere to the visit schedule in the TIME AND EVENTS 
SCHEDUL E. Treatment visits should be conducted at the site, but to allow for as complete 
follow up as possible, they may be conducted at home or at another discharge destination, if 
allowed by local regulatory  and IRB/Ethics Committee requirements. Day 7 and Day 75 visits 
may be conducted as a telephone visit. Visits conducted at home may only be performed by 
medically  qualified personnel (eg, training and education) as delegated by the Principal 
Investigator and as documented in the Delegation Log.  If a visit in the subject’s presence cannot 
be achieved, telephone contact with thesubject should be attempted. If telephone contact with 
the subject cannot be achieved, the site should attempt to contact others who have knowledge of 
the subject as allowed b y local and IRB/Ethics Committee requirements.
Day 7 Visit
The Day 7 Visit may be conducted at the clinic or other discharge destination including a home 
visit if allowed by local require ments or as a telephone visit. Visits conducted at home may only 
be performed by medically  qualified personnel as delegated by the Principal Investi gator and as 
documented in the Delegation Log.If the information is obtained via telephone contact, written 
documentation of the communication must be available for review in the source documents. The 
visit window is -2 day s/+5 day s. Study  personnel will confirm sufficient drug suppl y to allow for 
daily  dosing through the Day 21 Visit, and will reinforce the dosing schedule and procedure to
follow if a dose is missed. The clinical status review for suspected outcome events will be 
completed, as will the symptom assessment, consisting of a set of scripted questions 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
52
Status: Approved , 31 March 2017(Attachment 4). Adverse events will be collected as specified in Section 12, and concomitant 
medication will be collected as specified in Section 8.
Subject counseling provided at the randomization visit will be repeated in detail.
Day 21 Visit
The Day 21 Visit may  be conducted at the clinic or other discharge destination including a home 
visit if allowed by local requirements.  Visits conducted at home may only be performed by 
medically  qualified personnel (eg, training and education ) as delegated by the Principal 
Investigator and as documented in the Delegation Log. The Day 21 Visit should not be 
conducted as a telephone visit. Attendance in person is required to allow study  drug dispensing. 
The visit window is -3 days/+7 days to ensure compliance. Study  drug accountability  will be 
performed and a supply  of 30 tablets dispensed. Site staff will reinforce the dosing schedule and 
procedure to follow if a dose is missed. The clinical status review for suspected outcome events 
will be com pleted, as will the symptom assessment, consisting of a set of scripted questions 
(Attachment 4) and a clinical assessment. Adverse events will be collected as specified in 
Section 12, and concomitant medication will be collected as specified in Section 8.
Subject counseling provided at the randomization and Day 7  V isits will be again repeated in 
detail.
Day 45 Visit
The Day 45 Visit may  be conducted at the clinic or other discharge destination including a home 
visit if allowed by local requirements.  Visits conducted at home may only be performed by 
medically  qualified personnel (eg, training and education) as delegated by the Principal 
Investigator and as documented in the Delegation Log. The Day 45 Visit should not be 
conducted as a telephone visit. The visit window is -0 days/+4 days to ensure all events through 
the end of treatment are captured. The last dose of study  drug will be administered on D ay 45 
regardless of the day of the Day 45 visit. Regardless of the day on which the Day 45 Visit 
occurs, no study drug may be taken after Day 45.Study  drug accountability  will be performed. 
The clinical status review for suspected outcome events will be completed, as will the symptom 
assessment, consisting of a set of scripted questions (Attachment 4) and a clinical assessment. 
Adverse events will be collected as specified in Section 12, and concomitant medication will be 
collected as specified in Section 8.
Subject counseling provide d at the randomization, Day 7, and Day 21 Visits will be again 
repeated in detail.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
53
Status: Approved , 31 March 2017Unscheduled Visit
Subjects may  be seen b y the investigator between scheduled visits for any reason such as:
Suspected e fficacy  or bleeding outcome event
Early study drug permanent discontinuation
Adverse event, based upon the severit y and clinical judgment of the investigator
Lost m edication requiring replacement
Early Study Drug Permanent Discontinuation/Early Withdrawal from Study
If the subject permanently  discontinues study  drug before Day 45, he/she should be instructed to 
complete an unscheduled visit and the remaining scheduled visits, including the Day  7 (-2d/+5 d) 
and Day 21 (-3 d/+7d ) visits and the Day 45 (+4d )and Day 75 (±5 d)visits (see TIME AND 
EVENTS SCHEDULE ). Because the primary  efficacy  analysis of the study  is based upon the 
intention -to-treat (ITT) principle, the investigator should inform the subject of the importance of 
return ingfor all study visits. It is imperative for the integrit y of the trial and results to have vital 
status and other outcomes ascertainment. If the subject is unwilling or unable to return for any
visits, the site should collect as much follow -up information as possible, including contacting the 
subject or legall y acceptable representative by telephone or by mail to determine vital status and 
if an outcome has occurred, as agreed to by the subject during the initial informed consent 
process. If applicable, vital status and other outcomes should be obtained by reviewing the 
subject’s medical or public records unless this contact is not allowed by local regulations.
If the subject withdraws consent from the study , this must be documented in the source 
document and the subject will be asked to supplement the withdrawal of consent with a signed 
written statement documenting refusal for all subsequent contact.
9.1.4. Post -treatment Phase (Follow- Up)
Day 75 Visit
The Day 75 Visit may  be conducted at the clinic or other discharge destination including a home 
visit if allowed by local and IRB/Ethics Committee requirements or by a telephone visit.  Visits 
conducted at home may only be performed by medically  qualified perso nnel (eg, training and 
education) as delegated by the Principal Investigator and as documented in the Delegation Log. 
The visit window is -5 days/+5 days. The clinical status review for suspected outcome events 
will be completed, as will the symptom assess ment, consisting of a set of scripted questions 
(Attachment 4). Adverse events will be collected as specified in Section 12, and concomitant 
medication will be collected as specified in Section 8.
If the information is obtained via telephone contact, written documentation of the 
communication must be available for review in the source documents. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
54
Status: Approved , 31 March 2017Randomization in this study  is preceded by a hospitalization for an acute illness and the study 
drug treatment phase exten ds for 45 days after randomization to correspond to the period of 
greatest risk for VTE. Chronic therapy  with the study  drug is not being tested. For these reasons, 
rivaroxaban will not be provided to the subject after the subject completes the Day 75 (±5d) visit
unless required by local regulations . It will only be after data from the entire study  is analyzed 
that the sponsor will determine if the population at risk will benefit from treatment.
9.2. Efficacy Evaluations and Outcomes
As described in Section 1.1.5 , PE is reported by physicians to be the most commonly  missed or 
delay ed diagnosis. As MARINER is a symptomatic event -driven trial it is critical all efficacy  
outcome events, including symptomatic PE are appropriatel y diagnosed. Any suspected event 
that includes symptoms or signs suggestive of a PE must be sent for adjudication. Investigators 
are encouraged to give careful consideration of the diagnosis of PE for subjects admitted under 
their care with sy mptoms of or exacerbations of conditions such as (pneumonia, bronchitis, heart 
failure, cardiorespiratory failure and exacerbation of COPD). Investigators are also strongl y 
encouraged to expeditiously  contact the treating physician for any subject hospitalized with any 
of these conditions.2,32,12
9.2.1. Efficacy  Evaluations, Outcomes and A djudication
This is a clinical outcomes study. The primary  efficacy  outcome is the composite of all 
symptomatic VTE events ( lower extremity  DVT andnon-fatal PE) and VTE- related death (death 
due to PE or death in which PE cannot be ruled out as the cause) . 
Secondary  efficacy  outcomes are:
VTE-related death (death due to PE or death in which PE cannot be ruled out as the cause)
Symptomatic VTE ( lower ex tremity  DVT and non-fatal PE)
The composite of s ymptomatic VTE (lower extremity  DVT and non- fatal PE) and ACM
The composite of symptomatic VTE (lower extremity  DVT and non-fatal PE), MI, 
non-hemorrhagic stroke and CV death ( death due to a known CV cause and death in which a 
CV cause cannot be ruled out; by this definition, a VTE- related death is considered a CV 
death)
ACM 
Exploratory  efficacy  outcomes are:
Symptomatic lower ex tremity  DVT 
Symptomatic non-fatal PE
Symptomatic upper extremity  DVT
MI
Non-hemorrhagic stroke
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
55
Status: Approved , 31 March 2017Re-hospitalization for symptomatic VTE (lower extremity  DVT and non-fatal PE) within 
30daysafter randomization
Submission of a suspected event for adjudication will be required for:
All deaths
Suspected events that include sy mptoms or signs suggestive of PE or DVT.
Performance of any imaging or other diagnostic study  that could yield an incidental 
diagnosis of PE or DVT.  
Suspected events that include acute coronary  syndrome or MI. Chest pain determined not to 
be cardiac in origin does not need to be sent for adjudication.
Suspected events that include symptoms compatible with a TIAor stroke. Events 
determined not to be a TIA or stroke (eg, seizure, hypogly cemia) do not need to be sent for 
adjudication.
Any clinical event that suggests the possibility  that an efficacy  outcome event has occurred 
(including ACS and TIA) should be indicated on the Clinical Status page of the eCRF and will 
be sent for adjudication. Examples of objective testing diagnostic procedures that may  have been
performed as part of the standard of care are listed inAttachment 2. For imaging studies, a copy 
of the original study  should be sent with the adjudication package. For other tests, a repor t of the 
results will suffice. All clinical data must be sent to CEC for adjudication. The CEC may  request 
additional imaging in order to ensure appropriate adjudication. The CEC will apply  the 
definitions (seeAttachment 1) contained in the CEC charter to adjudicate and classify  the events 
while blinded to treatment assignment. Adjudicated results will be used for final anal yses.
9.2.2. Approach to the Subject with an Efficacy  Outcome Event
If a subject has a suspected efficacy  outcome event during the study , the treating physician 
should exercise clinical judgment and follow established guidelines to apply  the standard of 
care. At the treating physician’s discretion, the routine measures described below may be 
considered.
Temporaril y interrupt or permanentl y discontinue study  drug treatment as clinic ally 
indicated. Unblinding of study  drug should not be necessary , as anticoagulation regimens 
do not require adjustment regardless of treatment group assigned when study  drug is 
administered in the doses used in this study .
Perform necessary  diagnostic procedures and consider the usual treatment measures for VTE
and/or cardiac ischemic events if phy sical examination and diagnostic testing suggest benefit 
could be obtained.
After clinical evaluation of the suspected efficacy  outcome event is completed restarting study 
drug may be considered if none of the conditions requiring permanent discontinuation are 
present (Section 10.2.3 , Permanent Discontinuation of Study  Treatment ), and after consultation 
with the medical monitor. In the event that a decision is made to restart study  drug 
(Section 10.2.1 , Temporary  Interruption of Study  Treatment ), guidelines for restarting study  drug 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
56
Status: Approved , 31 March 2017(Section 10.2.2 , Approach to Subjects with Temporary  Interruption of Study  Treatment) may be 
followed if applicable based on the clinical judgment of the investigator.
9.3. Pharmacokinetics 
9.3.1. Evaluations
Pharmacokinetic samples will be collected at selected countries and sites that can provide the 
logistical requirements necessary  for the PKsampling. Fasting is not required tovalidate the
population PKmodel. Four sparse blood samples will be collected at 2visits for about 
600subjects (300 subjects in rivaroxaban subjects [200 subjects in the 10 mg daily and 100 in 
the 7.5 mg daily group] and 300 in the placebo group) (Table 3and Table 4).These data will be 
used to describe drug exposure. Blood samples (2.0 mL each) for determination of rivarox aban 
plasma concentrations will be collected at the time points indicated in the TIME AND EVENTS 
SCHEDUL E. The exact date and time of the administration of the current dose (plus the 2 
preceding doses) and the precise actual time of blood sample collection must be accuratel y 
documented in the eCRF or laboratory  requisition form, as appropriate. The PKsub-study  will 
only be conducted at specific sites (ie,those that have the capability  to draw, process, and store 
the PKsamples), where all subjects screened will be given the choice to participate. For the PK
sample population, drug should alway s be taken in the morning. At the Day 7 visit, the study  
drug must be administered under supervision following the collection of the trough sample. At 
the Day 21 visit, subjects will take the study  medication at home in the morning and visit the 
clinic for PKsampling. At the Day  21 visit, the date and time of the dose administration must be 
recorded and there needs to be a minimum of 3 hours between sample collection s. Subjects may 
be confined to the study site during PKsampling, if considered appropriate. Samples will be 
used to evaluate the PKs of rivaroxaban ( Attachment 3). 
Table 3 P harm acokinetic Suggested Sampling Schedule
PK Blood sampling 
(selected sites 
and subjects)Day 7 Day 21
Pre-doseHours
Post-doseHours
Post-dose
1-4
Hours3-7
Hours7-12
Hours
X X X X
Table 4: Summary of PK Suggested Observations for Rivaroxaban Arm
Active doses
(mg/day )Total number of subjects with 
measured samples on 
RivaroxabanNumber of  
Measurements
Plasma
Concentrations
7.5 100 400
10 200 800
Total 300 1,200
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
57
Status: Approved , 31 March 20179.3.2. Analytical Procedures
Pharmacokinetics
Plasma samples will be analyzed to determine concentrations of rivaroxaban using a validated, 
specific and sensitive liquid chromatograph y coupled to tandem mass spectrometry  (LC-MS/MS) 
method.
9.3.3. Pharmacokinetic Parameters
Based on the indiv idual plasma concentration- time data, using the actual dose taken and the 
actual sampling times, PKparameters and exposure information of rivaroxaban will be derived 
using population PKmodelling. Baseline covariates (eg,lean body  mass, age, serum creati nine) 
will be included in the model.
9.4. Medical Resource Utilization and Health Economics
Medical resource utilization and health economics data collection will include re-hospitalization 
(including ER visits, intensive care unit and cardiac care unit stays), length of stay and subject 
discharge destination (after re -hospitalization). 
9.5. Safety  Evaluations and Outcomes  
9.5.1. Bleeding Events
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the TIME AND EVENTS SCHEDUL E:ISTH major bleeding, non-major 
clinically  relevant bleeding ,other bleeding, adverse events, and clinical laboratory  tests.  
The study  will use the ISTH Bleeding Event Classification Scale to assess bleeding events as 
major, non-major clinically  relevant bleeding , or other bleeding .Similar to efficacy  outcome s, 
the same independent CEC will adjudicate and classify  bleeding events according to definitions 
in the CEC charter. The CEC will also classify  bleeding events using the Bleeding Academic 
Research Consortium scale as a supportive approach.27
The principal safet y outcome for this study  is major bleeding using validated ISTH bleeding 
criteria. Other safet y outcomes are non- major clinically  relevant bleeding and other bleeding .
An ISTH major bleeding event is defined as overt bleeding that is associated with:
A fall in hemoglobin of 2 g/dL or more, or
A transfusion of 2 or more units of packed red blood cells or whole blood, or
A critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, 
intramuscular with compartment sy ndrome, retroperitoneal, or 
A fatal outcome
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
58
Status: Approved , 31 March 2017Non-major clinicall y relevant bleeding is defined as overt bleeding not meeting the criteria for 
major bleeding but associated with medical intervention, unscheduled contact (visit or telephone 
call) with a physician, (temporary ) cessation of study  treatment, or associated with discomfort 
for the subject such as pain or impairment of activities of daily  life.
Examples of non -major clinically  relevant bleeding are:
Epistaxis if it lasts for more than 5 minutes, if it is repetitive (ie,2 or more episodes of true 
bleeding, ie,not spots on a handkerchief, within 24 hours), or leads to an intervention 
(packing, electrocautery , etc.)
Gingival bleeding if it occurs spontaneousl y (ie, unrelated to tooth brushing or eating), or if 
it lasts for more than 5 min utes
Hematuria if it is macroscopic, and either spontaneous or lasts for more than 24 hours after 
instrumentation ( eg,catheter placement or surgery) of the urogenital tract
Macroscopic gastrointestinal hemorrhage: at least 1 episode of melena or hematemes is, if 
clinically  apparent
Rectal blood loss, if more than a few spots
Hemopty sis, if more than a few speckles in the sputum, or
Intramuscular hematoma
Subcutaneous hematoma if the size is larger than 25 cm2or larger than 100 cm2if provoked
Multiple source bleeding
Other bleeding is defined as any  other overt bleeding episodes that d onot meet the ISTH criteria 
for major or non -major clinically  relevant bleeding.
Details of all bleeding events will be captured in the eCRF.
All suspected bleeding even ts will be submitted for adjudication.
9.5.2. Approach to the Subject with a Bleeding Event
If a subject has a serious bleeding event during study  drug treatment, the following routine 
measures should be considered: 
Delay  the next study  drug administration, or discontinue treatment if indicated. Rivaroxaban 
has a plasma half-life of approximately  5to9hours, and in some subject s up to 13 hours. 
Therefore, temporary  cessation of study  drug may allow control of bleedi ng.Unblinding of 
study  drug should not be necessary . As there is not a specific r eversal agent for rivaroxaban, 
management of the subject should not be impacted by  knowledge of study  drug treatment.
Consider the usual treatment measures for bleeding event s, including fluid replacement and 
hemody namic support, blood transfusion, and fresh frozen plasma, if physical examination 
and laboratory  testing suggest benefit could be obtained.
Consider that other causes besides antithrombotic medication can be contri butory  to the 
seriousness of the bleeding event (i.e., rule out disseminated intravascular coagulation, 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
59
Status: Approved , 31 March 2017thrombocy topenia, and other coagulopathies; kidney  and liver dysfunction; concomitant 
medications, etc.), and treat accordingl y.
If bleeding cannot be c ontrolled by  these measures, consider administration of 1 of the following 
procoagulants (according to the dosages advised in their respective package inserts) .43
Activated prothrombin complex concentrate 
Prothrombin complex concentrate 
Recombinant factor VIIa (NovoSeven®)
Any products administered to control bleeding should be entered in the CRF.
Note: Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity  of 
rivaroxaban. There is currentl y no scientific rationale for benefit, or experience with systemic 
hemostatics (eg, desmopressin, aprotinin, and epsilon aminocaproic acid).
After resolution of the bleeding event, restarting study  drug may be considered based on the 
clinical judgment of the investigator.  
9.5.3. Other Safety  Assessments
Adverse Events
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall y acceptable representative) for the duration of the study . Adverse events 
will be followed by  the investigator as specified in Section 12, Adverse Event Reporting.
Clinical Laboratory Tests
Separate laboratory  screening tests are not expected to be performed by the investigator as these 
will likely  be part of the subjects’ hospital evaluation. No pre-specified laboratory  tests will be 
performed for the duration of the study . However, these subjects are likely  to have local 
laboratory  tests performed during their index hospitalization. Any laboratory  test along with 
reference ranges relevant to a serious adverse event or an outcome event should be recorded on 
the appropriate eCRF page.
The following tests results with reference ranges will be obtained from the hospital 
laboratory /local laboratory  at the time of the index hospitalization:
hematology  
hemoglobin
platelet count
serum creatinine (CrCl to be calculated b y IWRS using Cockcroft -Gault formula6)
D-dimer
serum or urine pregnancy  testing for women of childbearing potential only
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
60
Status: Approved , 31 March 20179.6. Benefit -Risk Balance
Benefit -risk balance of rivaroxaban will be explored. Refer to Section 11.8, Benefit -Risk 
Analy sis for details.
9.7. Sample Collection and Handl ing
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of fluid slightly  greater than the dead space volume of the lock will be removed 
from the cannula and discarded before each blood sample is taken. After blood sample 
collection, the cannula should be managed per local practice.
Refer to the TIME AND EVENTS SCHEDULE for the timing and frequency  of all sample 
collections.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
The total duration for a subject who completes the study  after randomization is expected to be 
75days.
All feasible efforts and measures will be made to collect complete vital status and other outcome 
data from randomization to the Day 75 (±5d) visit for each subject randomized in this study , 
regardless of compliance with study  drug or visits. For subjects who are lost to follow -up or 
withdraw consent from the study , efforts will be made to obtain their vital status and other 
outcomes from permitted sources.  
It is important to note that withdrawal of consent does not withdraw permission to collect vital 
status and other outcomes. Withdrawal of permission to collect vital status and other outcomes
must be made separately . In cases where subjects indicate they do not want to “continue”, 
investigators must determine whether this refers to discontinuation of study  treatment (the most 
common expected scenario), unwillingness to attend follow -up visits, unwillingness to have 
telephone contact, unwillingness to have any contact with study  personnel, or unwillingness to 
allow contact with a third party  (eg,family member, doctor). In all cases, every  effort must be 
made to continue to follow the subject, and vital status and other outcome smust be determined 
for all randomized subjects.
10.2. Discontinuation of Study Treatment
If a subject's study  treatment must be discontinued before the end of the double -blind treatment 
phase, the subject must continue to be followed for efficacy  and safety  outcome s.
During the study , should the subject develop any condition, which in the inve stigator’s judgment 
requires long-term anticoagulation thromboprophy laxis, or fibrinol ysis, the subject will have 
study  treatment either temporarily  interrupted or permanentl y discontinued and will be managed 
as deemed appropriate by the treating physician. The subject will be asked to continue in the 
study  to be followed for efficacy  and safet y outcomes.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
61
Status: Approved , 31 March 201710.2.1. Temporary  Interruption of Study Treatment
If the subject requires re-hospitalization (re-hospitalization is defined as a combined total of 
inpatient and/or ERstay ≥24 hours ) during the study  drug treatment for reasons other than the 
primary  efficacy  outcome or bleeding, the subject should be maintained on the study  drug at the 
discretion of the investigator. If the treating physician feels that the subject requires any 
anticoagulation during the re -hospitalization, study  drug needs to be temporarily  interrupted, and 
can be resumed upon hospital discharge. Mechanical methods of prophy laxis may  be used during 
hospitalization. If this method is chosen, study  drug may  be continued.
In addition, the study  drug should be temporaril y interrupted if the subject: 
Develops any medical condition that may require use of anticoagulant therap y, 
thromboprophy laxis, fibrinoly sis or poses an increased bleeding risk.
Undergoes percutaneous coronary  intervention, coronary  artery  bypass graft, any other 
interventional procedure, that may require use of anticoagulant therapy , 
thromboprophy laxis, or poses an increased bleeding risk. For temporary  interruption of 
study  drugfor an elective procedure or surgery, it is suggested that investigators follow 
measures in Table 4and Table 5(Section 10.2.2 Approach to Subjects with Temporary 
Interruption of Study  Treatment ).
Experiences a major bleeding event other than intracranial bleeding. For less severe bleeding 
events, investigator discretion is allowed. If possible ,study  drug should be resumed when 
the bleeding event has resolved and the cause has been identified and corrected.
If a subject develops a new neurologic deficit or significant alteration in mental status
suggesting a cerebral vascular accident . Once a diagnosis is definitively  made and 
appropriate treatment is provided, the study  drug may be restarted at the discretion of the 
investigator.
Develops a platelet count less than 50,000/µL .If a repeat platelet count is obtained, and the 
result indicates that the abnormal platelet count was spurious, study  drug may be restarted.  
If the finding was not spurious, study  drug may be restarted after 2 consecutive values 
greater than 75,000/µL at least 1 week apart have been obtained.
Has a serious adverse event that is considered by  the investigator to be possibly related to, or 
exacerbated b y, stud y drug administration.
Requires a prohibited therap y on a temporary  basis (see Section 8, Prestudy  and 
Concomitant Therap y).
10.2.2. Approach to Subjects with Temporary  Interrupt ion of Study  
Treatment
If study  drug is temporarily  interrupted to allow a procedure to be performed, the routine 
measures described in Table 5and Table 6 should be considered: 
Table 5: Preoperative Interruption of Rivaroxaban: A Suggested Managem ent Approach (adapted from  
Spyropoulos and Douketis 2012)
Patient Renal 
FunctionLow Bleeding Risk Surgerya
(2-3 drug half -lives between last High Bleeding Risk Surgeryb
(4-5 drug half -lives between last 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
62
Status: Approved , 31 March 2017dose and surgery) dose and surgery)
Normal or mild 
impairm ent 
(CrCl ≥50mL/min), or 
moderate (CrCl ≥30 
and <50 mL/min)
impairm entLast dose : 2 days before surgery 
(skip 1 dose)Last dose : 3 days before surgery 
(skip 2 doses)
CrCl, creatinine clearance. 
aaiming for mild -to-moderate residual anticoagulant effect a t surgery (<12 -25%).
baiming for no or minimal residual anticoagulant effect (<3 -6%) at surgery.
Table 6: Postoperative Resumption of Rivaroxaban: A Suggested Managem ent Approach
Low Bleeding Risk Surgery High Bleeding Risk Surgery
resume on evening of or day after surgery (within 
24 hours postoperative)resume 2 to 3 days after surgery (within 48 to 
72 hours postoperative)
Spyropoulos, 201238.
10.2.3. Permanent Discontinuation of Study Treatment
If a subject must be permanentl y discontinued from study  drug before the end of the 
double -blind treatment phase , this will not result in automatic withdrawal of the subject from the 
study , and the subject should continue to be followed for efficacy  and safet y outcomes (for 
details see Section 3.1).
A subject should be permanently  discontinued from study  drug if:
The investigator believes that for safet y reasons ( ie,adverse event) it is in the best interest of 
the subject to stop study  drug.
The subject develops any condition which requires anticoagulation or thromboprophy laxis 
extending bey ond the treatment phase of the stud y (eg, atrial fibrillation, VTE).
The subject becomes pregnant.
The subject has a fall in CrCl to below 20 mL/min or 2 consecutive m easurements less than 
30 mL/min at least 1week apart (as calculated by Cockcroft -Gault formula , see 
Section 9.1.2 )during the study . 
The subject requires hemofiltration or dialy sis on a permanent basis
The subject requests to discontinue study  drug permanently
The subject has a hemorrhagic stroke, or intracranial bleeding
If the subject permanently  discontinues study  drug before Day 45, he/she should be instructed to 
complete an unscheduled visit and theremaining scheduled visits, including the Day 7 and 
Day 21 visits (if not yet completed), and Day 45 (+4d) and Day 75 (±5d) visits (Section 9.1.3 ). 
The Day 45visit should be a clinic visit; the Day 75visit may  be a telephone visit. 
The eCRF is to be completed to identify  the reason for permanent discontinuation of study  drug. 
The investigat or will provide a narrative to describe any adverse events that occur up to the 
Day75 (±5d) visit. The appropriate adverse event or serious adverse event sections of the eCRF 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
63
Status: Approved , 31 March 2017are to be completed. If study  drug is terminated for a serious adverse event, expedited reporting 
(within 24 hours) is also required as outlined in Section 12.3.2 , Serious Adverse Events.   
10.3. Withdrawal From the Study
A subject will be withdrawn from the study  for any  of the following reasons:
Lost to follow -up (only after all means of all subsequent contact, including locator services 
where permitted by law, up until the Day 75 (±5d ) visit, have been exhausted ,lost to 
follow -upwill be declared). 
Withdrawal of consent (unless specificall y refused by the subject, subject contact will be 
made to obtain vital status and other outcomes at the Day 75 (±5d ) visit ).
If a subject is lost to follow -up, every  reasonable effort must be made by the study  site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. The measures 
taken to follow up must be documented. 
Study  drug assigned to the withdrawn subject may not be assigned to another subject. Subje cts 
who withdraw will not be replaced.
If a subject withdraws consent from study  or is lost to follow -up, his or her vital status and other 
outcomes will be collected at the Day 75 (±5d )visit either by telephone or in person, or if 
applicable, by a  review of the subject’s medical or public records unless this contact is not 
allowed b y local regulations.
11. STATISTICA L METHODS
Statistical analy sis will be done by  the sponsor or under the authorit y of the sponsor. 
A general description of the statistical methods to be used to analyze the efficacy  and safet y of 
the study  drug is outlined below. A more detailed SAP,including detailed censoring rules for 
time to event analy ses and imputation rules for missing or partially  missing dates, will be 
provided in a separate document that will be finalized before the first subject is randomized.  
Summaries by treatment group using appropriate descriptive statistics will be provided for all 
study  variables including demographic and baseline characteristics. No imputation will be 
applied, unless specified otherwise in the SAP. Descriptive statistics such as mean, median, 
standard deviation, minimum, and maximum will be used to summarize continuous variables. 
Counts and percentages will be used to summarize categorical variables. Kaplan -Meier method 
will be used to summarize time-to-event variables. Graphical data displays may also be used to 
summarize the data.
Unless stated otherwise, all statistical tests will be interpreted at a nominal (that is, without 
adjustment for multiplicity ) 2-sided significance level of 0.05 and all CIs at a nominal 2-sided 
level of 95% .
Adjudicated results on efficacy  and safety  outcome swill be used for the interim and final 
analyses.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
64
Status: Approved , 31 March 201711.1. Analysis Setand Analysis Phase
Each analy sis involve sthe following 2 aspects : 1) analysis set, specify ingthe subjects to be 
included; and 2) analy sis phase , specify ing the time window within which data will be included.  
Key analysis sets and analy sis phase s are defined below.
11.1.1. Analysis Sets 
Intention- to-Treat (ITT) (as in the International Conference on Harmonisation [ICH]E9 
guideline) : This analysissetconsists of all randomized subjects who have a signed valid 
informed consent.  
Per-P rotocol (PP): This analysis setis a subset o f the ITT analysis set. Subjects with key
protocol deviations will be excluded from the PP analy sis set.Key protocol deviations will 
be defined in the SAP.
Safety : This analysis setis a subset of the ITT analysis set, consisting of subjects who 
receive at least 1dose of study  drug.
11.1.2. Analysis Phases
Up-to-Day-45: This analy sis phase includes all data from randomization to Day 45 
(inclusive).  
On-Treatment: This analysis phase includes all data from randomization to 2 days after the 
last dose of the study  drug (inc lusive).  
11.2. Sample Size Determination
This is an event -driven study . The targeted total number of primary  efficacy  outcome is 161, 
based on the ITTanalysis setand Up-to-Day-45 analy sis phase . If a subject has multiple events, 
only the first is counted towards study size determination.
This targeted total number of events is determined using statistical software East 5.3 based on the 
primary  efficacy  anal ysis (defined later) and the following assumptions:
40% relative risk reduction (RRR) in the primary  efficacy  outcome based on the 
ITTanalysis setand Up-to-Day-45 analysis phase (RRR is defined as 1 minus the hazard 
ratio (HR) of rivaroxaban versus placebo.) 
Power of 90% assuming the above RRR
Two-sided significance level of 0.05. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
65
Status: Approved , 31 March 2017To observe the targeted 161 events, it is estimated that a total of approximately  8,000 subjects 
will need to be randomized to either rivaroxaban or placebo in 1:1 ratio. This estimate is based 
on an estimated placebo incidence rate of the primary  efficacy outcome of 2.5%. In the event that 
the actual observed blinded pooled event rate is lower than the assumed rate, more subjects may 
be enrolled to accumulate additional outcome events. Randomization in this study  may be 
stopped at approximately 12,000 subjects for administrative considerations even if the targeted 
161 events have not been observed by then. The total number of VTE-related death events may 
also be taken into account when deciding to stop randomization.
The above assumptions are based on obser vations from the MAGELLaN study  and the 
IMPROVE VTE risk score published data.10, 11 , 31, 25,26, 37
Table 7below additionally  shows the approximate numbers of randomized subjects needed to 
observe 161 events based on several other placebo incidence rates.
Table 7: Approxim ate Num ber of Subjects Needed to Observe 161 Events
Placebo Incidence Rate Number of S ubjects
3.0% 6,700
2.75% 7,300
2.5% 8,000
2.25% 9,000
2.0% 10,100
11.3. Efficacy  Analyses
Primary Efficacy Outcome
The primary  efficacy  outcome will be analy zed based on the time from randomization to the first 
occurrence of s ymptomatic VTE (lower extremity  DVT and non- fatal PE) and VTE-related death
(death due to PE or death in which PE cannot be ruled out as the cause) in the ITTanalysis set
and Up-to-Day-45 analy sis phase .The primary  statistical alternative hypothesis is that 
rivaroxaban is superior to placebo on the primary efficacy  outcome, that is, time to event for the 
rivaroxaban group is stochasticall y later than that for the placebo group from randomization up 
to Day 45. More specifically , the survival function for the placebo group is lower than that for 
the rivaroxaban group. The null hypothesis is the negation of the alternative hypothesis, that is, 
the survival function for the placebo group is not lower than that for the rivaroxaban group.  As a 
further illustration of the hypotheses, for the case where hazard functions are proportional, the 
above alternative hypothesis can be expressed as that the HR of rivaroxaban versus placebo is 
less than 1, and the null hypothesis is that the HRis at least 1.   
The primary  statistical hy pothesis will be tested using Cox proportional ha zards model, stratified 
by subjects with CrCl ≥30 mL/min and <50 mL/min versus subjects with CrCl ≥50 mL/min, with 
the treatment (as random ized) as the only covariate. This primary  efficacy  analysis will bebased 
on the ITTanaly sis setand Up-to-Day 45 analysis phase . Subjects will be analyzed according to 
the treatment group to which they are randomized, regardless of actual treatment received.  As an 
operational arrangement, the 2-sided p-value will be reported ,and if itis less than the 2-sided 
alpha of 0.05, then superiority  of the study  drug will be declared when the observed survival 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
66
Status: Approved , 31 March 2017functions favor rivaroxaban. Note that the above testing procedure is equival ent to stratified 
logrank test40.The use of the Cox model format facilitates a consistent presentation of tests and 
CIs from analyses of efficacy and safety  outcome s and from subgroup and sensitivity  anal yses. 
The point estimate and corresponding 95% CIfor the HR (rivaroxaban to placebo) will be 
provided based on the Cox proportional hazards model. For the CIs, the plausibility  of 
proportional hazards assumption will be assessed by visuall y comparing the plot of the log of
cumulative hazard between treatments, and additionally  checked by adding a treatment by 
logarithm -transformed time interaction into the Cox model.  If there is strong indication that the 
proportional hazards assumption is not valid, the 95% CIfor relativ e risk of rivaroxaban versus 
placebo based onthe incidence of the primary efficacy  outcome from randomization up to 
Day 45 will be additionally  provided, using the Cochran –Mantel –Haenszel (CMH) statistic with 
stratification by  CrCl groups.
The cumulative event rate derived from the Kaplan -Meier method will be display ed graphically 
to evaluate the treatment effect over time. 
The following sensitivity  analyses of the primary efficacy  outcome will be conducted to assess 
the robustness of the conclusion from primary  efficacy  analysis: a) stratified Cox model as in the 
primary  efficacy  analysisbut additionally  stratified byregion, b) stratified Cox model as in the 
primary  efficacy  analysis but based on the per-protocol analysis setand on-treatment analysis 
phase . Additional post -hoc analyses may be conducted to investigate unexpected results . 
Off-treatment primary  efficacy  outcome events will be summarized by  treatment groups.
As described in Sections 9and 10, extensive efforts will be made to collect complete vital status 
and other outcome data for all subjects randomized inthis study . The amount of unavoidable 
missing follow -up in this study  with relativel y short treatment duration of 45 days is not 
expected to influence the conclusi on from the efficacy  analyses. To illustrate the extent of 
missingness, the numbers of subjects with missing follow -up and the percentages of missing 
follow -up time out of supposed follow -up time will be summarized.  Sensitivity  analyses will be 
conducted to estimate any additional events from the rivaroxaban andplacebo group during the 
missing follow -up time that are needed to overturn a superiority  conclusion from the primary  
efficacy  anal ysis.  Additional details will be provided in the SAP. 
Homogeneity  of treatment effects, both in HR and directi onin the following subgroups will be 
assessed by subgroup analy sis. Analy sis methods and any changes to these subgroups will be 
detailed in the SAP.
Age (< 65 vs ≥65; <75 vs ≥75 y ears)
Sex (men vs women)
Race (White vs others)
Geographic region (North America, South America, Western Europe, Eastern Europe, other)
CrCl (≥30 to<50, ≥50 to <80, ≥80 mL /min)
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
67
Status: Approved , 31 March 2017Body Mass Index (<25, ≥25 to < 35, ≥35 kg/m2)
Admitting diagnosis (HF with reduced ejection fraction , acute respiratory  insufficiency  or 
acute exacerbation of COPD, acute ischemic stroke, acute infectious disease ,and 
inflammatory  diseases)
History  of diabetes (y es vs no)
History  of cancer (y es vs no)
Baseline D -dimer level
Baseline aspirin use (y es vs no)
Baseline thienop yridine use (y es vs no)
Baseline proton pump inhibitor use (y es vs no)
Duration of index hospitalization (3 to 6, 7to 10 days)
Duration of anticoagulation during index hospitalization (3 to 6, 7to 10days)
LMWH or UFH during index hospitalization (LMWH vs UFH )
Total modified IMPROV EVTE risk factor score (2, 3, ≥4 )
Secondary Efficacy Outcomes
Each secondary  outcome will be analyzed based on time from randomization to the first 
occurrence inthe ITTanaly sis set,and the Up-to-Day-45 analysis phase .The same stratified Cox 
model as that for the primary  efficacy  outcome will be used.  Details will be provided in the 
SAP.
To control the family -wise type I error rate at alpha of 0.05 (2-sided) in testing for efficacy 
outcome s, if superiority of rivaroxa ban over placebo on the primary efficacy  outcome is 
established, superiorit y of rivaroxaban over placebo on secondary  outcome s will be tested 
sequent ially using a closed testing procedure in the following hierarchical order, each at alpha of 
0.05 (2- sided) :
VTE-related death (death due to PE or death in which PE cannot be ruled out as the cause)
Symptomatic VTE (lower extremity  DVT and non -fatal PE)
The composite of s ymptomatic VTE and ACM
The composite of symptomatic VTE (lower extremity  DVT and non-fatal PE), MI, 
non-hemorrhagic stroke and CV death (death due to a known CV cause and death in which a 
CV cause cannot be ruled out; by this definition, a VTE- related death is considered a CV 
death)  
ACM 
Exploratory Efficacy Outcomes
Each exploratory  outcome will be summarized by  treatment groups based on the ITTanalysis set
and Up -to-Day-45 analysis phase.  
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
68
Status: Approved , 31 March 201711.4. Pharmacokinetic A nalyses
The population PKmodel will characterize and predict the overall exposure to rivaroxaban and 
determine different PKparameters, such as, clearance (CL/F), volume of distribution (V/F), 
first-order absorption rate constant (Ka), area under the plasma concentration curve (AUC), 
maximum serum concentration (Cmax), minimum serum concentration (Cmin), time to reach 
maximum concentration in plasma (t max), and half -life (t 1/2).
A previously  developed population PKmodel will be used in an attempt to externally  validate it 
using data from the current study (ODIXa -DVT , 2006; EINSTEI N-DVT, 2006; 
BAY 59-7939 /12143 , 2008 ). The model will be utilized to predict the PKparameters for the 
current medically  ill population and to generate empirical Bayesian (individual) predictions for 
all concentrations in the current data set. Predictive performance check of the model will be
analyzed. Changes to the structural components of the model will be performed to address any 
observed model misspecifications.
11.5. Medical Resource Utilization and Health Economics Analyses
Medical resource utilization and health economics will be descriptive ly summarized by  treatment 
group.
11.6. Safety  Analyses
Bleeding Outcome s
The principal safet y outcome will be analyzed based on time from randomization to the first 
occurrence of ISTH major bleeding.  Treatments will be compared using the same Cox 
proportional hazards model as that for the primary  efficacy  outcome described earlier.  The 
analysis will be based on the safet y analysis setand on -treatment analysis phase . Subjects will be 
analyzed according to study  drug received. If a subject inadvertently  receives both drugs, the 
subject will be anal yzed as randomized.
Non-major clinicall y relevant bleeding and the composite of major plus non-major clinicall y 
relevant bleeding will be anal yzed based on time from randomization to the first occurrence. The 
same analysis as that for the principal safety  outcome will be used. Bleeding Academic Research 
Consortium bleeding event classification categories will be analy zed similarly . 
All bleeding , other bleeding, as well as sub-categories of major bleeding ,includ ing critical sites,
will be also summarized by  treatment groups.
Adverse Events
For adverse events that are collected as specified in Section 12, ADVERSE EVENT 
REPORTI NG, the verbatim terms reported in the eCRF by investigators to identify  adverse
events will be coded using the most current version of Medical Dictionary  for Regulatory 
Activities (MedDRA). For each MedDRA preferred term, the percenta ge of subjects who report 
at least 1 occurrence of the given event will be summarized by treatment group. Additional 
summaries, listings, or subject narratives may  be provided, as appropriate.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
69
Status: Approved , 31 March 2017Clinical Laboratory Tests
Because this study  will not collect laboratory data routinely , laboratory  datawill not be 
summarized . Local lab data may  be discussed in subject narratives.     
Vital Sign s
Descriptive statistics of pulse and blood pressure will be provided .
Physical Examination
Descriptive statistics of phy sical examination findings will be provided .
11.7. Interim A nalysis
An interim analy sis for futility  will be conducted when approximately  50% of subjects with 
adjudicated primary  efficacy  outcome events have been observed (about 50% of the expected 
total number of events based on the actual observed blinded pooled event rate even if this event 
rate is lower than the assumed rate) and there will be no alpha adjustment to the final analy sis.
The IDMC will review results of theplanned interim analy sis and make a recommendation 
whether the study  should be continued as planned, modified, or terminated prematurely  due to 
futility or safety .
The study  may be stopped early  for futility  when it would be unlikely  to establish superiority  on 
the primary  efficacy  outcome and/or a positive benefit over risk of rivaroxaban compared with
placebo, if the study  were to run to completion.  Detailed characteristics of non-binding futility  
criteria will be specified in the SAP.
11.8. Benefit -Risk A nalysis
The benefit -risk of rivaroxaban vs placebo will be evaluated based on the excess number of 
events between treatments for events intended to be prevented (benefits) and events that may be 
caused (risks). Excess number of events is defined as the difference in event rate times a 
hypothetical population size (eg, 10,000 patients). To have a comprehensive benefit -risk 
evaluation, several comparisons will be considered. One analy sis will be based on a comparison 
between the primary  efficacy  outcome (the composite of symptomatic VTE (lower extremity  
DVT and non -fatal PE) and VTE-related death (death due to PE and death in which PE cannot be 
ruled out as the cause) up to Day 45 post-hospital discharge) and the principal safet y outcome 
(the ISTH major bleeding). This analysis phase includ es all data from randomization to Day 45 
(inclusive), which is the period of treatment. In addition, benefit -risk balance may be further 
assessed for secondary  efficacy  outcomes in relation to major bleeding, while potentially  taking 
into consideration theclinical importance of those events, eg,in the context of irreversible harm. 
The Kaplan -Meier method will be used to display  and evaluate the benefits and risks over time. 
Also a bivariate approach to benefit -risk assessment will be explored.21Additional details for 
benefit -risk anal ysis will be specified in the SAP.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
70
Status: Approved , 31 March 201712. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor , and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
Rivaroxaban has been extensively  studied in Phase 1 through Phase 4clinical studies involving  
more than 70,000 patients and its overall adverse event profile has been well described. 
Appropriate information concerning adverse events were systematicall y collected and submitted 
to regulatory  authorities. For the purposes of this study  (and after discussion with appropriate 
regulatory  agencies) a value -driven approach to safet y data collection will be utilized. Certain
non-serious adverse events will not be col lected, while certain events will be collected as 
suspected outcome events and therefore not reported as serious adverse events. All data on safety  
and outcomes will be reviewed regularl y by an unblinded IDMC.
Section 12.1.1 describes the usual definitions of adverse events and serious adverse events.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untow ard medical occurrence in a clinical study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavor able 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that me dicinal (investigational or non -investigational) product. (Definition per ICH)
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 , All Adverse Events, for time of last adverse event recording).
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
71
Status: Approved , 31 March 2017Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significan t disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually  be considered serious.
For the purposes of this study , efficacy  and safety  outcomes will not be considered as adverse 
events or serious adverse events ( See Section 12.3.1 , All Adverse Events). 
Unlisted (Unexpected) Adverse Event /Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. For rivaroxaban , the expectedness of an adverse 
event will be determined by  whether or not it is listed in the I nvestigator's Brochure19.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likelyby the definitions listed in Section 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
72
Status: Approved , 31 March 2017Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg, confirmed by dechallenge). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and canno t be reasonabl y explained 
by an alternative explanation, eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive ( eg,it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interferen ce with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject ( eg,laboratory  abnormalities).
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
73
Status: Approved , 31 March 201712.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drug that may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor stud y drug
Inadvertent or accidental exposure to a sponsor study  drug
Any failure of expected pharmacologic action ( ie,lack of effect) of a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug, eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious ad verse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
In this study , recording of only a subset of adverse events is necessary . However, any adverse 
event of particular concern to the investigator may  be recorded in the eCRF to alert the sponsor.  
The following are excluded from adverse event collection and reporting, regardless of 
seriousness or severity . Exempted events will be captured on the eCRF as suspected outcome 
events only and will be waived from unblinding and exempted from expedited repor ting and 
include:
VTE- related death (death due to PE or death in which PE cannot be ruled out as the cause)
MI
ACS
Stroke
TIA
Symptomatic VTE ( lower or u pper ex tremity  DVT and PE)
Bleeding events
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
74
Status: Approved , 31 March 2017If the CEC determines that a suspected event does not meet the criteria for an outcome event as 
defined in the CEC charter, it willstillbe excluded from adverse event collection and reporting 
even if serious criteria were met .
Serious Adverse Events
All serious adverse events that are not outcome events as listed above should be reported to the 
sponsor as described in Section 12.3.2 .While one of the efficacy  outcome measures is ACM, 
any non-VTE- related death will be reported to the sponsor as a serious adverse event.
Certain adverse events are considered to be Adverse Events of Special Interest and should be 
reported as serious adverse events. These include : 
Suspected severe toxic effect on the bone ma rrow, such as severe thrombocy topenia (platelet 
count less than 50,000/µL), severe neutropenia (white blood cell count less than 500/µL ), 
pancy topenia, aplastic anemia
Suspected severe hypersensitivity  reaction (eg,anaphy laxis, angioedema, severe urticari a, 
bronchospasm, etc.)
Severe skin reactions such as Stevens -Johnson Sy ndrome
Suspected severe liver injury
Non-Serious Adverse Events
The following should be reported:
Non-serious adverse events leading to permanent study  drug discontinuation
All severe non-serious adverse events (regardless of relation to study  drug) including severe 
laboratory  abnormalities will be collected except the study  outcomes .   
Any other non-serious adverse events do not require reporting. However, any adverse event of 
particul ar concern to the investigator may  be recorded in the eCRF to alert the sponsor.  
Reporting Timelines and Processes
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a nysigned and dated I CF is obtained until completion of the subject's last 
study -related procedure (which may include contact for follow -up of safety ). Serious adverse 
events, including those spontaneously  reported to the investigator up to the Day 75 (±5d) visit, 
must be reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol.
All adverse events, regardless of seriousness, severity , or presu med relationship to study  drug, 
must be recorded using medical terminology  in the source document. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head con gestion should be reported as "upper respiratory  
infection"). Investigators must record their opinion concerning the relationship of the adverse 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
75
Status: Approved , 31 March 2017event to study  therapy . All measures required for adverse event management must be recorded in 
the source docum ent and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs). The 
investigator (or sponsor where required) must report SUSARs to the appropriate Independent 
Ethics Committee/Institutional Review Board (IEC/I RB) that approved the protocol unless 
otherwise required and documented by the IEC/I RB. A SUSAR will be reported to regulatory 
authorities unblinded. Participating investigators and IEC/I RB will receive a blinded SUSAR 
summary , unless otherwise specified. 
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all serious adverse events that are unlisted (unexpected) and associated 
with the use of the study  drug. The investig ator (or sponsor where required) must report these 
events to the appropriate Independent Ethics Committee/I nstitutional Review Board (IEC/IRB) 
that approved the protocol unless otherwise required and documented b y the IEC/I RB. 
12.3.2. Serious A dverse Events
All serious adverse events occurring during the study  must be reported to the appropriate sponsor
contact person b y stud y-site personnel within 24 hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to th e sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax , e-mail).
All serious adverse events that have not resolved by the end of the study , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
Theevent stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow-up efforts)
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the 
course of a subject's participation in a clinical study  must be reported as a serious adverse event, 
except hospitalizations for the following:
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
76
Status: Approved , 31 March 2017Social reasons in the absence of an adverse event
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ).
12.3.3. Pregnancy
All initial reports of pregnancy  must be reported to the sponsor by the study -site personnel 
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg,spontaneous abortion, stillbirth, and congenital 
anomaly ) are considered serious adverse events and must be reported using the Serious Adverse 
Event Form. Any subject who becomes pregnant during the study  must disc ontinue further study  
treatme nt. 
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male 
subjects included in the study  will be reported by the study -site personnel within 24 hours of 
their knowledge of the event using the appropriate pregnancy  notif ication form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required. 
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion ofa product defect related to 
manufacturing, labeling, or packaging, ie,any dissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and efficac y of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by regulatory  agencies worldwide. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event.
If the defect is combined with a serious adverse event, the study -site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor .
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
77
Status: Approved , 31 March 201713.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of S tudy Drug(s)
The study  drug supplied for this study  is rivaroxaban 10 mg, rivaroxaban 7.5mg and matching 
placebo.  All study  drugswill be provided as round white tablets. The crushed 10 mg tablet has 
been studied for bioequivalence and approved for administration as a crushed tablet; the crushed 
7.5 mg tablet has not been tested.
Refer to the Investigator's Brochure for a list of excipients19. 
14.2. Packaging
The study  drug will be supplied in bottles and dispensed in child -resistant packaging.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation Handling and Storage
The storage recommendation for rivaroxaban is at room temperature (approximately  15to 
30C).
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .The dispensing of study  drug to the subject, and the 
return of study  drug from the subject (if applicable), must be documented on the drug 
accountability  form. Subjects must be instructed to return all original containers, whether empty 
or containing stud y drug.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug must be available for verification by the sponsor's 
study  site monitor during on-site monitoring visits. The return to the sponsor of unused study  
drug will be documented on the drug return form. When the study  site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the drug return form.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospital/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject. Study  drug may not be relabeled or reassigned for use by other subjects. The 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
78
Status: Approved , 31 March 2017investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator Brochure
Pharmacy  manual/study  site investigational p roduct manual
IWRS Manual
electronic data capture ( eDC)Manual
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.   
This study  was designed to closely  mimic current clinical practice of discontinuing anticoagulation 
at hospital discharge. Over 90% of post-discharge patients do not continue thromboprophy laxis 
with anticoagulants. Furthermore, thromboprophylactic treatment is limited by the growing trend 
for shorter hospital sta ys (see Section 1.1). As VTE events still occur post-hospital di scharge, there 
is a need to evaluate the current standard of care. A placebo comparator group is therefore justified 
to evaluate this post-discharg e treatment paradigm. The bleeding risk will be reduced in this high 
risk medicall y ill population through dose adjustment and exclusion of patient subgroups with a 
comparativel y higher bleeding risk, eg,active cancer (see Exclusion Criteria Section 4.2). 
Any subject with a medical condition that requires use of any parenteral or oral anticoagu lation 
(eg, atrial fibrillation ) during the study  is not eligible for participation. During the study , should the 
subject develop any condition which in the investigator’s judgment requires anticoagulation , 
fibrinol ysis,or thromboprophy laxis, the subject will have study  treatment discontinued and will be 
manag ed as deemed appropriate by the treating physician. The subject will be asked to continue in 
the study  to be followed for efficacy  and safet y outcomes.
Rivaroxaban has been studied in over 70,000 patients for treating or preventing thrombotic 
associated diseases. Because the safety profile of rivaroxaban and the risk of bleeding with its use 
are well known, blood draws were kept to a minimum in this fragile group of subjects. Subjects 
will undergo all other treatments and diagnostic tests according to the standard of care in their 
localit y, thus making this study  minimall y intrusive in their regular routine health care. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
79
Status: Approved , 31 March 2017Investigators should inform thesubject ofthe importance to complete all study  visitsif their study 
drug isdiscontinued prematurel y due to an adverse event, or other reasons, in order to assess the 
vital status and determine if outcome events may have occurred. If these subjects refuse office 
visits, the investigator should remind the subject about the importance of allowing regular contac t 
until study  end, according to the TIME AND EVENTS SCHEDULE , either with them, or with a 
legall y acceptable representative, a close friend or relativ e, or their primary  care physician to 
determine vital status and if an efficacy  or safety  outcome event has occurred.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that origina ted in the Declaration of 
Helsinki, and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and compl ete copies of the following documents (as required by local 
regulations):
Final protocol and, if applicable, amendments
Sponsor -approved ICF (and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information ) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name of the sponsor , institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
80
Status: Approved , 31 March 2017approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
During the study  the investigato r (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to I CF and any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct), the amendment and applicable ICF revisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study . The 
reapproval should be documented in writing (excluding the ones that are purel y administrative, 
with no consequences for subjects, data, or stud y conduct) .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion. 
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/are used must be approved by both the sponsor and by the 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
81
Status: Approved , 31 March 2017reviewing IEC/I RB and be in a language that the subject can read and understand. The inform ed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized mem ber of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their partic ipation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that if they choose not to participate 
will not affect the care the subject will receive for the treatment of his or her disease . Subjects 
will be told that alternative treatments are available if they refuse to take part and that such 
refusal will not prejudice future treatment. Finally , they will be told that the investigator will 
maintain a subject identification register for the purposes of long-term follow -up if needed and 
that their records may be accessed by health authorities and authorized sponsor personnel 
without violating the confidentiality  of the subject, to the extent permitted by the applicable 
law(s) or regulations. By signing the ICF the subject is authorizing such access , including 
permission to obtain information about his or her survival status, and agrees to allow his or her 
study  physician to recontact the subject for the purpose of obtaining consent for additional safety 
evaluation s, if needed, and subsequent disease -related treatments , or to obtain information about 
his or her survival status.
If a subject is unwilling or unable to return for a Day 45 (+4d) and/orfollow -up Day 75 (±5d)
visit, sites should collect as much information as possible, including contacting the subject or 
legally  acceptable representative by telephone or by mail to determine vital status and if an 
outcome event has occurred, as agreed to by the subject during the initial informed consent 
process.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by means of the subject' s personall y dated signature. After having obtained the consent, a cop y of 
the ICF must be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes readi ng and explaining all written information) and 
should personally  date and sign the ICF after the oral consent of the subject.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to th ose data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
82
Status: Approved , 31 March 2017put in place. Sponsor personnel whose responsibilities require access topersonal data agree to 
keep the identit y of subjects confidential.
The informed consen t obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her origi nal 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the reques t, the 
conditions of the study , and the applicable laws and regulations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented witho ut prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provide d separatel y). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approv al/Notificat ion
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements are met.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
83
Status: Approved , 31 March 201717.2.2. Required Pre -study  Documentation
Thefollowing documents must be provided to the sponsor before shipment of study  drug to the 
study  site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) b y the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator ( eg,Form FDA 1572), if applicable
Documentation of investigator qualifications ( eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications ( eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg, accreditation/license), if applicable
17.3. Subject Identification Enrollment and Screening Logs
The investigator agrees to complete a subjec t identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. All 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
84
Status: Approved , 31 March 2017reports and communications relating to the study  will identi fy subjects by subject identification 
and date of birth. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility , and study identificati on; study  
discussion and date of signed informed consent; dates of visits; results of safety  and efficacy  
parameters as required by the protocol; record of all adverse events and follow -up of adverse 
events; concomitant medication; drug receipt/dispensing/ return records; study  drug
administration information ; and date of study  completion and reason for early discontinuation of 
study  drug or withdrawal from the study , if applicable. 
In addition, the author of an entry  in the source documents should be ident ifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
The following data will be recorded directl y into the eCRF and will be considered source data: 
History  of smoking
Blood pressure and pulse 
Height and weight 
17.5. Case Report Form Completion
Case report forms are provided for each subject in printed or electronic format. 
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
study -sitepersonnel from the source documents onto an eCRF, and transmitted in a secure 
manner to the sponsor within the timeframe agreed upon between the sponsor and the study  site. 
The electronic file will be considered to be the CRF.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to the 
study  must be recorded in CRFs prepared by the sponsor. Data must be entered into CRFs in 
Engl ish. Study  site personnel must complete the CRF as soon as possible after a subject visit, and 
the forms should be available for review at the next scheduled monitoring visit.
The investigator must verify  that all data entries in the CRFs are accurate and correct.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
85
Status: Approved , 31 March 2017All CRF entries, corrections, and alterations must be made by  the investigator or other authorized 
study -site personnel. If necessary , queries will be generated in the eDC tool. The investigator or 
an authorized member of the study -site personnel must adjust the CRF (if applicable) and 
complete the query .
The investigator or study -site personnel must adjust the CRF (if applicable) and complete the 
query .
If corrections to a CRF are needed after the initial entry  into the CRF, this can be done in 
3different way s:
Study  site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool).
Study  site manager can generate a query  for resolution by  the study -site personnel.
Clinical data manager can generate a query  for resolution by  the study -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , andperiodic monitoring visits by the sponsor, and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for CRF completion will be provided and reviewed with study -site personnel before 
the start of the study .The sponsor will review CRFs for accuracy  and completeness during on-
site monitoring visits and after their return to the sponsor; any discrepancies will be resolved 
with the investigator or designee, as appropriate. The data will be entered into the study  database 
and verified for accuracy and con sistency  with the data sources. 
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retaine d for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
86
Status: Approved , 31 March 2017If theresponsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such 
reports.
17.8. Monitoring   
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the vis its in a study  site visit log that will be kept at the study  site.  At these visits, 
the monitor will compare a sample of the data entered into the CRFs with the hospital or clinic 
records (source documents).  The nature and location of all source document s will be identified 
to ensure that all sources of original data required to complete the CRF are known to the sponsor 
and study -site personnel and are accessible for verification by the sponsor study -site contact. If 
electronic records are maintained at the study  site, the method of verification must be discussed 
with the study -site personnel. 
Remote data surveillance will be performed to monitor the study .  Key  subject demographic data, 
site performance data and other key variable data will be monitored remotely  as part of routine 
data surveillance on a monthly  basis for all sites and be compared to the results seen overall for 
that country  and region. Sites identified as having subjects with data that deviates substantially  
from the norm may  also be subj ect to additional in- person monitoring visits.  
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the CRF are consistent with the original source data.  Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel. 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study  to provide feedback on the study  conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study -site personnel will be available to provide an update on the progress 
of the study  at the site.  
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject 
participating in the study . The final data from the study  site will be sent to the sponsor 
(ordesignee) after completion of the final subject assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
87
Status: Approved , 31 March 201717.9.2. Study Termination
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the i ntended termination.
Reasons for the early closure of a study  site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  siteat 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and compari son with the CRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediat ely notify  the sponsor if he or she has 
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding rivaroxaban or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including exploratory research data, generated as a result of 
this study , are considered confidential and remain the sole propert y of the sponsor. The 
investigator agrees to maintain this information in confidence and use this information only to 
accomplish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of rivaroxaban , and thus may  be disclosed 
as requir ed to other clinical investigators or regulatory  agencies. To permit the information 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
88
Status: Approved , 31 March 2017derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain CRF data from all study  sites that participated in the study , and direct transmission 
of clinical laboratory  data from a central laboratory  into the sponsor's database . Recruitment
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator. Results of exploratory  analyses 
performed after the Clinical Study  Report has been issued will bereported in a separate report 
and will not require a revision of the Clinical Study  Report. Study  subject identifiers will not be 
used in publication of results. Any  work created in connection with performance of the study  and 
contained in the data that can benefit from copyright protection (except any publication by the 
investigator as provided for below) shall be the propert y of the sponsor as author and owner of 
copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the prima ry data are published. If an investigator wishes to publish 
information from the study , a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  outcome s of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study  by not submitting for publication
data derived from the individual study  site until the combined results from the completed study  
have been submitted for publication, within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
89
Status: Approved , 31 March 2017REFERENCES    
1. AHRQ Center for Delivery, Organization, and Markets, Healthcare Utilization Project Inpatient Sample, 1 993-
2008.
2. Alonso -Martínez JL, Sánchez FJ, Echezarreta MA. Delay and misdiagnosis in sub -massive and non -massive 
acute pulmonary embolism. Eur J Intern Med. 2010 Aug;21(4):278 -82. 
3. Barbar, , Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Torm ene D, Pagnan A, Prandoni 
P. A risk assessment model for the identification of hospitalized medical patients at risk for venous 
thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11):2450 -7.
4. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or 
symptomatic? Stroke. 2001;32:1330 -1335.
5. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne -Amrani A, et al; ENOXACAN II 
Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for 
cancer. N Engl J Med. 2002; 346:975 -80.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31 -41.
7. Cohen A, Davidson B, Gallus A, et al. Efficacy and safety of fondaparinux for the prevention of venous 
thromboembolism in older acute medical patents: randomized placebo controlled trial. BMJ. 2006;332:325 -94.
8. Cohen AT. Discoveries in thrombosis care for medical patients. Semin Thromb Hemost. 2002:28(s upl 3):13 -
17.
9. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE 
events and associated morbidity and mortality. Thromb Haemost. 2007;98:756 -64.
10. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophyl axis in acutely ill medical patients. N 
Engl J Med 2013;368:513 -23. 
11. Cohen AT ,Spiro TE, Spyropoulos AC et al, 2014 D -dimer as a predictor of venous thromboembolism in 
acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb 
Haem ost, 2014;12: 479 –487
12. Darze ES, Latado AL, Guimarães AG, et al. Incidence and clinical predictors of pulmonary embolism in severe 
heart failure patients admitted to a coronary care unit. Chest. 2005 Oct;128(4):2576- 80.
13. Eikelboom JW, Qui nlan DJ, Douketis JD. Extended -duration prophylaxis against venous thromboembolism 
after total hip or knee replacement: a meta -analysis of the randomised trials. Lancet. 2001 Jul 7;358(9275):9 -
15.
14. Goldhaber SZ. Pulmonary Embolism. Zipes DP, Libby P, Bonow  RO, Braunwald E, editors. Philadelphia, PA, 
USA: Elsevier Saunders; 2008.
15. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban vs. enoxaparin for thromboprophylaxis in 
medically ill patients. New Engl J Med 2011;365(23):2167 -2177.
16. Hull RD, Pineo GF, Ste in PD, Mah AF, MacIsaac SM, Dahl OE, et al. Extended out -of-hospital low -
molecular -weight heparin prophylaxis against deep venous thrombosis in patients after elective hip 
arthroplasty: a systematic review . Ann Intern Med. 2001;135:858 -69.
17. Hull RD, Schello ng SM, Tapson VF, et al. Extended -duration venous thromboembolism prophylaxis in acutely 
ill medical patients with recently reduced mobility: A randomized trial. Ann Intern Med. 2010;153(1):8 -18.
18. Hull RD, Merali T, Mills A, Stevenson AL, Liang J. Venous Thromboembolism in Elderly High -Risk Medical 
Patients: Time Course of Events and Influence of Risk Factors. Clin Appl Thromb Hemost. 2013. 19(4) 357 -
362.
19. Investigator’s Brochure BAY 59 -7939 ,v22 (Ri varoxaban). Bayer HealthCare AG . (October 2014 ).
20. Kahn SR, Lim W, Dunn AS, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical 
patients: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physici ans 
Evidence -Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e195S -e226S.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
90
Status: Approved , 31 March 201721. Kaatz S1, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa 
inhibitors. Am J Hematol. 2012 May;87 Suppl 1:S141 -5.
22. Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt 
WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Balancing risk and 
benefit in venous thromboembolism trials: concept for a bivariat e endpoint trial design and analytic approach. J 
Thromb Haemost. 2013 Aug;11(8):1443 -8.
23. LaPorte S, Liotier J, Bertoletti L, Kleber F -X, Pineo GF, Chapelle C, Moulins N and Mismetti P. Individual 
patient data meta -analysis of enoxaparin vs. Unfractionated h eparin for venous thromboembolism prevention 
in medical patients. J Thromb Haemost 2011; 9: 464 -472.
24. Leizorovicz A, Cohen A, Turpie AGG, Olssen CG, Vaitkus P, Goldhaber S. Randomized, placebo -controlled 
trial of dalteparin for the prevention of venous thro mboembolism  in acutely ill medical patients. Circulation. 
2004;110:874 -9.
25. Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle N, Cook RJ, Dairkee U, Spyropoulos AC.External validation of 
a risk assessment model for venous thromboembolism in the hospitalised acutely -ill medical patient (VTE-
VALOURR). Thromb Haemost. 2014 Oct;112(4):692 -9. 
26. Mebazaa A , Spiro TE, Büller HR, et al. Predicting the risk of venous thromboembolism in patients hospitalized 
with heart failure. Circulation. 2014 Jul 29;130:410 -8.
27. Mehran R, Rao S, et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials.  A Consensus 
Report From the Bleeding Academic Research Consortium.  Circulation 2011; 123: 2736 -2747.
28. NIH stroke scale. http://www.ninds.nih.gov/doctors/nih_stroke_sca le.pdf.  Accessed 21 January 2014.
29. OECD Health Data 2012, Eurostat Statistics Database; WHO European Health for all Databases Patel MR, 
Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker 
RC, Nessel CC, Paolini JF, Berkow itz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban 
versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883 -91.
30. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary  hypertension after 
pulmonary embolism. N Engl J Med. 2004;350:2257 -64.
31. Rasmussen MS, Jorgensen LN, Wille -Jørgensen P, Nielsen JD, Horn A, Mohn AC, et al; FAME Investigators. 
Prolonged prophylaxis with dalteparin to prevent late thromboembolic complicati ons in patients undergoing 
major abdominal surgery: a multicenter randomized open -label study. J T hromb Haemost. 2006;4:2384 -90.
32. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a 
systematic review and metaanaly sis. Chest. 2009 Mar;135(3):786 -93. 
33. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the 
risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism 
(IMPROVE) for medical patients in a tertiary health system.J Am Heart Assoc. 2014 Nov 17;3(6): 1-7.
34. Sam ama MM, Cohen AT, Darmon, et al. A comparison of enoxaparin with placebo for the prevention of 
venous thromboembolism in acutely ill medical patient. N Engl J Med. 1999;341:7 93-800.
35. Schiff GD, Hasan O, Kim S, et al. Diagnostic error in medicine: analysis of 583 physician -reported errors. 
Arch Intern Med. 2009 Nov 9;169(20):1881 -7. 
36. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient se tting. 
Arch Intern Med 2007;167:1471 -5.
37. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and associative models to identify 
hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706 -714.
38. Spyropoulos AC, Douketis JD. How  I treat a nticoagulated patients undergoing an elective procedure or 
surgery? Blood. 2012;120(15):2954 -62.
39. Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis 
in hospitalized patients. Am J Cardiol. 2005;95:1525 -6.
40. Therneau, Terry M. and Patricia M. Grambsch (2000). Modeling Survival Data: Extending the Cox Model. 
Statistics for Biology and Health. Springer, New York. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
91
Status: Approved , 31 March 201741. Torres -Macho J, Mancebo -Plaza AB, Crespo -Giménez A, et al. Clinical features of patients inappropriately 
undiagnosed of pulmonary embolism. Am J Emerg Med. 2013 Dec;31(12):1646 -1650. 
42. Weitz JI, Linkins LA. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin 
Investig Drugs. 2007;16:271 -82. Review .
43. White RH. The epidem iology of venous thromboembolism. Circulation. 2003;107 (23 Suppl 1):I4 -8.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
92
Status: Approved , 31 March 2017Attachment 1: Efficacy  Outcomes
All efficacy evaluations and outcomes described in Section 9.2will be evaluated and adjudicated by the 
CEC (defined below). Safety outcomes are defined in Section 9.5.
1.Death will be assigned to 1of the following:
a.CV death 
i)VTE -related 
(1) VTE -related death –death due to confirmed PE documented by objective testing or 
autopsy,
(2) VTE -related, PE cannot be ruled out –death, which cannot be attributed to a documented 
cause and for which pulmonary embolism cannot be ruled out (unexplained death)
ii)Other CV death
b.Non-CV death – death not included in 1 of the above categories 
2.Symptomatic DVT –displaying signs or symptoms of proximal or distal lower ex tremity DVT , upper 
extremity DV T, or other DVT and confirmed by adjudication, based on 1or more of the following 
diagnostic criteria:
a.a non- compressible venous segment on compression ultrasonography, or in patients with a history 
of previous DVT, either a new non -compressible venous segment or a substantial increase (4 mm 
or more) in the diameter of the vein during full compression in a previously abnormal segment on 
ultrasonography, or 
b.the presence of an intraluminal filling defect on venography, or
c.DVT documented at autopsy.  
If in patients with history of previous DVT or incomplete documentation of the previous episode is 
available, additional criteria may be integrated into the adjudication of the current event, such as: 
ultrasonography appearance o f the thrombus, or D-dimer at presentation. Soleal or muscular branch 
DVTs, l ower extremity superficial DVT will not be included .The totality of available clinical, 
imaging and laboratory findings should be considered 
3.Symptomatic PE –displaying signs or symptoms suggestive of PE  and confirmed by adjudication 
based on 1 or more of the following diagnostic criteria: 
a.an intraluminal filling defect on computed tomogr aphy (CT) angiography or spiral CT, or 
b.an intraluminal filling defect on pulmonary angiography or cutoff of a vessel more than 2.5 mm 
in diameter, or 
c.a perfusion lung scan defect of at least 75% of a segment with corresponding normal ventilation 
(high probability ventilation -perfusion (V -Q) scan), or 
d.a non- high probability V-Q scan abnormality associated with DVT documented by 
ultrasonography or venography, or 
e.in the absence of imaging test in a hemodynamically unstable patient, evidence of right 
ventricular dysfunction by transthoracic or trans esophageal echocardiogram ( ESC criteria), or 
f.PE documented at autopsy.  
The anatomic extent of PE will be classified by the adjudication committee as either segmental or 
greater, or sub -segmental.  The totality of available clinical, imaging and laboratory findings should 
be cons idered.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
93
Status: Approved , 31 March 20174.Myocardial infarction
Requires combination of evidence of myocardial necrosis (either changes in cardiac biomarkers or 
post-mortem pathological findings), andsupporting information from clinical presentation, ECG 
changes or the results of myocardial imaging or coronary artery imaging.  The totality of available 
clinical, ECG and cardiac biomarker should be considered:
1.Clinical Presentation consistent with the diagnosis of myocardial ischemia and infarction, 
taking into account differential conditions associated with elevations in cardiac biomarkers
2.Biomarker elevations
a.Elevations relative to URL in CK, CK -MB or troponin
3.ECG changes 
a.ECG manifestations of acute myocardial ischemia (in absence of left ventricular 
hypertrophy and left bundle branch block); abnormalities may be lesser in patients 
with abnormal biomarkers
i.New ST elevation at the J point in 2contiguous leads with the cut -points: 
≥0.1 mV in all leads other than leads V2 -V3 where the following cut -points 
apply: ≥0.2 mV in men ≥ 40 years ( ≥0.25 mV in men < 40 years) or ≥0.15 mV in 
women
ii.New horizontal or down- sloping ST depression ≥0.05 mV in 2contiguous leads 
and/or new T inversion ≥0.1 mV in 2 contiguou s leads with prominent R wave or 
R/S ratio>1
b.Criteria for pathological Q -wave
i.Any Q -wave in leads V2- V3 (abnormalities may be lesser in patients with 
abnormal biomarkers) 0.02 seconds or QS complex in leads V2 and V3
ii.Q-wave ≥0.03 seconds and ≥0.1mV deep or QS complex n leads I, II, aVL, aVF, 
or V4- V6 in any 2 leads of a contiguous lead grouping (I, aVL, V1 -V6, II, III, 
and aVF; the same criteria are used for supplemental leads V7 -V9 and for the 
Cabrera frontal plane lead grouping)
c.ECG changes with prior myocardial infarction
i.Pathological Q -waves, as defined above
ii.R-wave ≥0.04 seconds in V1- V2 and R/S ≥1 with a concordant positive T -wave 
in the absence of a conduction defect
d.Criteria for prior myocardial infarction
i.Pathological Q waves with or without symptoms in the absence of non -ischemic 
causes
ii.Imaging evidence of a region of loss viable myocardium that is thinned and fails 
to contract, in the absence of a non -ischemic change
iii. Pathological findings of a prior myocardial infarction
5. Stroke –an acute episode of focal or global neurological dysfunction caused by non -traumatic brain or
spinal cord injury as a result of hemorrhage or infarction
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
94
Status: Approved , 31 March 2017Attachment 2: Suspected Event Supporting Documentation
The following supporting material, if available, w ill be requested to be submit tedfor each suspected event 
by the investigative site. The totality of available clinical, imaging and laboratory findings should be 
considered. Supporting materials to be completed/collected, not limited to:
1.Death with cause 
1.Complete Death eCRF data 
2.Hospital admission history and physical /death summary
3.Autopsy reports 
2. Suspected Symptomatic deep venous thrombosis (DVT) 
1.Complete Symptomatic Deep Vein Thrombosis eCRF data
2.Imaging 
3.Hospital admission history and physical
4.Hospital discharge summary
5.Duplex ultrasound 
6.Venography  
7.Computed tomography (CT) scan or MRI
8. D- Dimer 
9.Autopsy reports 
3. Suspected Symptomatic PE
1.Complete Symptomatic Pulmonary Embolism eCRF data 
2.Hospital admission history and physical
3.Hospital discharge summary
4. D- Dimer 
5.High resolution CT pulmonary angiogram or helical chest CT scan
6.Ventilation/perfusion scan
7.Transthoracic or transesophageal echocardiogram in hemodynamically unstable 
patient
8.MRI
9.Chest X -Ray 
10.Duplex Ultrasound or venogra phy 
11.Electrocardiogram
12.Autopsy reports 
4. Suspected Myocardial infarction / acute coronary syndrome
1.Complete Myocardial Infarction eCRF data 
2.Hospital admission history and physical
3.Hospital discharge summary
4.Electrocardiogram
5.Cardiac Biomarkers
6.Autopsy reports 
5. Suspected Stroke / transient ischemic attack
1.Complete Stroke eCRF data 
2.Hospital admission history and physical
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
95
Status: Approved , 31 March 20173.Hospital discharge summary
4.Computed tomography (CT) scan 
5.Magnetic resonance imaging (MRI)
6. Suspected Major bleeding (MB)
1. C omplete Bleeding Event eCRF data 
2.Hospital admission history and physical
3.Hospital discharge summary
4.Procedure notes
5.CBC laboratory test
7. Suspected Non-major clinically relevant bleeding (NMCR) 
1.Complete Bleeding Event eCRF data
2.Hospital admission history and physical
3.Hospital discharge summary
4.Procedure notes
5.CBC laboratory test
8. Suspected Other Bleeding
1.Complete Bleeding Event eCRF data
2.Hospital admission history and physical
3.Hospital discharge summary
4.Procedure notes
5.CBC laboratory test
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
96
Status: Approved , 31 March 2017Attachment 3: Pharmacokinetic Sample Collection and Handling
Materials and Labeling
Blood must be collected in glass or plastic blood collection tubes (eg,Vacutainer®) containing appropriate 
anticoagulants. Resulting plasma samples must be stored in polypropylene storage tubes. No tubes with 
separation gel should be used.
Use of alternative materials will not result in a protocol amendment if preapproved by the Bio-analysis 
Scientist.
All tubes and containers will be labeled with preprinted labels. The preprinted information will include 
the study number, CRF identification number (CRF I.D.  #), treatment arm or treatment period, scheduled 
sampling day and time as stipulated in the flow chart, and the analyte name if applicable. No other 
information will be written on the labels. Labels should be attached to the storage tubes at least 12 hours 
before being frozen to ensure proper adherence.
Labels should be applied to the sample tubes as follows:
Apply  labels to the sample tubes so that they  do not o verlap and obscure any information. 
If possible, expose an area between the 2 ends of the label to allow viewing of the 
contents of the tube.
Do not alter the orientation of the label on the sample tube.
Apply  labels to all tubes in the same manner.
Prepar ation of Plasma Pharmacokinetic Samples for Rivaroxaban
Collect 2 mL  of blood into the appropriate K 2EDTA -containing collection tube ( eg,
Vacutainer) at each time point.
Record the exact date and time of sampling in the CRF.
Gently  invert the tubes 8 to 10 times to afford mixing, before processing.
Centrifuge blood samples at room temperature within 1 hour of collection in a clinical 
centrifuge at 1,300 g for 15 minutes or centrifuge for 10 minutes at 1,500 -1,600 g, 
unless otherwise specified by  the supplier, to yield approximately  1 mL of plasma from 
each 2 mL whole blood sample.
Transfer all separated plasma immediately  with a clean, disposable glass or poly ethylene 
pipette (use 1 new pipette per sample) to a pre- labeled storage tube (1.8 mL NUNC 
tubes ).
Store plasma samples in an upright position in a fr eezer, at a set temperature of -20°C 
until transfer to the bio -analy tical facilit y.
The time between blood collection and freezing the plasma will not exceed 2 hours.
Ship specimens according to the ins tructions provided.
Ship specimens to the bio- analytical facility , sorted by  subject, by  sample collection date 
and time.
Questions regarding handling the plasma PK specimens should be addressed to the 
contact person for the sponsor.
Alternative procedures will not result in a protocol amendment if approved by  the 
Bioanal ysis Scientist.
Please refer to the Stud y Lab Manual for proper shipping instructions.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
97
Status: Approved , 31 March 2017Attachment 4: Symptom Assessment
During all contacts, the treatment and clinical course of the subject is to be evaluated using a 
standard list of questions. Please ask the subject s ystematically the following questions -
1.Since the last contact did you experience new or increased?
Shortness of Breath Yes     No 
Chest Pain especially while breathing Yes     No 
Cough Yes     No 
Blood in Sputum Yes     No 
Dizziness or Fainting Yes     No 
Rapid BreathingYes     No 
Rapid Heart RateYes     No 
Blue Lips or FingersYes     No 
Weakness on one side of face/bodyYes     No 
FeverYes     No 
If PE is clinically  suspected, perform objective testing and complete the adjudication package as 
described in Attachment 2 (Suspected Event Supporting Documentation) of the protocol.
2.Since the last contact did you experience new or increased?
Calf pain, tenderness or swelling Yes     No 
Appearance of veins on the surface of the 
skin on legsYes     No 
Tenderness along deep veins of legs Yes     No 
Swelling of entire leg Yes     No 
Puffiness o f leg Yes     No 
If DVT is clinically  suspected, perform objective testing and complete the adjudication package 
as described in Attachment 2 (Suspected Event Supporting Documentation) of the protocol.
3.Since the last contact did you experience any?
Bleeding Yes     No 
If yes, complete the adjudication package as described in Attachment 2 (Suspected Event 
Supporting Documentation) of the protocol.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
98
Status: Approved , 31 March 2017Attachment 5: INT-1 to INT -5/ Amendm ent Changes
Amendment INT -5(15 June 2015)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reasons for the a mendment are to modify study procedures 
(including the risk score criterion) and to add patient training material.  
Applicable Section(s) Description of Change(s)
Rationale: Emerging literature has indicated that the required risk score of the subjects enrolled w ere not sufficient 
to attain the desired event rate. Because the outcome events are all symptomatic in this study, additional site and 
subject training is necessary to ensure capturing events.
Applicable Section(s) Description of Change(s)
Synopsis 
Objective and Hypothesis: 
Secondary Objectives, 
Exploratory Objectives, 
Hypothesis, Section 2.1, 
Objectives, Section 2.2, 
Hypothesis, 11.3.Efficacy 
Analyses, Secondary Efficacy 
OutcomesDefinition of VTE -related death was added. .
Com posite out come was added to Secondary Objectives and Hypothesis.
Synopsis
Overvie w Of Study Design, 
Section 3.1, Overview of Study 
DesignDefinition of VTE -related death was added.
CHF was replaced w ith HF with reduced LVEF.
Upper limit of index hospitalization was changed to 10 days.
Additional inclusion criterion regarding VTE risk score was added.
Figure 3 w as replaced and the new figure updates index hospitalization.
Synopsis
Subject PopulationCHF was replaced w ith HF with reduced LVEF.
Upper limit of index hospitalization was changed to 10 days.
Additional inclusion criteria regarding VTE risk score w ere added.
Synopsis
Dosage and Administration,
Interruption of Study DrugStatement that study drug needs to be discontinued was replaced w ith 
‘temporarily int errupted’.
Clarifications regarding use of anticoagulation thromboprophylaxis were added.
Synopsis
Efficacy Evaluations/OutcomesDefinition of VTE -related death was added. The composite outcome was added 
to efficacy outcomes.
Synopsis 
Exploratory Object ives“Symptomatic” was added to upper extremity DVT and the composite outcome 
was deleted.
Synopsis
Dosage and AdministrationClarification was added that “Regardless of the day on which the Day 45 Visit 
occurs, no study drug may be taken after Day 45”.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
99
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Time and Events Schedule, and 
Section 9.1.2. Screening PhaseTreatment window upper limit on Day 7 and Day 21 w as modified. 
Protocol activities were further clarified by modifying or adding more detailed 
footnotes, ie, admitting diagnosis, D -dimer scree ning, training on signs and 
symptoms of disease. Symptom Assessment and Subject Counseling were added. 
Consent language was changed to allow  for screening to occur any time after 
admission of index hospitalization and once the informed consent is obtained .  
Also, drug accountability/dispensation at Day 7 was removed and Day 7 visit 
may now be performed by telephone.
Synopsis
Statistical Methods, Sample 
Size Determination,
Efficacy AnalysesFurther details were added regarding stop of randomization. Definition of VTE -
related death w as added. The composite outcome was added to efficacy analyses.
Throughout the
protocolDefinition of VTE -related death was added. CHF was replaced w ith ‘HF with 
reduced LVEF’.
Section 1.1.5, Studies 
Examining Extended 
Thromboprophylaxis in 
Patients Hospitalized for Acute 
Medical Conditions and 
MARINER ApproachAddition of paragraph regarding IMPROVE VTE risk score and missed diagnosis 
of PE.
Section 3.2, Study Design 
RationaleClarification regarding comparator treatmen t discontinuation was added. Non -
hemorrhagic was deleted from non -hemorrhagic stroke.
3.3.1, Executive Committee Addition of ad hoc member appointment as necessary.
Section 3.3.3, Clinical Events 
CommitteeSuspected outcome events were modified for DVT, MI, stroke, and bleeding.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
100
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Rationale: Modified inclusion criteria to enrich for subjects w ith higher level of risk of VTE and to align with 
standard of care for stroke patients.
4. SUBJECT POPULATION, 
Section 4.1 Inclusion Criteria.Consent language was changed to allow  for screening to occur any time after 
admission of index hospitalization and once the informed consent is obtained.  
For Sections 4.1. Inclusion Criteria, 4.2. Exclusion Criteria and 4.3. Prohibitions 
and Restrictions, detailed protocol am endm ent m odifications are described in 
Attachment 6, and a shorter version is provided in -text.
Inclusion Criterion # 1. 
The allow ed duration of the hospitalization was decreased from 14 to 10 days.
Detail was added regarding the type and extent of CHF present to be eligible for 
the study.  Patients with preserved ventricular function will not be enrolled 
because of the low er risk of VTE than in patients with reduced ventricular 
function.
In the previous version of the protocol (INT -4), subjects w ere not allow ed to have 
received fibrinolysis during the index hospitalization. This has been updated 
based on the standard of care for stroke patients.  
Inclusion Criterion # 2. 
An elevated D- dimer will now be required to be eligible if the VTE risk score is 2
or 3.  Direction to verify at randomization that the IMPROVE Risk Score 
calculated at screening was calculated correctly.
In Table 1, the footnote was simplified to mirror the cancer exclusion.
Inclusion Criterion # 4. 
Maximum daily dose of thromboproph ylactic agents allowed w as added to ensure 
that subjects have not received off -label use of thromboprophylaxis.   
Rationale: Modified exclusion criteria to align with standard of care and to provide more clarity for enrollment.
Section 4.2 Exclusion Criteria. Exclusion Criterion #1. The phrase about recent bleeding that w ould allow  the 
investigator to make a determination of whether or not the bleeding would 
contraindicate the use of pharmacologic thromboprophylaxis w as rem oved.
Exclusion Criterion # 2. Guidance on differentiating major from minor surgery 
has been added. 
According to the standard of care, ongoing thromboprophylaxis is generally not 
discontinued for the performance of cataract surgery, so the notation that recent 
cataract surgery is not an exclusion criterion has been added.
The exclusion period for recent head trauma was reduced from 3 months to 
4weeks, based on expert input.
Exclusion Criterion #3. Reference was changed for consistency with the new 
location of the item referenced.
Exclusion Criterion #5. Addition of any intracranial bleeding.
Exclusion Criterion #6 was removed. 
Exclusion Criterion #7. For intracranial neoplasm, it was clarified that the 
presence of either a malignant or a benign neoplasm would result in exclusi on.
Exclusion Criterion #10. Subjects with cancer not in remission will be excluded.  
The previous requirement for a remission of at least 6 months duration has been 
removed, allowing the clinician to determine what time period is appropriate.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
101
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Exclusion Criterion #19. Use of an intravascular device for blood pressure 
support during the index hospitalization was added as an exclusion because the 
vascular access required for the use of such devices w ould present an 
unacceptable bleeding risk.
Exclusion Cri terion #23. In the previous version (INT -4) of the protocol, it w as 
specified that the use of fibrinolysis during the index hospitalization precluded 
inclusion in the study.  This has been modified to accommodate the inclusion 
criterion revision that allow s the inclusion of subjects with ischemic stroke and 
use of fibrinolysis, if fibrinolysis occurred at least 3 days before randomization.
Exclusion Criterion #24. The antiplatelet exclusion criteria have been grouped 
together and the prohibition of use of these antiplatelet regimens has been 
extended to the beginning of the index hospitalization instead of planned use 
during the study.  
Exclusion Criterion #27 w as rem oved and was added to the list of medications 
excluded at index hospitalization within Ex clusion Criterion #24.
Exclusion Criterion #28. Use of NSAIDs was further clarified.
Exclusion Criterion #31. The exclusion criterion related to PPIs and clopidogrel 
concomitant use has been removed as the drugs discussed are not study 
treatments.
Rationale: Modified exclusion criteria to align with standard of care and to provide more clarity for enrollment.
Section 4.3. Prohibitions and 
RestrictionsDiscontinuation of the study drug was further clarified.
Criteria #1 and #5 w ere removed and content was added to criterion #7.1.
Criterion #7. The antiplatelet exclusion criteria have been grouped together and 
the prohibition of use of these antiplatelet regimens has been extended to the 
beginning of the index hospitalization instead of planned use during the study.  
Section 5. Tr eatment Allocation 
and Blinding, Treatment 
Allocation, UnblindingTo allow  the ability to achieve a regionally heterogeneous population, this change 
allows the sponsor to cap enrollment by region without a protocol amendment.
A header identifying the posi tion of description of unblinding processes has been 
added to better direct the reader.
A statement was added to indicate that even in the event of an outcome or 
bleeding event, an investigator w ill be able to unblind a subject’s treatment.
Section 5 Trea tment Allocation 
and Blinding, Section 6. 
Dosage and Administration, 
Interruption of Study Drug,
10.2.1. Temporary Interruption 
of Study Treatment, Section 
10.2.2 Approach to Subjects 
with Dose Interruption, Section 
7. Treatment Compliance,
Section 9.2.2. Approach to 
the Subject w ith an Efficacy 
Outcome EventStudy drug interruption and drug accountability were further clarified, and minor 
modifications were made to Table 6.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
102
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Section 8. Prestudy and 
Concomitant TherapyFurther clarifications were added on m edications taken during the index 
hospitalization and recording of drug identities.
Section 9.1.2. Screening Phase, 
9.5.3.Other Safety AssessmentsA baseline D -dimer screening was added to assess its contribution to VTE risk in 
the study population.
Section 9.1.3. Double -Blind 
Treatment PhaseDetails for the randomization and treatment visits were added to guide the reader.
Section 9.1.4. Post -treatment 
Phase (Follow -Up)Details for follow -up visit were added.
Section 9.2. Efficacy 
Evaluations and O utcomesParagraph w as added regarding the judicious diagnosis of PE by the 
investigators. 
Section 2.1. Objectives, Section 
9.2.1. Efficacy Evaluations and 
OutcomesRequirements for submission of a suspected event for adjudication were added. 
For explorat ory efficacy outcomes, “Symptomatic” was added for clarification to 
“Upper extremity DVT”.
Section 9.5.1. Bleeding Events, 
11.6. Safety Analyses, Bleeding 
OutcomesAdditional resource for CEC classification of bleeding events w as added.
Section 11.2. Sample Size 
DeterminationFurther details were added regarding stop of randomization.
Section 11.3. Efficacy Analyses For subgroup analyses, geographic regions were added, and admitting diagnosis 
was modified.
Section 11.8. Benefit -Risk 
AnalysisA bivari ate approach to benefit -risk assessment that will be explored w as added.
Section 12.3.1. All Adverse 
EventsNon-hemorrhagic was deleted from non -hemorrhagic stroke.  Adverse event 
reporting w as clarified further.
Section 14.1. Physical 
Description of Stu dy Drug(s)Information about crushed tablets was added.
References List was updated.
Attachment 1: Efficacy 
OutcomesAssignment of death was modified for clarity. Stroke was modified for clarity 
(eg, non -hemorrhagic was removed).
Attachment 2: Suspected Event 
Supporting DocumentationAll events, with the exception of death, were defined as suspected. For 4.) 
Suspected MI/ACS, Cardiac Biomarkers are now included for supporting 
documentation.
Attachment 4: Symptom 
AssessmentAttachment was added to captur e clinical status for suspected outcome events 
and symptom assessment.
Attachment 5: INT -1 to INT -4/ 
Amendment Changes, and Attachment was added to the protocol. 
Attachment 6: Complete 
Amendment History of INT -5 
Inclusion and Exclusion 
Criteria, and Pr ohibitions and 
Restrictions for Data Collection 
PurposesAttachment was added to the protocol.
Throughout the protocol Minor grammatical, formatting, and spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
103
Status: Approved , 31 March 2017Amendment INT -4(19 January 2015)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor the scientific value of the study.  
The overall reason for the amendment: The overall reason for the amendment is to provide further clarifications.  
Applicable Section(s) Description of Change(s)
Rationale: Clarification of study design and the correction to exclusionary medications.
Applicable Section(s) Description of Change(s)
Time and Events Schedule, and 
Section 9.1.2. Screening PhaseMinor edits to footnotes for clarification. 
Section 4.2 Exclusion Criteria. Exclusion criteria # 2.1 and #3.1 modified w ith correct references in parenthesis. 
Exclusion criteria #22.2.a and #22.2.b modified to specify correct exclusionary 
medications.
Section 4.3 Prohibitions and 
RestrictionsProhibitions and Restricti ons criteria #2 and 3 modified to specify correct 
exclusionary medications.
Amendment INT -3(8 December 2014)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor the scientific value of the study.  
The overall reason for the amendment: The overall reason for the amendment is to provide further clarifications 
in response to questions from regulatory agencies and investigator sites
Applicable Section(s) Description of Change(s)
Rationale: Clarification of study design, simplification of conduct, to enhance data collection, also to avoid 
scheduling difficulties, or subject population (in response to comments from sites in attendance at investigator 
meetings, health authority, site, or Ethic s Committee queries), and congruent to the Statistical Analysis Plan.   
Synopsis Objective and 
Hypothesis: Primary Objective, 
Secondary Objectives, 
Exploratory Objectives, 
Hypothesis, Efficacy 
Evaluations/Outcomes; Section 
2.1. Exploratory Objectives; 
Section 2.2. Hypotheses; Section 
9.2. Efficacy Evaluations and 
Outcomes  Increased the level of detail in the exploratory objectives. For symptomatic 
DVT, the additional descriptor "low er extremity" was added. For symptomatic 
PE, "non -fatal" w as added in keeping with the SAP. For CV events, "fatal and 
non-fatal" w as removed as the combination results simply in all CV events.
The paragraph “If a subject….drug treatment” was added to clarify that 
unblinding is unlikely to impact the care of the subjects.
The paragraph “Rivaroxaban will not be….benefit from study treatment” has 
been added as an explanation of whether or not study treatment will be provided 
after the subject completes participation in the study. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
104
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Synopsis Overview of Study 
Design; Section 3. St udy 
Design and Rationale
Synopsis Subject Population; 
Section 3.1. Overview of Study 
Design; 4.1 Inclusion CriteriaRe-worded subject population for better interpretation.
The term "hospital discharge" has been removed and replaced w ith “leaving the 
hospit al”,
The phrase “ne w onset or exacerbation” has been added to reinforce that the 
reason for the hospitalization that qualifies a patient for inclusion is broadly 
defined.
The phrase “including spinal cord infarction” has been moved from its own 
inclusion criterion to be closer to the reason for hospitalization that it modifies.
The phrase, “placebo…hospital discharge” has been added to provide a rationale 
for selection of placebo as the comparator, w ith a more extensive explanation 
later in the protocol.
Time and Events Schedule Minor edits, including addition of Discharge Destination to all visits, and change 
from +3d to +4d for the Day 45 visit.
Reformatted, added, and renamed protocol activity, eg, added LMWH/UFH use 
and index hospitalization and mo dified footnotes eg, collection of hemoglobin, , 
platelet count, vital signs clinical assessment requirement and criteria, and CrCl,
D-dimer, fasting and PK samples, and instructions regarding discontinuing for 
consistency with protocol body and eCRF. Dele ted hematocrit, hemogram (CBC) 
and auto differentiation.  
Section 4.1 Inclusion Criteria. Inclusion Criteria 1, 2, 3, 4, and 6 w ere m odified and Inclusion Criterion 5 was 
deleted.
Specifically:
Inclusion Criterion #1 w as divided into 3 sub -criteria, “ind ex hospitalization” 
definition added to improve the clarity of counting the number of days, term 
“hospital discharge” has been removed and “the day the patient leaves the 
hospital” has been edited. 
Inclusion Criterion #2, the explanations in the footnotes of the risk score table 
were expanded w ith content of INT -2 Appendices, age modified from > to ≥60
and split into 2sub-sections to enhance data collection, and guidelines for the 
definition of major surgery have been added.
Inclusion Criterion #3, term “post -discharge” has been removed as unnecessary.
Inclusion Criterion #4, concrete guidance added regarding thromboprophylaxis.
Inclusion Criterion #5 deleted and content now incorporated into inclusion 
criterion #1.
Inclusion Criterion #6 modified to excl ude legally acceptable representatives 
from providing informed consent.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
105
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Section 4.2, Exclusion Criteria Criteria 2, 3, 5, 5, 6, 9, 10, 11, 12, 
14, 15, 1822, 23, 24, 25, 26, 27, and 28 w ere m odified. Criterion 31 w as added.
Specifically:
Exclusion Criterion #2 and #3, added references to the guidelines for the 
definition of major surgery.
Exclusion Criterion #4 modified to allow  for normalization of the INR during the 
index hospitalization.
Exclusion Criterion #5 modified to include information that was formerly 
provided in an appendix.
Exclusion Criterion #6 modified to provide guidance clarifying the meaning of 
“severe head trauma”.
Exclusion Criterion #9 modified to allow  for normalization of or spurious platelet 
counts during the index hospitalization.
Exclusion Criterion #10 modified to clarify that non -melanoma skin cancer is not 
an exclusion criterion and that leuprolide acetate is not a prohibited medication.
Exclusion Criterion #11modified to specify the anticoagulants that are prohibited.
Exclusion Criterion #12, added unilateral below the knee amputation.
Exclusion Criterion #14 modified to include a reference to calculating the 
creatinine clearance.
Exclusion Criterion #15 modified to indicate that the degree of liver insufficiency 
which w ould result in exclusion is liver disease associated with a coagulopathy.
Exclusion Criterion #18 modified to allow  the investigator to use discretion in 
determining the degree of alcohol abuse that would lead to exclusion from the 
study.
Exclusion Criterio n #22 modified to include both inducers and inhibitors and the 
most up -to-date language.
Exclusion Criterion #23 modified to remove “systemic” as any fibrinolysis 
during the index hospitalization will result in exclusion, and that actual receipt of 
a fibrinolytic w ould result in exclusion.
Exclusion Criterion #24 divided into 2 sub -sections to allow for enhanced data 
collection and a note has been added to indicate that dipyridamole is allowed.
Exclusion Criterion #25 modified to reflect current standa rd language.
Exclusion Criterion #26, minor w ording changes.
Exclusion Criterion #27, minor w ording changes.
Exclusion Criterion #28 minor w ording changes.
Exclusion Criterion #31added to reflect the usual exclusion criteria language for 
the drug under stu dy.
Overvie w of Study Design, 
Section 3.1 Overview of Study, 
Section 4.1, Inclusion CriteriaDefinition of index hospitalization has been added to clarify the way days are 
counted for the index hospitalization.  
Overvie w of Study Design, 
Section 3.1 Ov erview of Study 
Design, 9.1.3. Double- Blind 
Treatment PhaseThe definition of “discharge” has been clarified further, to allow  the sites more 
flexibility with the timing of randomization relative to hospital discharge. 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
106
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Section 1.1 Background, 
Sections 1. 2 Overall Rationale 
for the Study, Section 3.1 
Overvie w of Study Design, 
Dosage and Administration, 
Efficacy Analyses, Section 3.2 
Blinding Control Study 
Phase/Periods Treatment 
Groups, 3.2 Dose Selection, 3.2 
Pharm acokinetics Analysis, 
Section 5 Treatment Allocation 
& Blinding, Section 6. Dosage 
and Administration, 
Attachment 1, Section 11.3 
Primary Efficacy OutcomeTo provide clarity regarding stratum assignment for subjects with CrCl >30 and 
<49mL/min was changed to CrCl >30 and <50 mL/min.  
Synopsis Choice of Safety 
Measures, Section 3.2 Study 
Design Rationale, Section 
12.3.1 All Adverse EventsAddition of acute coronary syndrome and transient ischemic attack as serious 
adverse events.
Section 3.2 Study Design 
RationaleProvided rationale f or placebo comparator selection.
Overvie w of Study Design, 
Section 3.1 Overview of Study 
Design, 6. Dosage and 
AdministrationReinforced that the first dose of study drug should be administered as soon after 
randomization as possible.
Diagram of study design updated to reflect changes.
Overvie w of Study Design, 
Section 3.1 Overview of Study 
Design, 4.1 Inclusion Criteria
Section 1.1 BackgroundParenteral anticoagulation requirement (LMWH, UFH) and duration were 
specified.
Section 3.3.3 Clinical Events 
CommitteeEvents to be adjudicated w ere clarified.  
Section 4. Subject Population Clarified time to screening subjects relative to “discharge from hospital” and to 
“index hospitalization”.
Section 4.1 Inclusion Criteria, 
16.2.3 Informed Consent, 
Section 16.2.4 Privacy of 
Personal DataDeleted option for legally acceptable representative to sign the informed consent 
on behalf of the subject.
Section 4.3 Prohibitions and 
RestrictionsRevised section to match exclusion criteria and detailed concomitant therapy that 
should not be administered before or during study and clarified restrictions.
Section 5 Treatment Allocation 
and BlindingAdded statement for risk factor groups to allow for a heterogeneous population.
Paragraph w as added to clari fy that unblinding is unlikely to impact the care of 
the subject.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
107
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Synopsis Dosage and 
Administration, Section 6. 
Dosage and AdministrationAdded clarification regarding the chronic therapy with rivaroxaban.
Added comment about dosing in the event of a change in creatinine clearance.
Added instructions about timing of first dose of study drug administration.
Added paragraph about whether study drug will be provided after the subject 
completes study participation.
Section 9.1.2. Screening Phase Clarification was added regarding when screening activities may begin.
Statement was added regarding local D- dimer laboratory collection.
Added the details on creatinine clearance calculations, and deleted from INT -2 
attachment.
Section 9.1.3. Double -Blind 
Treatment PhaseAdded more reasons for unscheduled visits and timing and location of 
randomization have been simplified and broadened.
Section 9.1.3 Post -treatment 
Phase (Follow -Up)Added paragraph about whether study treatment will be provided after th e subject 
completes study participation.
Section 9.2.1. Efficacy 
Evaluations and OutcomesAdded further clarification to outcome event processing, and adding ACS and 
TIA to encourage the investigator that events that suggest the possibility of MI or 
strok e be sent for adjudication.
Added instructions about the handling of images for enhanced submitting CEC 
packages.
Section 9.2.2 Approach to the 
Subject w ith an Efficacy 
Outcome EventNew  section added to provide guidance to treating physician for efficacy
outcomes events.
Section 9.3.1 Evaluations Modified to include non -fasting status for PK sampling.
Section 9.5 Safety Evaluations 
and Outcomes: Clinical 
Laboratory TestsSerum pregnancy test added as an option to match the Time And Events 
Schedule.
Section 9.5.2. Approach to the 
Subject w ith a Bleeding EventNew  section added to provide guidance for serious bleeding events.
Synopsis, Dosage and 
Administration, Section 3.2 
Study Design, Section 10.2 
Discontinuation of Study 
Treatment, 10.2.1 Temporar y 
Discontinuation of Study 
Treatment, 16.1 Ethical 
Aspects.  Added further guidance on any condition that in the investigator’s judgment 
requires anticoagulation, thromboprophylaxis, or fibrinolysis.
Added instructions about possibility for restarting study drug in the event that a 
low platelet count is noted
Section 10.2.1. Temporary 
Discontinuation of Study 
TreatmentAdded instructions about possibility for restarting study drug in the event that a 
low platelet count is noted.
Section 10.2. Discontinuation 
of Study TreatmentAdded paragraph about management in the event that the subject develops a need 
for anticoagulation.
Section 10.2.2. Approach to 
Subjects with Dose InterruptionMoved section from previous INT -2 Attachment for increased accessibility of the 
information.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
108
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Section 10.2.3 Permanent 
Discontinuation of Study 
TreatmentAdded an additional criterion for discontinuation of study treatment to allow  for 
drops in creatinine clearance to below  the level that resulted in exclusion fro m 
the study.
Section 12.3.1 All Adverse 
EventsSection was modified and for more clarity, with addition of ACS and Transient 
ischemic attack, and ne w sub -categories, ie, Serious Adverse Events, Non -
Serious Adverse Events, and Reporting Timelines and Proce sses. ACS and TIA 
events will be sent for adjudication.
Section 12.3.3 Pregnancy Added clarifications regarding partner pregnancy and infant follow -up.
Section 16.1. Study -Specific 
Design ConsiderationsAdded guidance regarding required use of parenteral or oral anticoagulation.
Section 17.4 Source 
DocumentationRace was removed as an item recorded directly into the eCRF.
Throughout the protocol Minor editorial changes. 
Added “lower extremity” to symptomatic DVT, added “non -fatal” to 
symptomatic PE.
Attachments, 
Attachment 1 , Efficacy 
OutcomesAdded Attachment 2, Event Supporting Documentation.
Moved INT -2 Attachments 1, 2, 3, and 4 to main body of protocol. 
For INT -3 Attachment 1, the definitions of prior INT -2 Attachment 5 were 
updated to match the CEC charter.
Rationale: Modified safety and exclusion measures to ensure that adverse events secondary to the study agent are 
captured correctly.
Section 3.2 Choice of Safety 
MeasuresIncluded ACS and transient ischemic attack as measures of efficacy.
Section 12.3.1. All Adverse 
EventSection updated to provide clarification and addition of ACS and TIA as events 
to be exempt from unblinding and expedited reporting.
Rationale: Clarifications added to ensure consistency (eg, with charter, USPI )
Section 3.3.3 Clinical Events 
Committee.Added ‘other bleeding’ to list of events to be adjudicated by CEC.
Section 4.2 Exclusion Criteria Revised criterion related to strong CYP3A4 inhibitors and inducers.
Amendment INT -2(11 April 2014)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor the scientific value of the study.  
The overall reason for the amendment: The overall reason for the amendment is to provide clear description on 
study procedures.
Applicable Section(s) Description of Change(s)
Rationale: Clarification on baseline values.   
Time and Events Schedule and 
9.1.2. Screening PhaseClarifications that the latest value will be taken as baseline if there are multiple 
values during screening period and that complete blood count and CrCl must be 
performed/calculated within defined time window  before hospital discharge.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
109
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Section 3.3. Committees Deleted section based on decision not to form a Steering Committee.
Synopsis Section 11. Statistical 
MethodsReplaced analysis population with analysis set to comply with International 
Conference on Harmonisation [ICH] E9 guideline.
Section 11.3. Efficacy analyses Changed the subgroup definition to include the agent used (LMWH or UFH).
Section 12.3.1. All Adver se 
EventsDeleted “e -CRF” to address an inconsistent description in the section.
Amendment INT -1(14 March 2014)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/men tal integrity of subjects, nor the scientific value of the study.  
The overall reason for the amendment: The overall reason for the amendment is to provide clear descriptions 
and/or definitions on study endpoints, visits, procedures, and terms. 
Applicable Section(s) Description of Change(s)
Rationale: To provide more clarity on the EOT and EOS clinic visits and total study duration.
Synopsis; 
3.1. Overview  of Study DesignDeletion of both the 30 -day time point follow -up contact, and phone call as 
follow -up option.
Time and Events Schedule Addition of “EOT” to Header column for Day 45 and “EOS” for Day 75.
7. Treatment Compliance Additional clarification regarding treatment compliance on Day 45. 
10.1. Completion Replacement of statements regarding completion of the study with clarifying 
information on expected total duration of 75 days after randomization.
16.2.3. Informed Consent Deletion of redundant collection information for subjects unable to return for an 
EOT and follow -up (EOS) vi sit.
Rationale: To em phasize zero tolerance on missing endpoint data.
Throughout the
protocolWhere appropriate, addition of “and other outcomes” to “vital status.
Rationale: To provide more clarity, including the definition of terms.
Throughout the
protocol“Observation period” w as changed to “analysis phase”.
“Approximately” was added to 9,000 subjects.
The IDMC charter w as deleted.
11.6. Safety Analyses “Temperature” was deleted from the vital signs that will have descriptive statistics 
provided.
Rationale: To provide more clarity on potential IDMC recommendations.
Throughout the
protocolClarification that the IDMC can recommend to modify and terminate the study 
prematurely for safety. 
Rationale: To delete redundant and unclear expressions as any single missing dose will be captured in eCRF.
6. Dosage andAdministration Deletion of statement that an occasionally forgotten dose need not be recorded, 
and limitation of reporting to unintentional stopping of study drug for >7 days.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
110
Status: Approved , 31 March 2017Applicable Section(s) Description of Change(s)
Rationale: To reflect that hematocrit values are not part of the ISTH definition for major bleeding.
9.5. Safety Evaluations and 
OutcomesDeletion of stated reduced drop in hemoglobin based on hematocrit values.
Rationale: Clarification that VTE is also a condition that requires permanent anticoagulation.
10.2.2. Permanent 
Discontinuation of Study 
TreatmentAddition of “VTE” as an example for a condition which requires permanent 
anticoagulation that will result in permanently discontinuing a subject fro m study 
drug.
Rationale: For consistency with T&E.
17.4. Source Documentation Deletion of heart rate as source data for the eCRF.
Rationale: Update of instructions in Attachment 6 for sample analysis at the bioanalytical lab chosen for the study.
Attachment 6: 
Pharm acokinetic Sample 
Collection and HandlingAddition of K 2EDTA usage for the preparation of plasma PK samples for 
rivaroxaban.
Correction of blood sample centrifugation time to 1 hour.
Addition of statement regarding the Study Lab Manual f or proper shipping 
instructions.
Rationale: To avoid miscommunication of the applicable procedures for labeling and shipment of PK samples.
Attachments 7 and 8 Deletion of both attachments.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
111
Status: Approved , 31 March 2017Attachment 6: Complete Amendm ent History of INT-6 Inclusion and Exclusion Criteria, and Prohibitions 
and Restrictions for Data Collection Purposes
4.1. Inclusion Criteria 
Each potential subject must satisfy all of the following criteria to be enrolled in the study . 
1. Criterion Modified per Amendm ent INT-3
1.1. Criterion Modified per Amendment INT -5
1.2.  
a. Subject must be a man or woman, ≥40 years of age .
b. The duration of the index hospitalization must have been at least 3 and no more than 
10consecutive days. 
The index hospitalization is defined as a hospitalization that ended on the day of or 
the day before randomization and is a continuous period of time at an acute care 
facility (including hospital, observation unit, ER and/or transferring facility; 
collectively referred to as "hospital "). The first day that the subject spends any part of 
the day in the hospital will be counted when determining the duration of the index 
hospitalization, but the day the patient leaves the hospital will not be counted.
c. The reason for the index hospitali zation must have been a new diagnosis or 
exacerbation of 1 of the following medical conditions:
Heart Failure (HF) 
Subject must have a documented LVEF ≤45% within 1 year before 
randomization or during the index hospitalization. The ejection fraction may 
be determined by one of the following methods: echocardiogram, nuclear 
multi- gated acquisition (MUGA) scan, cardiac magnetic resonance imaging 
(MRI), cardiac computed tomograph y (CT)scan, or left ventriculograph y). If 
more than 1 value for LVEF is availabl e, the most recent one should be used.
Acute respiratory  insufficiency  or acute exacerbation of COPD
Acute ischemic stroke (including spinal cord infarction if no evidence of 
intramedullary , subdural or epidural hemorrhage) 
If the subject received fibrinoly sis as part of the initial treatment for stroke, 
fibrinolysis must have been administered at least 3 full days before the 
subject is randomized. These subjects must have had a CT/MRI  scan at 
presentation and a repeat scan performed at least 24 hours after 
administration of fibrinoly sis that documents the absence of hemorrhage. 
Subjects with hemorrhagic transformation of an ischemic infarct prior to 
randomization are not excluded unless there is evidence of parench ymal 
hemorrhage (types PH-1 and PH-2). Allplanned diagnostic tests for stroke 
evaluation must be completed before randomization. Brain imaging and 24 
hour cardiac monitoring must have been repeated if new symptoms of 
stroke/TIA occurred after the initial stroke evaluation, as does 24-hour 
cardiac monitoring if s ymptoms suggestive of AF occur.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
112
Status: Approved , 31 March 2017Acute infectious disease
Inflammatory  disease, including rheumatic disease
2. Criterion Modified per Amendment INT -3
2.1. Criterion Modified per Amendment INT -5
2.2. The subject must be at increased risk for VTE by  the total modified IMPROVE VTE 
Risk Score (Table 1; modified from Spyropoulos37) assessed at screening and verified at 
randomization.
a. If the total modified IMPROVE VTE Risk Score is ≥4, the subject meets this 
inclusion criterion.
b. If the total modified IMPROVE VTE R isk Score is 2 or 3, a D-dimer >2X ULN must 
have been obtained after the beginning of the index hospitalization and before 
randomization 
Table 1: Modified IMPROVE VTE Risk Score
VTE Risk Factor VTE Risk Score
Previous VTE 3
Known thrombophiliaa2
Current lower limb paralysis or paresisb2
History of cancerc2
ICU/CCU stay 1
Complete immobilizationd≥ 1 day 1
Age ≥60 years 1
CCU= cardiac care unit; ICU= intensive care unit; VTE= venous 
thromboembolism.
a: A congenital or acquired condition leading to excess risk of thrombosis 
(eg, factor V Leiden, lupus anticoagulant, factor C or factor S deficiency).
b: Leg falls to bed by 5 seconds, but has some effort against gravity (taken 
from NIH stroke scale).25
c: Cancer (excluding non -melanoma skin cancer) present at any time in the 
last 5 years (cancer must be in remission to meet eligibility criteria)
d:Immobilization is being confined to b ed or chair w ith or without bath -
room  privileges.
3. Criterion Modified per Amendment INT -3
3.1. L ife expectancy  of at least 3 months. 
4. Criterion modified per Amendment INT -3
4.1. Criterion modified per Amendment INT -5
4.2. Criterion modified per Amendment INT -6
4.3. Prescribed thromboprophy laxis (according to ACCP guidelines)20with UFH or 
LMWH (eg, dalteparin and enoxaparin) not exceeding 15000 U on any given day for 
UFH and not exceeding 5000 U on an y given day for LMWH.
Table 2below provides the minimum number of doses required by index hospitalization 
duration. For ischemic stroke with thrombol ysis, do not use the index hospital duration 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
113
Status: Approved , 31 March 2017to determine the number of doses required. Instead, use the number of days the patient 
was in the hospital after the first day  the patient was prescribed thromboprophy laxis.
Table 2: Minimum Number of Heparin Doses Required for 
Study Eligibility by Duration of Index Hospitalization
Index Hospitalization 
Duration (days)LMWH doses 
requiredUFH doses 
required
3 2 3
4 2 4
5 3 6
6 4 7
7 4 8
8 5 10
9 6 11
10 6 12
LMWH= low molecular weight heparin, UFH= unfractionated heparin.
Note: In the event that both LMWH and UFH are used during the index 
hospitalization, the number of doses of LMWH received should be 
doubled and added to the number of UFH doses received, and the UFH 
doses required column should be used to determine whether the 
requirement was met.
5. Criteria deleted per Amendment INT -3
6. Criterion modified per Amendment INT -3
6.1. Each subject must sign an informed consent form (ICF) indicating that he or she 
understands the purpose of and procedures required for the study  and is willing to 
participate in the study .  
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study .  
Bleeding Risk -Related Criteria
1. Criterion Modified per Amendment INT -5
1.1. Any bleeding (defined as bleeding requiring hospitalization, transfusion, surgical 
intervention, invasive procedures, occurring in a critical anatomical site, or causing 
disability ) within 3 months prior to randomization or occurring during index 
hospitalization. 
2. Criterion Modifie d per Amendment INT -3
2.1. Criterion Modified per Amendment INT -4
2.2. Criterion Modified per Amendment INT -5
2.3. Major surgery , biopsy  of a parench ymal organ, ophthalmic surgery  (excluding 
cataract surgery), or serious trauma (including head trauma) within 4 weeks before 
randomization.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
114
Status: Approved , 31 March 2017Investigator discretion should be applied, but the following guidance may be considered 
for the purpose of this study.
Major surgery often involves opening 1 of the major body cavities the abdomen, the 
chest, or the skull and can stress vital organs. Major surgery usually is done using 
general anesthesia in a hospital operating room by a surgeon(s) and usually requires a 
stay of at least 1 night in the hospital after surgery.
In contrast, with minor surgery , major body cavities are not opened. Minor surgery can 
involve the use of local, regional, or general anesthesia and may be done in an 
emergency department, an ambulatory surgical center, or a doctor's office. Vital organs 
usually are not stressed, and surgery can bedone by a single doctor, who may or may 
not be a surgeon. Usually, the person can return home on the same day that minor 
surgery is done.
Investigator discretion should be applied, but fracture or concussion would be 
considered serious head trauma , while external trauma without fracture or concussion 
could be considered for inclusion.
3.Criterion Modified per Amendment INT -3
3.1. Criterion Modified per Amendment INT -4
3.2. Criterion Modified per Amendment INT -5
3.3. Any planned major surgery  (see exclusio n criterion #2.3) or major invasive 
diagnostic procedure intended during the duration of the trial.  
4.Criterion Modified per Amendment INT -3
4.1. Subjects with any known coagulopathy  or bleeding diathesis, or an INR >1.5 during 
the index hospitalization without a subsequent value (the last value before randomization) 
that is ≤ 1.5. 
5.Criterion Modified per Amendment INT -3
5.1. Criterion Modified per Amendment INT -5
5.2. A history  of hemorrhagic strok e or any intracranial bleeding at any time in the past, 
evidence of primary  intracranial hemorrhage on CTor magnetic resonance imaging scan 
of the brain, or clinical presentation consistent with intracranial hemorrhage. This applies 
as well to subjects hospitalized for ischemic stroke upon randomization.
Subjects with hemorrhagic transformation of an ischemic infarct prior to randomization 
are not excluded unless there is evidence of parenchy mal hemorrhage (types PH-1 and 
PH-2): 
Hemorrhagic infarction type 1 (HI -1) is defined as small petechiae along the m argins of 
the infarct, and HI type 2 (HI-2) is defined as more confluent petechiae within the 
infarcted area but without space -occupying effect. PH type 1 (PH-1) is defined as 
hematoma in ≤30% of the infarcted area with some slight space -occupying effect; PH 
type 2 (PH-2) is defined as dense hematoma >30% of the infarcted area with 
substantial space -occupying effect or as any hemorrhagic lesion outside the infarcted 
area ( Berger, 20012). 
Hemorrhagic infarction type 1 and HI -2 subjects are NOT excluded from this study, but 
PH-1 and PH -2 subjects ARE excluded from this study. 
6.Criterion Modified per Amendment INT -3
6.1. Criterion deleted per Amendment INT -5
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
115
Status: Approved , 31 March 20177. Criterion Modified per Amendment INT -5
7.1. Subject has a history  of or current intracranial neoplasm (benign or malignant), 
cerebral metastases, arteriovenous (AV) malformation, or aneury sm.
8. Active gastroduodenal ulcer, defined as diagnosed within 3 months or currentl y symptomatic 
or known AV malformations of the gastrointestinal tract.
9. Criterion Modified per Amendment INT -3
9.1. Screening platelet count <75 x 109cells/L. 
Concomitant Conditions or Diseases
10. Criterion Modifie d per Amendment INT -3
10.1. Criterion Modified per Amendment INT -5
10.2. Active cancer (excluding non-melanoma skin cancer) defined as cancer not in 
remission or requiring active chemotherap y or adjunctive therapies such as 
immunotherapy or radiotherap y.Chronic hormonal therap y (eg, tamoxifen, anastrazole, 
leuprolide acetate) for cancer in remission is allowed.
11. Criterion Modified per Amendment INT -3
11.1. Any medical condition (eg, atrial fibrillation) that requires use of any parenteral or 
oral antico agulant(s) (eg, warfarin sodium or vitamin K antagonists, Factor II or Xa 
inhibitors, fibrinoly tics) concomitantly  with study medication.
12. Criterion Modified per Amendment INT -3
12.1. Bilateral and unilateral above -knee lower extremity  amputation.
13. S ubject has known allergies, hypersensitivity , or intolerance to rivaroxaban or any of its 
excipients.
14.Criterion Modified per Amendment INT -3
14.1. Severe renal insufficiency  (baseline CrCl <30 mL/min calculated using the 
Cockcroft -Gault 6formula provided in Section 9.1.2 ).
15.Criterion Modified per Amendment INT -3
15.1. Known significant liver disease (eg, acute hepatitis, chronic active hepatitis, 
cirrhosis) which is associated with coagulopathy  or moderate or severe hepatic 
impairment. 
16. Known HIV infection.
17. Sustain ed uncontrolled systolic blood pressure (BP) of ≥180 mmHg or diastolic BP of 
≥100 mmHg at randomization despite treatment.
18.Criterion Modified per Amendment INT -3
18.1. Current drug or alcohol abuse, based on investigator’s assessment.
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
116
Status: Approved , 31 March 201719. Criterion Mod ified per Amendment INT -5
19.1. Cardiogenic or septic shock with the need for vasopressor(s) or devices for blood 
pressure support during index hospitalization.
20. Presence of inferior vena caval filter
21. Severe bronchiectasis or cavitary  tuberculosis or any other pulmonary  condition 
(eg,vasculitis) at risk for major hemopty sis 
Drugs or Procedures 
22.Criterion Modified per Amendment INT -3
22.1. Criterion Modified per Amendment INT -4
22.2.
a. Combined P-gp and strong CYP3A4 inhibitors (such as but not limited to 
ketoconazole, telithromy cin or protease inhibitors) use within 4 days before 
randomization, or planned use during the study . Itraconazole use is prohibited within 7 
days before rando mization and during the study . 
b. Combined P-gp and strong CYP3A4 inducers (such as but not limited to 
rifampin/rifampicin, rifabutin, rifapentine, phen ytoin, phenobarbital, carbamazepine, 
or St. John's Wort) use within 2 weeks before randomization, or planned use during 
the study . 
23.Criterion Modified per Amendment INT -3
23.1. Criterion Modified per Amendment INT -5
23.2. Received fibrinolysis during index hospitalization, unless received for ischemic 
stroke at least 3 full day s before randomization.
24.Criterion Modified per Amendment INT -3
24.1. Criterion Modified per Amendment INT -5
24.2. Use of antiplatelet therap y during the index hospitalization, including:
a. ASA >162 mg/day  
b. Clopidogrel >75 mg/day  or ticlopidine >250 mg twice dail y
c. Clopidogrel at an y dose in combination with omeperazole or esomeprazole
d. Dipy ridamole >400 mg/day
e. Cilostazol >200 mg/day
f. Dual therap y with 2 or more antiplatelet agents (dipyridamole with ASA is permitted) 
g. Other P2Y12 receptor antagonists (eg, prasugr el, ticagrelor)
h. Thrombin -receptor antagonists (eg, vorapaxar)
25.Criterion Modified per Amendment INT -3
25.1. Childbearing potential without proper contraceptive measures, pregnancy  or breast 
feeding.
a. Before randomization, a woman must be either:
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
117
Status: Approved , 31 March 2017 Not of childbearing potential: premenarchal; postmenopausal (>45 years 
of age with amenorrhea for at least 12 months or any age with amenorrhea for at 
least 6 months and a serum follicle stimulating hormone (FSH) level >40IU/L]); 
permanentl y sterilized (eg, tubal occlusion, hysterectom y, bilateral 
salpingectomy); or otherwise be incapable of pregnancy ,
 Of childbearing potential and practicing a highl y effective method of birth 
control consistent with local regulations regarding the use of birth control 
methods for subjects participating in clinical studies: eg, established use of oral, 
injected or implanted hormonal methods of contraception; placement of an 
intrauterine device or intrauterine system; barrier methods: condom with 
spermicidal foam/gel/film/cr eam/suppository  or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository ; male 
partner sterilization (the vasectomized partner should be the sole partner for that 
subject); true abstinence (when this is in line w ith the preferred and usual lifesty le 
of the subject). 
Note: If the childbearing potential changes after start of the study  (eg, woman 
who is not heterosexually  active becomes active, premenarchal woman 
experiences menarche) a woman must begin a highl y effective method of birth 
control, as described above. The initiation of hormonal contraception for the 
purpose of the stud y is not recommended.
A woman of childbearing potential must have a negative serum (β human 
chorionic gonadotropin [β hCG]) or urine pr egnancy  test at screening.  
b. A man who is sexually active with a woman of childbearing potential and has not had a 
vasectom y must agree to use a double -barrier method of birth control eg, either 
condom with spermicidal foam/gel/film/cream/suppository  orpartner with occlusive 
cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository , and all men must also not donate sperm during the 
study , from the time of the first dose to the last dose of study  drug.
26. Participation in another pharmacotherapeutic study  or experimental medical device within 
30days before the start of study  treatment.
27.Criterion deleted per Amendment INT -3
28.Criterion Modified per Amendment INT -3
28.1. Criterion Modified per Amendment INT -5
28.2. Prescribed daily use of nonsteroidal anti-inflammatory  agents (NSAIDs) during the 
index hospitalization  
29.Subject is unwilling or unable to complete all study  visits as well as follow -up visit.
30. Subject is an employ ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as well 
as family  members of the employ ees or the investigator.
31.Criterion deleted per Amendment INT -5
NOTE: Investigators should ensure that all study  enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory  results or receipt of additional medical records) 
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
118
Status: Approved , 31 March 2017after screening but before randomization such that he or she no longer meets all eligibility  
criteria, the subject should not be randomized. But if the subject has been randomized, he/she 
should not be excluded from participation in the study  and must be followed until the Day 75 
(±5d) visit. Section 17.4, Source Documentation, describes the required documentation to 
support meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation. If subjects require or 
take prohibited medications during the study  as outlined below, they must either temporarily 
interrupt or permanently  discontinue the study drug, as appropriate for the duration of the 
therap y with the prohibited medication:
1.Criterion Modified per Amendment INT -3
1.1. Criterion deleted per Amendment INT -5
2.Criterion Modified p er Amendment INT -3
2.1. Criterion Modified per Amendment INT -4
2.2. Combined P-gp and strong CYP3A4 inhibitors (such as but not limited to 
ketoconazole, telithromy cin or protease inhibitors) use within 4 days before 
randomization, or planned use during thestudy. Itraconazole use is prohibited within 
7days before randomization and during the study . 
3.Criterion Modified per Amendment INT -3
3.1. Criterion Modified per Amendment INT -4
3.2. Combined P-gp and strong CYP3A4 inducers (such as but not limited to
rifampin/rifampicin, rifabutin, rifapentine, phen ytoin, phenobarbital, carbamazepine, or 
St. John's Wort) use within 2 weeks before randomization, or planned use during the 
study . 
4. Criterion Modified per Amendment INT -5
4.1. Anticoagulant (eg, warfarin sodium or other vitamin K antagonists, Factor II or Xa 
inhibitors) is prohibited as concomitant therap y during the study . Study  drug should be 
discontinued in subjects who develop any condition which requires anticoagulation or 
thromboprophy laxis (eg, atrial fibrillation, VTE) that will extend beyond the end of the 
study  treatment phase. 
5.Criterion deleted per Amendment INT -5
6.Criterion Modified per Amendment INT -5
6.1. Fibrinoly tic therapy  (see Section 10.2.1 for guidance) 
7.Criterion Modified per Amendment INT -5
7.1. Use of antiplatelet therap y, including:
a. ASA >162 mg/day  
b. Clopidogrel >75 mg/day  or ticlopidine > 250 mg twice dail y
c. Clopidogrel at an y dose in combination with omeprazole or esomeprazole
d. Dipy ridamole >400 mg/day
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
119
Status: Approved , 31 March 2017e. Cilostazol >200 mg/day
f. Dual therapy  with 2 or more antiplatelet agents (dipyridamole with ASA is 
permitted) 
g. Other P2Y12 receptor antagonists (eg, prasugrel, ticagrelor)
h. Thrombin -receptor antagonists (eg, vorapaxar)
i. Prescribed daily  non-steroid al anti-inflammatory  drugs (temporary  use as needed is 
allowed).
8.Criterion deleted per Amendment INT -5
9.Modification of an effective pre-existing therap y should not be made for the explicit purpose 
of entering a subject into the study .
[STUDY_ID_REMOVED]
JNJ-39039039; BAY 59 -7939 (rivaroxaban)
Clinical Protocol RIVAROXDVT3002 –Amendment INT-7
120
Status: Approved , 31 March 2017INVESTIGA TOR AGREEMENT
I have read this protocol and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined herein and will complete the study within the time designated.
I will provide copies of the protocol and all pertinent information to all individuals responsible to me who 
assist in the conduct of this study. I will discuss this material with them to ensure that they are fully 
informed regarding the study drug, the conduct of the study, and the obligations o f confidentiality.
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: Date:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: Date:
(Day Month Year)
Sponsor's Responsible Medical Officer:
Nam e (typed or printed): Elliot Barnathan,MD, FACC
Institution: Janssen Research & Development 
Signature: electronic signature appended at the end of the protocol Date: 31March 2017
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by the investigator to the sponsor, and a protocol amendment will not be required.
[STUDY_ID_REMOVED]
  
SIGNATURES 
    
Signed by  Date  
 Justification  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Elliot Barnathan
31Mar2017, 15:46:53 PM, UTC
Document Approval
[STUDY_ID_REMOVED]